beta

ABBV

AbbVie Inc.

Abbv

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-02-2018 07-27-2018 04-26-2018 01-26-2018 10-27-2017 07-28-2017 04-27-2017
Actual EPS 2.14 2.0 1.87 1.48 1.41 1.42 1.28
Consensus EPS 2.01 1.98 1.8 1.44 1.39 1.4 1.26
Estimated EPS 2.01 1.98 1.8 1.44 1.39 1.4 1.26
Number of Estimates 8 8 9 8 9 10 9
EPS Surprise $0.13 $0.02 $0.07 $0.04 $0.02 $0.02 $0.02

Stats

Summary

AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.

Market Cap: 173 Billion

Primary Exchange: New York Stock Exchange

Website: http://www.abbvie.com

Shares Outstanding: 1.6 Billion

Float: 1.6 Billion

Dividend: 2.84 (2.62%)

Beta: 1.579436

Sector: Healthcare

Industry: Drug Manufacturers

Short Interest (Jan 12, 2018): 16.2 Million

Ethical Flags

Animal testing

Longest drawdown: 476 trading days

From: 2015-07-28 To: 2017-06-16

Lowest Point:

Healthcare And Biotechnology Dashboard - Update

via: SeekingAlpha at 2018-12-11 18:38:19:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology looks underpriced regarding the historical averages of its valuation … read more...

Valero's Vast Upside Paces 38 S&P 500 "Safer" Dividend Gains Per December Broker Targets

via: SeekingAlpha at 2018-12-11 15:51:13:000

Source: YCharts.com Actionable Conclusions (1-10): Brokers Estimate Top Ten 'Safer' Dividend S&P 500 Stocks Could Net 24.97% to 53.33% Gains By December, 2019 Four of the ten tops-by-yield 'safer' Dividend S&P 500 (tinted in the chart above) were among the top ten gainers for t… read more...

Lanny's Stock Purchases November 16th Through November 30th

via: SeekingAlpha at 2018-12-11 14:20:53:000

The dividend stock purchases machine keeps rolling! Yes, this is yet another round of dividend stock purchases, covering the last two weeks of activity in November. The stock market has continued its roller-coaster ride, creating value on dividend stocks I currently or have wanted to own. Ther… read more...

Portfolio Update: Stocks Getting Slammed As Dividends Shine Bright

via: SeekingAlpha at 2018-12-11 10:45:56:000

My investment career is still very short (roughly 2.5 years) and as such the volatility we are now experiencing daily in the markets is certainly new to me. That said I have been actively watching how the stock markets behaved from 2007 - 2010 and although I am deeply regretting it not to have… read more...

Dividend Sensei's Portfolio Update 63: Why I'm Now In Recession Prep Mode

via: SeekingAlpha at 2018-12-11 08:46:52:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Th… read more...

Dividend Income Update November 2018

via: SeekingAlpha at 2018-12-11 06:07:16:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online as it only provides further proof that dividend invest… read more...

Talking Turkey: The Brown Bag Portfolio November Review

via: SeekingAlpha at 2018-12-10 17:17:35:000

My first thought upon completing my October review article was, thank God October is over, now on with the November recovery. I was nave. Had I more experience investing I would probably have been aware that after the upheaval many others and I experienced in October that… read more...

Challenges For Gilead's 2 New CEOs

via: SeekingAlpha at 2018-12-10 13:23:58:000

Introduction: Gilead ( GILD ) will have three CEO's in less than three months In January 2016, GILD announced that its long-serving CEO, John Martin, was being succeeded by GILD lifer John Milligan, with Dr. Martin moving up to the role of executive CEO. Following a multi-month search, GI… read more...

Bert's November Dividend Income Summary

via: SeekingAlpha at 2018-12-10 01:17:47:000

It's the most wonderful time of the year! The winter is upon us and the holiday season is right around the corner. It is time to bust out the Christmas Trees, decorations, menorahs, and whatever else you and your families use to celebrate the holidays. I know our house is ready to go! On top o… read more...

Top 'Safer' Dividend Aristocrats Are G. Dynamics; Chevron; Nucor; VF; Lowe's; Per December Targets

via: SeekingAlpha at 2018-12-09 15:04:33:000

Actionable Conclusions (1-10): Brokers Expect Top Ten 'Safer' Dividend Aristocrats to Net 14.46% to 24.87% Gains To December, 2019 Four of ten biggest yield "safer" Dividend Aristocrats (tinted in the chart above) showed up in the Top ten gainers for the coming year based on analyst 1 year… read more...

Cancer Research Highlight: Curtains Begin To Close On AbbVie's Small Cell Program

via: SeekingAlpha at 2018-12-09 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you're interested in this serv… read more...

Crushing $12,000 In Projected Dividend Income (As Well As Another Goal Too!)

via: SeekingAlpha at 2018-12-09 05:16:55:000

Everyone, I made it. I made it to this illustrious milestone. I can't believe this moment. In November, after one of my dividend stock purchases, I crossed over $12,000 in projected dividend income! Crossing the $12,000 milestone means a great deal to me. I am sure you already know why, but … read more...

Ten Top Dividend Aristocrats Net Large Gains Per Broker December Targets

via: SeekingAlpha at 2018-12-08 15:56:20:000

Source: YCharts.com Actionable Conclusions (1-10): Analysts Predicted 14.46% To 23.03% Net Gains To December, 2019 Five of the 10 top Aristocrats by yield were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray i… read more...

How To Retire At 62 With Just Half A Million

via: SeekingAlpha at 2018-12-08 09:43:00:000

In the previous article that we wrote on our hypothetical couple - John and Lisa - we tried to demonstrate how they could retire in 10 years, starting with a modest savings of $300,000 at the age of 50 years that would grow to $1 Million by the time they actually retire at 60. We had assumed… read more...

How Safe Is AbbVie's Dividend?

via: SeekingAlpha at 2018-12-07 23:34:04:000

AbbVie Inc. ( ABBV ) has one of the highest dividend yields among the Dividend Aristocrats Index. Since AbbVie's spinoff from Abbott Laboratories in 2013, the company's stock has been used by many dividend growth investors to increase the yields of their investment portfolios. Unfortunately,… read more...

Rose 91 Stock Portfolio Bountiful November Dividends Along With Historic Buy Yields + Transactions

via: SeekingAlpha at 2018-12-07 15:03:45:000

The Rose Portfolio It is real and contains 91 investments from 3 combined brokerage accounts including 2 Roth, 1 taxable along with 9 separate stocks held privately at each company. In this last article, I discuss goals and reveal all available S&P credit ratings. Bountiful divid… read more...

Worse Than Useless

via: SeekingAlpha at 2018-12-07 08:28:54:000

Time for another look at AbbVie's (ABBV) work on Rova-T (an antibody-drug conjugate targeting the tumor antigen DLL3), and for some hard thoughts about what drug development is really like. The last time I wrote about this program, things didn't look good. Now they look even worse. A Phase I… read more...

Dividend Update - November 2018

via: SeekingAlpha at 2018-12-07 01:59:39:000

November was a busy month. Lots of family events to go to. It has been nice to relax and unwind a bit before everything gets hectic in December. Free capital has been tight, so I have been unable to purchase any new shares. Lots of expenses coming up at year end or the beginning of next year t… read more...

AbbVie Just Solidified Evidence Of Blockbuster Drug With Long-Term Study

via: SeekingAlpha at 2018-12-06 15:37:58:000

Recently, AbbVie ( ABBV ) and its partner Johnson & Johnson ( JNJ ) announced strong results from its long-term studies using its cancer drug Imbruvica. This study was an important one because they were seven-year follow up studies for these patients with chronic lymphocytic leukem… read more...

March To Freedom Fund November Update

via: SeekingAlpha at 2018-12-06 10:46:52:000

We are now in the home stretch for 2018 and our portfolio has performed quite well this year. The March to Freedom Fund has a total return for the year of 9.63%. As always, this includes just share price appreciation and dividends received, but not the contributions that weve made. The… read more...

AbbVie: A Compelling Buy

via: SeekingAlpha at 2018-12-06 09:30:00:000

(Source: TheStreet ) Investment Thesis The biopharmaceutical company AbbVie Inc. ( ABBV ) has been one of the more controversial names in the large-cap health care space over the last year, with a number of strong arguments being made on both the bullish and the bearish sides. ABBV had be… read more...

AbbVie terminates enrollment in late-stage study of Rova-T in lung cancer on safety signal; shares down 2% premarket

via: SeekingAlpha at 2018-12-06 06:45:44:000

AbbVie (NYSE: ABBV ) is down 2% premarket on light volume following its announcement that it has stopped enrollment in its Phase 3 clinical trial, TAHOE , evaluating antibody-drug conjugate Rovalpituzumab Tesirine (Rova-T) for the second-line treatment of advanced/metastatic s… read more...

Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted

via: PR Newswire at 2018-12-05 16:01:00:000

NORTH CHICAGO, Ill. , Dec. 5, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, todayannounced the decision to stop enrollment for the TAHOE trial, a Phase 3 study evaluating Rovalpituzumab Tesirine (Rova-T) as a second-line therapy for adv… read more...

November 2018 Portfolio Update

via: SeekingAlpha at 2018-12-05 01:44:41:000

The dividend growth investing philosophy is built around consistency and compounding. Those who put it best to use are the investors who are diligent about the inflow of dividends, contributing new capital to their portfolios, and allowing time to do its magic with the right selection of high-… read more...

Dividend Sensei's Portfolio Update 62: Why I Bought $15,000 Worth Of This 7.2% Yielding Stock

via: SeekingAlpha at 2018-12-04 13:07:23:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Th… read more...

Dividend Aristocrat Performance: November 2018

via: SeekingAlpha at 2018-12-04 11:58:23:000

Dividend growth investing is one of my " 5 Ways to Beat the Market ". The Dividend Aristocrats ( NOBL ), S&P 500 constituent companies that have successfully increased their dividends for at least 25 years have outperformed the S&P 500 on both an absolute and risk-adjusted basis over t… read more...

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018

via: PR Newswire at 2018-12-04 11:52:00:000

NORTH CHICAGO, Ill. , Dec. 4, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today shared results from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), National Cancer Institute (NCI)-sponsored, Phase 3 study (E1912) evaluating IMBRUVIC… read more...

BeiGene Mounts Its Assault On The Ibrutinib Hegemony

via: SeekingAlpha at 2018-12-04 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. BeiGene ( BGNE ) is a Chinese … read more...

5%+ Dividend Yield Portfolio: Profiting From A Return To Normal (October 2018 Review)

via: SeekingAlpha at 2018-12-03 23:14:30:000

Outlook Volatility has returned to the markets. By this I dont mean the big dig from the recent price highs… I am referring to the "normal" week-to-week and month-to-month gyrations that have are closer to the historical trends than the quiet uptrend that has mostly defined the... read more...

IMBRUVICA® (ibrutinib) Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

via: PR Newswire at 2018-12-03 14:17:00:000

NORTH CHICAGO, Ill. , Dec. 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results from the Phase 3 iLLUMINATE (PCYC-1130) trial, evaluating the chemotherapy-free, anti-CD20 combination of IMBRUVICA (ibrutinib) p… read more...

41 'Safer' Dividend Healthcare Pre-December WallStars From Dividend Dogcatcher

via: SeekingAlpha at 2018-12-03 13:45:10:000

Source: YCharts Actionable Conclusions (1-10): Brokers Forecast Ten High Yield Top Healthcare 'Safer' Dividend Stocks to Net 12.6% to 26.75% Gains To November 2019 Four of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the t… read more...

Celgene CAR-T candidate shows positive action in heavily-pretreated CLL & SLL patients

via: SeekingAlpha at 2018-12-03 09:25:20:000

81% (n=13/16) of the patients failed to respond to ibrutinib and 50% (n=8/16) received prior treatment with ibrutinib plus venetoclax. More news on: Celgene Corporation, AbbVie Inc., Healthcare stocks news, Read more … read more...

AbbVie and Roche's venetoclax shows long-term treatment benefit in late-stage leukemia study

via: SeekingAlpha at 2018-12-02 16:43:32:000

The estimated progression-free survival (PFS) rate at 36 months in patients receiving VenR was 71.4% compared to 15.2% for patients receiving chemo agent bendamustine plus rituximab (BR). More news on: AbbVie Inc., Roche Holding Ltd ADR, Healthcare stocks news, Read more … read more...

IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a Bruton's Tyrosine Kinase Inhibitor to Date

via: PR Newswire at 2018-12-02 12:00:00:000

NORTH CHICAGO, Ill. , Dec. 2, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the results of up to seven years of clinical trial follow-up for IMBRUVICA (ibrutinib) monotherapy in chronic lymphocytic leukemia/small … read more...

Cancer Research Highlight: Astellas Takes Us Into A New Generation Of Therapy For AML

via: SeekingAlpha at 2018-12-02 09:58:34:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you've followed my news cov… read more...

AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course

via: PR Newswire at 2018-12-01 17:47:00:000

NORTH CHICAGO, Ill. , Dec. 1, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company today presented updated data from the pivotal Phase 3 MURANO trial of venetoclax (VENCLEXTA or VENCLYXTO ) in combination with rituximab (VenR). Th… read more...

EV Charging Gets $240M Push As Trump Threatens Cuts

via: SeekingAlpha at 2018-12-01 11:46:54:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. EV charging: Chevron (CVX) Technology Ventures and American Electric Power (AEP) were among the investors in a … read more...

AbbVie's Latest Approval In The AML Space Is Only The Beginning

via: SeekingAlpha at 2018-11-30 13:42:55:000

Recently, AbbVie ( ABBV ) with its partner Roche ( RHHBY ) announced that they had received FDA approval for Venclexta for treating patients with newly diagnosed acute myeloid leukemia ((AML)) who are not eligible for intensive chemotherapy. This approval is good for these patients who h… read more...

Stocks waver ahead of Trump-Xi meeting at G-20

via: SeekingAlpha at 2018-11-30 12:28:09:000

It's a mixed and tepidmidday in U.S. stock markets as eyes turn to the G-20 summit and the long-anticipated dinner meeting between President Trump and Chinese Leader Xi Jinping. More news on: Marriott International, Inc., AbbVie Inc., Pfizer Inc., News on the U.S. economy, Global new… read more...

Healthcare Yields Of 3% To 4.8% From Top 10 WallStars In November

via: SeekingAlpha at 2018-11-30 11:58:26:000

Actionable Conclusions (1-10): Analysts Projected 14.7% To 40.7% Net Gains For Top Ten Healthcare WallStars By November 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. … read more...

My Growth And Dividend Portfolio: What I'm Going To Add In December

via: SeekingAlpha at 2018-11-30 11:30:15:000

Introduction Over the past two years, I have spent intensively most of my spare time building out a methodology that matches my risk profile and investment horizon. But as you already know, an investment portfolio is never finished, and further improvements can always be made to reduce the r… read more...

Pfizer secures Humira license from AbbVie

via: SeekingAlpha at 2018-11-30 10:32:45:000

AbbVie ( ABBV +0.8% ) has granted a non-exclusive license to Humira (adalimumab) to Pfizer ( PFE +1.1% ) that will allow it to market a biosimilar as early as November 20, 2023. PFE will pay ABBV an undisclosed royalty on net sales of its product. More news on: AbbVie Inc., Pfizer In… read more...

AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Pfizer

via: PR Newswire at 2018-11-30 10:00:00:000

NORTH CHICAGO, Ill. , Nov. 30, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV) announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Pfizer a non-exclusive license on specified dates to Abb… read more...

Bert's November Stock Purchases

via: SeekingAlpha at 2018-11-29 04:56:32:000

Like Lanny, as he noted in his November purchase article , this has been a relatively quiet month from a purchasing perspective. After a crazy October that saw wild swings in the market and a lot of small purchases, November was calmer as many companies rebounded from that rough October. Of… read more...

December 2018 Stock Considerations

via: SeekingAlpha at 2018-11-28 18:25:42:000

As we soon enter the last month of 2018, it is time, once again, to highlight some of my potential stock buys for December. It's funny how, some months, I prepare a long list of potential stocks to buy, and, other months, I barely scrape a few names together. With the start of December at hand… read more...

Boehringer Ingelheim bails on biosimilars ex-U.S.

via: SeekingAlpha at 2018-11-28 11:45:19:000

Following Merck KGaA's ( OTCPK:MKGAF ) lead, Boehringer Ingelheim (BI) has decided to abandon biosimilars outside of the U.S. despite its Humira (adalimumab) biosimilar, Cyltezo, being approved in the EU since 2017. It says it will focus on commercializing Cyltezo in the U.S., approved by … read more...

Dividend Sensei's Portfolio Update 61: 3 Reasons We Live In The Golden Age Of Investing

via: SeekingAlpha at 2018-11-27 15:57:30:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Th… read more...

Jane's October Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-11-27 15:35:06:000

Investment Thesis October marks the eighth month that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Up to this point, Jane's retirement accounts from January 1st to September 30th of 2018 have demonstrated the following inc… read more...

AbbVie, Inc. (ABBV) Management Presents at Evercore ISI HEALTHCONx Healthcare Conference (Transcript)

via: SeekingAlpha at 2018-11-27 15:24:20:000

AbbVie, Inc. (ABBV) Evercore ISI HEALTHCONx Healthcare Conference November 27, 2018 08:00 AM ET Executives Bill Chase - Chief Financial Officer Rob Michael - Chief Financial Officer Scott Brun - VP of Scientific Affairs and Head of AbbVie Ventures Analysts Josh Schimmer - … read more...

Cancer Research Highlight: AbbVie And Pfizer Blitz Acute Myeloid Leukemia

via: SeekingAlpha at 2018-11-27 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Until very recently, patients … read more...

Top Holdings Of Dividend ETFs (Part 2: The Top 10 By Sector)

via: SeekingAlpha at 2018-11-26 16:40:16:000

In Part 1 of this article , I presented a virtual portfolio of the top holdings of 47 dividend ETFs. Using a proportional scoring system that favors larger investments and larger ETFs, I calculate an aggregate score for each ticker in the top 25 holdings of the dividend ETFs. Sorting the aggr… read more...

Why I'm Buying The Dip In Altria

via: SeekingAlpha at 2018-11-26 08:55:33:000

Article summary Since the beginning of November, shares of Altria ( MO ) have come down significantly due to the FDA's plan to ban menthol cigarettes that are of vital importance to Altria's sales. This news was another blow for tobacco companies given the numerous risks we already see tod… read more...

Eyes On Cyber Monday, Argentina And Mars (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-11-25 08:08:53:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f… read more...

Stocks To Watch: Eyes On Cyber Monday, Argentina And Mars

via: SeekingAlpha at 2018-11-24 09:03:18:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors will be looking for some soothing signs of global cooperation next week a… read more...

SunTrust: Venclexta could add $1B+ for AbbVie

via: SeekingAlpha at 2018-11-23 11:04:07:000

SunTrust says the FDA's new approval of AbbVie's ( ABBV +0.2% )Venclexta could add $1B+ in peak annual sales. More news on: AbbVie Inc., Pfizer Inc., Healthcare stocks news, Read more … read more...

Venclexta gets accelerated approval for newly-diagnosed AML

via: SeekingAlpha at 2018-11-21 14:55:45:000

Genentech ( OTCQX:RHHBY ) announces that the FDA granted accelerated approval to Venclexta in combination with hypomethylating agentor low-dose cytarabine for newly-diagnosed acute myeloid leukemia(ages 75+) orhose ineligible for intensive induction chemotherapy. Mo… read more...

Venclexta gets accelerated approval for newly-diagnosed AML

via: SeekingAlpha at 2018-11-21 14:55:45:000

Genentech ( OTCQX:RHHBY ) announces that the FDA granted accelerated approval to Venclexta in combination with hypomethylating agentor low-dose cytarabine for newly-diagnosed acute myeloid leukemia(ages 75+) orhose ineligible for intensive induction chemotherapy. Mo… read more...

AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

via: PR Newswire at 2018-11-21 14:14:00:000

NORTH CHICAGO, Ill. , Nov. 21, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VENCLEXTA (venetoclax tablets) in combination with … read more...

AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

via: PR Newswire at 2018-11-21 14:14:00:000

NORTH CHICAGO, Ill. , Nov. 21, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VENCLEXTA (venetoclax tablets) in combination with … read more...

How I Filter And Screen To Find The Best Stocks

via: SeekingAlpha at 2018-11-20 13:17:49:000

Introduction Most of my articles involve analysis of a company or two. I usually offer my readers an analysis of a specific company from a specific sector. Sometimes I offer a comparison between two similar companies, as I try to offer my insights about both, and which one of them is mo… read more...

Top Holdings Of Dividend ETFs (Part 1: The Top 50)

via: SeekingAlpha at 2018-11-20 10:30:19:000

From time to time, I compile a virtual portfolio of the top holdings of Dividend ETFs. I find the exercise insightful and certainly worth the effort. Comparing my portfolio to the virtual portfolio is informative, as it helps me to identify candidate stocks for analysis and possible investment… read more...

AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition

via: PR Newswire at 2018-11-20 08:32:00:000

NORTH CHICAGO, Ill. , Nov. 20, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that data from nearly 40 abstracts, including 13 oral presentations and more than 20 poster presentations, will be presented during the upcoming… read more...

Dividend Sensei's Portfolio Update 60: 2 Amazing Investing Opportunities I Bought This Week

via: SeekingAlpha at 2018-11-20 01:43:11:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. … read more...

Biotech Analysis Central Pharma News: AstraZeneca's Setback, AbbVie's Success, Arena's Cash Influx

via: SeekingAlpha at 2018-11-19 17:22:12:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. AstraZeneca Suffers Setback With Late-Stage MYSTIC Trial News: Recently, AstraZeneca ( AZN ) announced that it had failed its late-stage study know… read more...

DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-19 11:41:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934… read more...

Recent Stock Purchase November 2018

via: SeekingAlpha at 2018-11-17 13:40:18:000

Volatility behind us? Not a chance. Looks like November is picking up right where October left off. Of course, being a dividend growth investor means we have an opportunity to take advantage of all this volatility and pick up some traditional, solid paying dividend payers on sale. These days t… read more...

Recent Stock Purchase November 2018

via: SeekingAlpha at 2018-11-17 13:40:18:000

Volatility behind us? Not a chance. Looks like November is picking up right where October left off. Of course, being a dividend growth investor means we have an opportunity to take advantage of all this volatility and pick up some traditional, solid paying dividend payers on sale. These days t… read more...

5% Income Strategy For 2019 And Beyond

via: SeekingAlpha at 2018-11-17 09:00:00:000

The stock market had a 10% correction last month, and it has been stuck in a narrow range since then. The battle between the bulls and bears is not over yet, and the future direction of the market remains unclear. The risks are elevated due to concerns about future earnings growth, stretched v… read more...

5% Income Strategy For 2019 And Beyond

via: SeekingAlpha at 2018-11-17 09:00:00:000

The stock market had a 10% correction last month, and it has been stuck in a narrow range since then. The battle between the bulls and bears is not over yet, and the future direction of the market remains unclear. The risks are elevated due to concerns about future earnings growth, stretched v… read more...

CytomX' Translational Data On CX-072 Point Towards A Positive Readout From CX-2009

via: SeekingAlpha at 2018-11-15 10:17:24:000

Introduction Since first covering CytomX ( CTMX ) back in January , the company's stock has been on a wild ride while the company has made significant strides towards the validation of its game-changing 'probody' platform: Annotated 1-year chart created by the author. In my init… read more...

CytomX' Translational Data On CX-072 Point Towards A Positive Readout From CX-2009

via: SeekingAlpha at 2018-11-15 10:17:24:000

Introduction Since first covering CytomX ( CTMX ) back in January , the company's stock has been on a wild ride while the company has made significant strides towards the validation of its game-changing 'probody' platform: Annotated 1-year chart created by the author. In my init… read more...

Biotech Giant Should Deliver Mid-Teens Total Returns

via: SeekingAlpha at 2018-11-15 09:30:48:000

Thesis AbbVie ( ABBV ) has turned into one of the most profitable biotech companies in the world. Unlike many of its peers, AbbVie is focused on sharing its profits with investors via dividend payments. AbbVie offers a high dividend yield, generous dividend increases, and its dividend look… read more...

Biotech Giant Should Deliver Mid-Teens Total Returns

via: SeekingAlpha at 2018-11-15 09:30:48:000

Thesis AbbVie ( ABBV ) has turned into one of the most profitable biotech companies in the world. Unlike many of its peers, AbbVie is focused on sharing its profits with investors via dividend payments. AbbVie offers a high dividend yield, generous dividend increases, and its dividend look… read more...

AbbVie teams up with Mission Therapeutics in Alzheimer's and Parkinson's

via: SeekingAlpha at 2018-11-15 07:34:35:000

AbbVie (NYSE: ABBV ) inks a collaboration agreement with Mission Therapeutics aimed at developing deubiquitylating enzymes (DUBs) for the potential treatment of Alzheimer's disease and Parkinson's disease. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

AbbVie teams up with Mission Therapeutics in Alzheimer's and Parkinson's

via: SeekingAlpha at 2018-11-15 07:34:35:000

AbbVie (NYSE: ABBV ) inks a collaboration agreement with Mission Therapeutics aimed at developing deubiquitylating enzymes (DUBs) for the potential treatment of Alzheimer's disease and Parkinson's disease. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

AbbVie's elagolix successful in late-stage uterine fibroid studies

via: SeekingAlpha at 2018-11-15 07:13:06:000

AbbVie (NYSE: ABBV ) and collaboration partner Neurocrine Biosciences (NASDAQ: NBIX ) announce positive results from two Phase 3 clinical trials, ELARIS UF-1 and ELARIS UF-2, evaluating elagolix in women with uterine fibroids. The data were presented at the American Association of Gynecolo… read more...

AbbVie's elagolix successful in late-stage uterine fibroid studies

via: SeekingAlpha at 2018-11-15 07:13:06:000

AbbVie (NYSE: ABBV ) and collaboration partner Neurocrine Biosciences (NASDAQ: NBIX ) announce positive results from two Phase 3 clinical trials, ELARIS UF-1 and ELARIS UF-2, evaluating elagolix in women with uterine fibroids. The data were presented at the American Association of Gynecolo… read more...

AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress

via: PR Newswire at 2018-11-14 17:35:00:000

NORTH CHICAGO, Ill. , Nov. 14, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today presented for the first time additional results from two replicate pivotal Phase 3 clinical tr… read more...

Biotech Bio Series #4: Regeneron Is Not Done

via: SeekingAlpha at 2018-11-14 09:30:03:000

This is the fourth article of the Biotech Bio Series. Big pharma and biotechnology is one of the most exciting sectors in the world today, researching and developing drugs that allow all of us to live longer than ever before. For companies behind this innovation, the approval of one drug may c… read more...

ABBV Is An Even Bigger Buy After The Midterms

via: SeekingAlpha at 2018-11-14 09:00:00:000

Investment Thesis Now that the midterm election is in the rearview mirror, for the most part, investors do not have the uncertainty of who will control Congress hanging over their heads. A lot of industries were watching the results of the elections very closely, drug makers being one of the… read more...

Road To Financial Independence: Growing Dividends, Endless Opportunities But Limited Capital

via: SeekingAlpha at 2018-11-14 08:50:00:000

October was another really intense month as ongoing trade woes, a hawkish interest rate environment and purely black-and-white earnings season mixed a toxic cocktail for most of the stocks. At times with the markets slipping into 10% correction mode the selling into the close was extreme and… read more...

Regeneron: More Downside Ahead

via: SeekingAlpha at 2018-11-14 05:07:06:000

When I last asked if Regeneron ( REGN ) would trade at or above the $400 level back on August 22, the bullish call was hardly going out on a limb. The stock went on to top out at around $400-$410 three times. By late-October, momentum for this wonderfully run firm ran out of steam. The s… read more...

Dividend Sensei's Portfolio Update 59: How To Profit From Buffett's Most Important 'Secret To Success'

via: SeekingAlpha at 2018-11-13 23:14:12:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Th… read more...

AbbVie's MAVYRET(TM) (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

via: PR Newswire at 2018-11-13 11:30:00:000

NORTH CHICAGO, Ill. , Nov. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data for its pan-genotypic chronic hepatitis C virus (HCV) treatment, MAVYRET (glecaprevir/pibrentasvir), in treatment-nave patient… read more...

Express Scripts launches new formulary aimed at reducing drug costs

via: SeekingAlpha at 2018-11-13 09:43:56:000

Express Scripts (NASDAQ: ESRX ) introduces its National Preferred Flex Formulary covering more than 3,800 branded and generic medicines. More news on: Express Scripts, Inc., Bausch Health Companies Inc., Roche Holding Ltd ADR, Healthcare stocks news, Read more … read more...

AbbVie to Present at the Evercore ISI Conference

via: PR Newswire at 2018-11-13 08:00:00:000

NORTH CHICAGO, Ill. , Nov. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Evercore ISI HealthConX Conference onTuesday, November 27, 2018. Bill Chase , executive vice president, finance and administration, wi… read more...

A Red Scary October For The Rose Portfolio Of 94 Holdings For Value, Yet Dividend Income Was Up 43.5% From 2017

via: SeekingAlpha at 2018-11-12 15:10:50:000

Scary red October was not so bad as I have goals and a plan for The Rose portfolio of 94 holdings that I would like to share. Portfolio Goals or Plans 1. Make investing easy with quality For common stock, I enjoy owning those with an Investment Grade or "IG" rating. If they are a div… read more...

Tracking Yacktman Asset Management Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-10 11:36:08:000

This article is part of a series that provides an ongoing analysis of the changes made to Yacktmans 13F stock portfolio on a quarterly basis. It is based on Yacktman Asset Managements regulatory 13F Form filed on 11/08/2018. Please visit our Tracking Yacktman Asset Managemen… read more...

Tracking Yacktman Asset Management Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-10 11:36:08:000

This article is part of a series that provides an ongoing analysis of the changes made to Yacktmans 13F stock portfolio on a quarterly basis. It is based on Yacktman Asset Managements regulatory 13F Form filed on 11/08/2018. Please visit our Tracking Yacktman Asset Managemen… read more...

Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors of Ongoing Investigation of AbbVie's Humira Sales Practices

via: PR Newswire at 2018-11-09 18:24:00:000

SAN FRANCISCO , Nov. 9, 2018 /PRNewswire/ --Hagens Berman Sobol Shapiro LLP reminds investors in AbbVie Inc. (NYSE: ABBV) of the Firm's ongoing investigation of AbbVie's Humira sales practices. If you purchased or otherwise acquired AbbVie securities between October 25, 2013… read more...

CytomX: A Growth Stock Trading At A Bargain

via: SeekingAlpha at 2018-11-09 09:12:19:000

We all are learning, modifying, or destroying ideas all the time. Rapid destruction of your ideas when the time is right is one of the most valuable qualities you can acquire. You must force yourself to consider arguments on the other side. - Charlie Munger In our continuous search for bar… read more...

AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape in the United States Using Comprehensive Dataset

via: PR Newswire at 2018-11-09 08:00:00:000

NORTH CHICAGO, Ill. , Nov. 9, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data from two studies that assessed HCV screening and diagnosis practices and linkage to care in the United States (US) at The … read more...

10 'Safer' Dividend Champions, Contenders, And Challengers To Gain 24.2% To 64.7% By November 2019

via: SeekingAlpha at 2018-11-08 17:38:46:000

Actionable Conclusions (1-10): Brokers Say Ten WallStar CCC 'Safer' Dividend Stocks Could Net 24.22% to 64.68% Gains To November 2019 Two top yield "safer" dividend CCC dogs (tinted gray in the chart above) were among these top ten gainers for the coming year based on analyst one-year targ… read more...

AbbVie Delivers A Solid Beat And Raise Quarter

via: SeekingAlpha at 2018-11-08 12:22:22:000

AbbVie ( ABBV ) delivered a strong quarter producing financial results that exceeded street expectations. Revenues grew 19% and earnings per share soared 52%. Global net revenues were $8.236 billion in the 3rd quarter which increased 19% excluding a 0.7% unfavorable foreign exchange impact. … read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline - ABBV

via: PR Newswire at 2018-11-07 17:54:00:000

NEW YORK , Nov. 7, 2018 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) and certain of its officers. The class action, filed in United States District Court, Northern D… read more...

AbbVie sues Britain's NHS over HCV eradication plan

via: SeekingAlpha at 2018-11-07 13:26:15:000

Apparent rancor over the drug procurement process has prompted AbbVie ( ABBV +3.4% ) to sue England's National Health Service (NHS)over its plan to rid the country of hepatitis C virus (HCV) infections by 2025. More news on: AbbVie Inc., Healthcare stocks news, Read more … ... read more...

BeiGene launches comparative study of BTK inhibitors in blood cancers

via: SeekingAlpha at 2018-11-07 10:02:09:000

BeiGene ( BGNE -3.1% ) commences a global Phase 3 head-to-head clinical trial evaluating its BTK inhibitor zanubrutinib against AbbVie's ( ABBV +2.7% ) IMBRUVICA (ibrutinib) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). M… read more...

5 Reasons Why This 5.2% Yielding Dividend Aristocrat Is Now My Biggest Holding

via: SeekingAlpha at 2018-11-06 17:56:05:000

(Source: imgflip ) I'm a contrarian value investor whose high-yield income growth retirement portfolio is focused on three things: maximum safe yield (5+%) double-digit long-term dividend growth buying stocks at extremely undervalued levels (high margin of safety, the average st… read more...

Dividend Sensei's Portfolio Update 58: Bull Markets Make You Money, Bear Markets Make You Rich

via: SeekingAlpha at 2018-11-06 17:19:40:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Th… read more...

AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Momenta

via: PR Newswire at 2018-11-06 16:45:00:000

NORTH CHICAGO, Ill. , Nov. 6, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV) announced today patent license agreements with Momenta over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Momenta a non-exclusive license on specified dates to Ab… read more...

Dividend Increases: October 29-November 2, 2018

via: SeekingAlpha at 2018-11-06 13:11:38:000

One way to identify dividend growth stocks for further analysis is to monitor dividend increases. Companies that regularly increase their dividends show confidence in future earnings growth potential. The CCC List provides a good starting point, but I limit the number of stocks to monitor … read more...

Healthcare And Biotechnology Dashboard - Update

via: SeekingAlpha at 2018-11-06 11:32:19:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued regarding historical averages, but profitability measu… read more...

Analysts offer different views on AbbVie as shares recoup losses from Friday's reversal, up 4%

via: SeekingAlpha at 2018-11-05 13:26:55:000

AbbVie ( ABBV +4.4% ) is up, albeit on below-average volume, as shares recoup a good chunk of Friday's bearish reversal of almost 6% from the intraday high of $84.42 as investors digest the company's prospects after its Q3 earnings call and the potential encroachment of biosimi… read more...

November 2018 Stock Considerations

via: SeekingAlpha at 2018-11-03 15:59:33:000

As the calendar shows November, it is time, once again, to highlight some of my potential stock buys for the upcoming month. Are we having fun yet? Are any of you making sense of the market these days? I can honestly tell you that I have zero idea about what's going on and where we'll be in … read more...

November 2018 Stock Considerations

via: SeekingAlpha at 2018-11-03 15:59:33:000

As the calendar shows November, it is time, once again, to highlight some of my potential stock buys for the upcoming month. Are we having fun yet? Are any of you making sense of the market these days? I can honestly tell you that I have zero idea about what's going on and where we'll be in … read more...

Street Fighting Man: Buying More AbbVie

via: SeekingAlpha at 2018-11-02 16:50:44:000

AbbVie's beat and raise The large biotech AbbVie ( ABBV ) reported a beat-and-raise Q3 pre-market Friday. These were the lead bullet points in its press release: Reports Third-Quarter Diluted EPS of $1.81 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 51.8 Percent … read more...

AbbVie (ABBV) Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-02 12:22:23:000

AbbVie, Inc. (ABBV) Q3 2018 Earnings Call November 02, 2018 9:00 am ET Executives Elizabeth Shea - AbbVie, Inc. Richard A. Gonzalez - AbbVie, Inc. Michael E. Severino - AbbVie, Inc. William J. Chase - AbbVie, Inc. Analysts Steve Scala - Cowen & Co. LLC Jason M. Gerb… read more...

5%+ Dividend Yield Portfolio: Playing Offense, Not Running Scared (October 2018 Review)

via: SeekingAlpha at 2018-11-02 08:55:34:000

Outlook Well that was unpleasant, says basically any market participant of October 2018. With all major markets in/flirting with correction territory, there was no place to hide from a decline. However, not all declines were of equal magnitude as a 2X4 was taken to the fo… read more...

AbbVie Q3 revenues up 18%; non-GAAP EPS up 55%; raises non-GAAP EPS guidance

via: SeekingAlpha at 2018-11-02 08:26:04:000

AbbVie ( ABBV ) Q3 results: Revenues: $8,236M (+17.7%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

AbbVie beats by $0.13, beats on revenue

via: SeekingAlpha at 2018-11-02 07:48:15:000

AbbVie (NYSE: ABBV ): Q3 Non-GAAP EPS of $2.14 beats by $0.13 ; GAAP EPS of $1.81 beats by $0.06 . More news on: AbbVie Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

Economy Is Cooling - Cramer's Mad Money (11/1/18)

via: SeekingAlpha at 2018-11-02 07:47:15:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , November 1. President's softening stance on China and Fed not raising rates are the two events the market wants. That's what happened on Thursday when Trump tweeted China and the U.S. had their … read more...

AbbVie Reports Third-Quarter 2018 Financial Results

via: PR Newswire at 2018-11-02 07:47:00:000

NORTH CHICAGO,Ill., Nov.2, 2018 /PRNewswire/ --AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September30, 2018. "We delivered another exceptional quarter, with results well ahead of our expectations, including operational revenue growth … read more...

Notable earnings before Friday's open

via: SeekingAlpha at 2018-11-01 17:30:12:000

ABBV , ABR , ASIX , AXL , BABA , BPL , CBOE , CCJ , CNK , CVX , DOC , DUK , EAF , ENB , EXTR , FTS , HMSY , HRC , IMGN , IMO , ITT , MOG.A , MSGN , NPTN , NWL , RLGY , ROLL , RUTH , STX , TDS , TGH , TRTN , TWI , USM , VG , VST , WLTW , WPC , XOM F… read more...

TG Therapeutics up 7% on positive umbralisib + ublituximab data

via: SeekingAlpha at 2018-11-01 11:04:18:000

TG Therapeutics ( TGTX +6.9% ) is up on light volume following its announcement of updated data on PI3K delta inhibitor umbralisib and anti-CD20 monoclonal antibody ublituximab (doublet therapy called "U2"). The results will be presented at ASH in San Diego December 2-3. More news on: … read more...

Jane's September Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-11-01 09:59:36:000

Investment Thesis September marks the seventh month that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Jane's retirement account from February 1st to August 31st of 2018 have demonstrated the following income characterist… read more...

FDA OKs genetic test to inform on drug metabolism

via: SeekingAlpha at 2018-11-01 09:33:04:000

The FDA approves a consumer-targeted molecular diagnostic test from privately held 23andme , the Personal Genome Service Pharmacogenetic Reports, that detects 33 variants for multiple genes from a saliva sample. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnolog… read more...

AbbVie's venetoclax successful in late-stage study in first-line CLL

via: SeekingAlpha at 2018-11-01 07:43:26:000

A Phase 3 clinical trial, CLL14, evaluating AbbVie's (NYSE: ABBV ) venetoclax plus development partner Roche's ( OTCQX:RHHBY ) Gazyva (obinutuzumab) compared to Gazyva plus chlorambucil in treatment-naive patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions me… read more...

AbbVie's Venclyxto OK'd in Europe for treatment-resistant CLL

via: SeekingAlpha at 2018-11-01 07:18:17:000

The European Commission approves AbbVie's (NYSE: ABBV ) VENCLYXTO (venetoclax), combined with Roche's ( OTCQX:RHHBY ) Rituxan (rituximab), for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who have received at least one prior line of therapy. More … read more...

AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy

via: PR Newswire at 2018-11-01 00:02:00:000

NORTH CHICAGO, Ill. , Nov. 1,2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the European Commission (EC) has approved the type-II variation application forVENCLYXTO (venetoclax) in combination with rituxi… read more...

AbbVie Announces Positive Results from CLL14, a Phase 3 Trial Evaluating a Venetoclax Combination as First-Line Therapy with a Fixed Duration of Treatment in Patients with Chronic Lymphocytic Leukemia

via: PR Newswire at 2018-10-31 16:14:00:000

NORTH CHICAGO, Ill. , Oct. 31, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive results from CLL14, a Phase 3, randomized clinical trial evaluating venetoclax plus obinutuzumab versus obinutuzumab plus chlorambucil, a st… read more...

AbbVie down 4% on Humira price cut in Europe

via: SeekingAlpha at 2018-10-31 15:35:35:000

AbbVie ( ABBV -3.9% ) slips on more than 60% higher volume in what would be a reasonable reaction by investors following the FDA nod for Novartis' Humira biosimilar Myrimoz. More news on: AbbVie Inc., Amgen Inc., Biogen Inc., Healthcare stocks news, Stocks on the move, Read more … ... read more...

DivGro Pulse: October 2018

via: SeekingAlpha at 2018-10-31 08:00:58:000

DivGro is my portfolio of dividend growth stocks and I write monthly pulse articles that monitor DivGro's health. These articles are strategy-focused and my overall aim is to reduce portfolio risk and to further diversify my holdings. In the third quarter of 2018, I focused specifically on s… read more...

52 Of 95 S&P 500 'Safer' Dividend Stocks Yield 3.26% To 6.67% To October 2019

via: SeekingAlpha at 2018-10-30 20:15:23:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten 'Safer' Dividend S&P 500 Stocks Could Net 27.99% to 48.7% Gains By October 2019 Three of the ten tops-by-yield 'safer' Dividend S&P 500 (tinted in the chart above) were among the top ten gainers for the coming year based o… read more...

Your 50 Top S&P 500 Stocks For Yield, Gains And Upside For October

via: SeekingAlpha at 2018-10-30 07:33:52:000

Actionable Conclusions (1-10): Analysts Estimated 27.99% To 41.8% Net Gains For Ten S&P 500 Dogs To October 2019 Two of ten top S&P 500 dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in t… read more...

Dividend Sensei's Portfolio Update 57: The 11 Stocks I'm Buying During This Correction

via: SeekingAlpha at 2018-10-29 22:45:27:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Th… read more...

'Safer' Dividend Aristocrats Offer 20.7%-35.85% October Gains Per One Year Broker Targets

via: SeekingAlpha at 2018-10-29 18:38:28:000

Actionable Conclusions (1-10): Brokers Expect Top Ten 'Safer' Dividend Aristocrats to Net 20.7% to 35.85% Gains To October, 2019 Three of ten biggest yield "safer" Dividend Aristocrats (tinted in the chart above) showed up in the Top ten gainers for the coming year based on analyst 1 year … read more...

AbbVie: The Humira Company Is Growing Up

via: SeekingAlpha at 2018-10-29 15:39:07:000

There are two responses that are common when a solid stock market performer starts to falter; timid souls look for exits; others evaluate whether opportunity is brewing. AbbVie's ( ABBV ) recent fall from grace presents a case in point. I was fortunate enough to hold a modest position in Abb… read more...

10 Dividend Aristocrats Cast 17%-34% Net Gains Per October Broker Targets

via: SeekingAlpha at 2018-10-29 14:30:51:000

Actionable Conclusions (1-10): Analysts Predicted 17.3% To 34.4% Net Gains To October 2019 Five of the 10 top Aristocrats by yield were verified as being among the top 10 gainers for the coming year based on analyst one-year target prices. (They are tinted gray in the chart above). Thus,… read more...

This Is Another Great Medical Devices Company To Consider

via: SeekingAlpha at 2018-10-29 11:33:07:000

Introduction In a previous article, I analyzed Becton, Dickinson and Company ( BDX ) and Medtronic ( MDT ). I found them to be great companies which are also dividend aristocrats. In the current article, I am going to analyze and try to see whether Abbott Laboratories ( ABT ) is a more attra… read more...

ViiV Healthcare's cabotegravir and rilpivirine regimen shows durable treatment effect in mid-stage HIV study

via: SeekingAlpha at 2018-10-29 07:27:12:000

Three-year data from a Phase 2b clinical trial, LATTE-2 , evaluating ViiV Healthcare's injectable two-drug regimen of cabotegravir and rilpivirine in HIV patients showed a durable treatment effect. The results were presented at the HIV Glasgow Drug Therapy meeting in Scotland. More new… read more...

This Is A Great Time To Build A Dividend Portfolio

via: SeekingAlpha at 2018-10-29 06:56:47:000

A year ago, I expected to begin taking distributions from my IRA in early 2018 to coincide with leaving my "day job." Due to a 6-month delay in this transition (and partly due to a simple lifestyle), distributions from my IRA have been postponed until sometime in 2019, perhaps beginning in Jan… read more...

Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-10-28 09:11:09:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for… read more...

Recent Stock Purchase II October 2018

via: SeekingAlpha at 2018-10-27 14:36:34:000

Are you enjoying October yet? Markets rocket higher only to drop the next day. The Dow swinging by hundreds of points seemingly on a whim without any justification. The talking heads speak of all the market troubles on down days and are surprisingly positive and jubilant on up days. What gives… read more...

Apple Looks To Recharge Tech Sector

via: SeekingAlpha at 2018-10-27 08:44:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are being put to the rest with major indexes now down sharply on the year… read more...

5 Safe Dividend Stocks To Invest - October 2018 (Retirement Series)

via: SeekingAlpha at 2018-10-27 08:15:00:000

Recently, the markets have been volatile and are down significantly from their all-time highs. However, they are not in the correction territory, at least as yet. We do not know if the current turmoil will develop into a full-blown correction or is it just a temporary blip on the market&#x2019… read more...

Abbott and AbbVie to pay $25M to settle TriCor case

via: SeekingAlpha at 2018-10-26 16:42:10:000

Reuters reports that Abbott (NYSE: ABT ) and AbbVie (NYSE: ABBV ) have agreed to pay a total of $25M to settle a whistleblower lawsuit accusing the companies of an alleged kickback scheme to doctors aimed at driving prescriptions for cholesterol med TriCor (fenofibrate) and for allegedly p… read more...

Trump mulling tieing U.S. drug prices to Europe's

via: SeekingAlpha at 2018-10-26 08:08:52:000

U.S. drug makers are facing a down day today after President Trump announced his first potential tactic aimed at lowering drug prices. Specifically, he is exploring benchmarking Medicare reimbursement to the average price in Europe for drugs administered by doctors, a group of medicines do… read more...

More Revenue Declines For Gilead?

via: SeekingAlpha at 2018-10-25 13:59:11:000

Gilead ( GILD ) reports Q3 earnings after-hours. Analysts expect revenue of $5.38 billion and EPS of $1.63. The revenue estimate implies a 4% decline sequentially. Investors should focus on the following key items: It's All About The HIV Franchise… Gilead's HCV regimen has been transfo... read more...

Proteostasis up 12% premarket following Galapagos CF data

via: SeekingAlpha at 2018-10-25 08:13:36:000

Proteostasis Therapeutics (NYSE: PTI ) is up 12% premarket on light volume in apparent reaction to the release of preliminary data from a Phase 1b clinical trial, FALCON , evaluating Galapagos NV's (NASDAQ: GLPG ) triplet therapy for cystic fibrosis (CF), GLPG2451, GLPG2222 an… read more...

AbbVie to take over cystic fibrosis program from Galapagos

via: SeekingAlpha at 2018-10-25 06:56:49:000

AbbVie (NYSE: ABBV ) will assume full development and commercial responsibility for the cystic fibrosis (CF) program from collaboration partner Galapagos (NASDAQ: GLPG ). More news on: AbbVie Inc., Galapagos, Vertex Pharmaceuticals Incorporated, Healthcare stocks news, Read more … ... read more...

AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program

via: PR Newswire at 2018-10-24 16:09:00:000

NORTH CHICAGO, Ill. , Oct. 24, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that it will assume full development and commercial responsibility for its collaboration with Galapagos (Euronext: GLPG) to discover and develop new … read more...

Biogen: Examining The Upside Potential

via: SeekingAlpha at 2018-10-24 10:58:38:000

Biogen ( BIIB ) reports Q3 I'd like to make a few comments about BIIB's Q3 results, its pipeline, and how its valuation ties into a theme I've noticed about biotechs the past few years since their fall from grace. All relevant links are BIIB's earnings report, slides and conference call can … read more...

Trump signs STOP Act aimed at opioid crisis

via: SeekingAlpha at 2018-10-24 09:24:12:000

President Trump signs the STOP Act today, sweeping bipartisan legislation aimed at addressing the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

ABBVIE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In AbbVie, Inc. To Contact The Firm

via: Business Wire at 2018-10-23 16:07:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AbbVie, Inc. (AbbVie or the Company) (NYSE:ABBV) of the November 20, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been file… read more...

AbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data

via: PR Newswire at 2018-10-23 09:00:00:000

NORTH CHICAGO, Ill. , Oct. 23, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from the ongoing Phase 3 SELECT-MONOTHERAPY trial evaluating upadacitinib (15 mg and 30 mg, once-daily), an invest… read more...

Dividend Sensei's Portfolio Update 56: The Smart Way To Win A $1.6-Billion Jackpot

via: SeekingAlpha at 2018-10-22 23:48:20:000

(Source: Imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watchlists. This is to avoid excessively long articles and maximize the utility to my readers. Thi… read more...

Positive Phase 2b Data for AbbVie's Upadacitinib Show Significant Induction of Clinical Remission and Response in Patients with Ulcerative Colitis

via: PR Newswire at 2018-10-22 18:01:00:000

NORTH CHICAGO, Ill. , Oct. 22, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b /3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor… read more...

Why The Market Is Likely To Rally Soon And 4 High-Yield Stocks To Buy Before It Does

via: SeekingAlpha at 2018-10-22 10:27:19:000

(Source: imgflip ) It's been a rough October so far for the stock market. The S&P 500 ( SPY ), Dow Jones Industrial Average ( DIA ), and Nasdaq are all off significantly, at least from the perspective of many fearful investors. SPY data by YCharts Some investors are worried th… read more...

AbbVie, Inc.: A Great Dividend Growth Stock On Sale

via: SeekingAlpha at 2018-10-22 09:00:00:000

Investment Thesis AbbVie, Inc. ( ABBV ) sells the worlds best-selling drug Humira. According to EvaluatePharma, Humira sales will not be topped until 2024, when U.S. biosimilars will begin to emerge. We have had our doubts about the company being a one trick pony, in fear they would … read more...

Baby DivHut Dividend Income Portfolio Update Q3 2018

via: SeekingAlpha at 2018-10-22 06:55:41:000

With nine months of the year already behind us, it is time for me to highlight baby DivHut's quarterly dividend income/portfolio progress. Generally speaking, there is not much change in his portfolio on a month-to-month basis as fresh capital is not always available to make trades for him. … read more...

Dividend Growth Portfolio 2018 Q2/Q3 Update

via: SeekingAlpha at 2018-10-19 18:24:21:000

Q2/Q3 Review My apologies for not publishing a Q2 review. Time was in short supply this summer between a new job and some vacations. The good news is the DGTR portfolio continued its solid performance in both quarters, delivering a 4.01% Q2 return and a 7.87% Q3 return, exceeding the S&amp… read more...

Dividend Growth Portfolio 2018 Q2/Q3 Update

via: SeekingAlpha at 2018-10-19 18:24:21:000

Q2/Q3 Review My apologies for not publishing a Q2 review. Time was in short supply this summer between a new job and some vacations. The good news is the DGTR portfolio continued its solid performance in both quarters, delivering a 4.01% Q2 return and a 7.87% Q3 return, exceeding the S&amp… read more...

Dividend Growth Portfolio 2018 Q2/Q3 Update

via: SeekingAlpha at 2018-10-19 18:24:21:000

Q2/Q3 Review My apologies for not publishing a Q2 review. Time was in short supply this summer between a new job and some vacations. The good news is the DGTR portfolio continued its solid performance in both quarters, delivering a 4.01% Q2 return and a 7.87% Q3 return, exceeding the S&amp… read more...

Value Or Growth? Both!

via: SeekingAlpha at 2018-10-19 11:57:30:000

Value investing is not just about buying stocks with low valuation metrics, that's a too simplistic and myopic approach. The true essence of value investing is buying a company for a market price below the intrinsic value of the business. All else the same, a business with superior growth ra… read more...

Value Or Growth? Both!

via: SeekingAlpha at 2018-10-19 11:57:30:000

Value investing is not just about buying stocks with low valuation metrics, that's a too simplistic and myopic approach. The true essence of value investing is buying a company for a market price below the intrinsic value of the business. All else the same, a business with superior growth ra… read more...

Value Or Growth? Both!

via: SeekingAlpha at 2018-10-19 11:57:30:000

Value investing is not just about buying stocks with low valuation metrics, that's a too simplistic and myopic approach. The true essence of value investing is buying a company for a market price below the intrinsic value of the business. All else the same, a business with superior growth ra… read more...

AbbVie's CFO William J. Chase plans to retire

via: SeekingAlpha at 2018-10-19 09:35:17:000

AbbVie (NYSE: ABBV ) announces that William J. Chase, Executive VP, Chief Financial Officer (CFO) plans to retire from the company in mid-2019. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

AbbVie's CFO William J. Chase plans to retire

via: SeekingAlpha at 2018-10-19 09:35:17:000

AbbVie (NYSE: ABBV ) announces that William J. Chase, Executive VP, Chief Financial Officer (CFO) plans to retire from the company in mid-2019. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

AbbVie's CFO William J. Chase plans to retire

via: SeekingAlpha at 2018-10-19 09:35:17:000

AbbVie (NYSE: ABBV ) announces that William J. Chase, Executive VP, Chief Financial Officer (CFO) plans to retire from the company in mid-2019. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

Gamida IPO: Phase 3 Of Development

via: SeekingAlpha at 2018-10-18 15:23:15:000

With an expected enterprise value of $185 million, Gamida (GMDA) does not seem undervalued as compared to other peers with similar size. With that, the company could represent an opportunity. There are relevant institutional investors inside. The target market is expected to represent $37.61… read more...

AbbVie settles Humira patent dispute with Fresenius Kabi

via: SeekingAlpha at 2018-10-18 09:27:56:000

AbbVie (NYSE: ABBV ) has resolved all IP-related litigation with Fresenius Kabi related to its proposed biosimilar to top seller HUMIRA (adalimumab), granting it a non-exclusive license beginning on September 30, 2023. ABBV will earn undisclosed royalties on net sales of Kabi's offering. … read more...

AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Fresenius Kabi

via: PR Newswire at 2018-10-18 08:50:00:000

NORTH CHICAGO, Ill. , Oct. 18, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV) announced today global resolution of all intellectual property-related litigation with Fresenius Kabi over its proposed biosimilar adalimumab product. Under the terms of the settlement agreements, AbbVie will gra… read more...

AbbVie teams up with Morphic Therapeutic in fibrotic diseases

via: SeekingAlpha at 2018-10-18 08:23:21:000

AbbVie (NYSE: ABBV ) inks an R&D collaboration agreement with Morphic Therapeutic aimed at advancing the latter's oral integrin therapies for fibrosis-related disorders. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases

via: PR Newswire at 2018-10-18 08:00:00:000

NORTH CHICAGO, Ill. and WALTHAM, Mass. , Oct. 18, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Morphic Therapeutic, a biotechnology company developing oral integrin therapies, announced today that the companies have entered into a… read more...

Building A Dividend Growth Portfolio From Scratch: 15 'A' Rated Or Better Fairly Valued Opportunities

via: SeekingAlpha at 2018-10-17 23:27:00:000

Introduction We remain in one of the longest bull markets in history. Generally, with bull markets stocks tend to become highly valued. Additionally, we also continue to find ourselves in a low interest rate environment based on historical standards. However, after bottoming out in Janua… read more...

FDA accepts AbbVie's application for Imbruvica + Gazyva in certain blood cancers

via: SeekingAlpha at 2018-10-17 08:40:22:000

Under Priority Review status, the FDA accepts for review AbbVie's (NYSE: ABBV ) marketing application seeking approval for IMBRUVICA (ibrutinib), combined with Roche's ( OTCQX:RHHBY ) GAZYVA (obinutuzumab), in treatment-naive adult patients with chronic lymphocytic leukemia (CLL) or small … read more...

AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-10-17 08:00:00:000

NORTH CHICAGO, Ill. , Oct. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Priority Review for IMBRUVICA (ibru… read more...

The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AbbVie Inc. (ABBV)

via: Business Wire at 2018-10-16 19:26:00:000

Law Offices of Howard G. Smithreminds investors of the October 22, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) securities between&… read more...

It's Literally The Best Time Ever To Buy This High-Yield Blue Chip

via: SeekingAlpha at 2018-10-16 17:40:43:000

(Source: imgflip ) The three core strategies of my high-yield income growth retirement portfolio are: maximum safe yield (good dividend coverage, strong balance sheets, recession resistant business models) good long-term growth potential (clear growth runway long into the future) … read more...

Beat The Recession With Dividends - Part 3

via: SeekingAlpha at 2018-10-16 12:48:30:000

This is the third article of this series focusing solely on dividend income to beat a recession. While price may fall in a recession, dividends may rise. In the first article " Beat The Recession With Dividends ," I created three portfolios of safe high-yield dividend aristocrats with a combin… read more...

AbbVie Reinforces Leadership in Gastroenterology with New Data Showcasing Research Advancements Across Robust Portfolio at United European Gastroenterology (UEG) Week 2018

via: PR Newswire at 2018-10-16 12:38:00:000

NORTH CHICAGO, Ill. , Oct. 16, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present new data across investigational medicines and HUMIRA (adalimumab) at United European Gastroenterology (UEG) Week 2018 from O… read more...

The Cancer Stem Cell Saga

via: SeekingAlpha at 2018-10-16 10:08:10:000

In this 2015 post , I looked at the cancer stem cell field - the idea that some tumor types are kept going by a stem cell population, and that unless these are dealt with, no durable response to treatment can be expected. A number of pharma companies have looked into this idea, most famously … read more...

10 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targets And Dividends

via: SeekingAlpha at 2018-10-16 08:28:14:000

Actionable Conclusions (1-10): Brokers Forecast Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 12.36% to 23.08% Gains To October 2019 Five of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for t… read more...

FDA issues new guidance aimed at more efficient drug development

via: SeekingAlpha at 2018-10-15 13:49:33:000

The FDA has issued two guidance documents that it says should help make the drug development process more efficient. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund, Healthcare stocks news, News on ETFs, … read more...

Healthcare Stocks: Rally In Jeopardy?

via: SeekingAlpha at 2018-10-15 12:17:22:000

In recent sessions, downside volatility has taken the major stock benchmarks by storm. Many of the gains produced by the broader equities markets have been given back, and the S&P 500 is now showing a rise of only 3.5% on a YTD basis. The bearish activity has led to speculation that the un… read more...

12 Dividend Aristocrats In Bear Market

via: SeekingAlpha at 2018-10-15 10:00:00:000

With the recent drawdown in equity markets, I noted in The Hidden Bear Market that nearly one-third of the S&P 500 ( SPY ) was trading in a bear market. While that is a surprising fact with the broad equity market just 6% from its recent all-time high, what is likely more surprising is… read more...

Healthcare 16-24% Target Net Gains Pace WallStars For October

via: SeekingAlpha at 2018-10-15 09:57:51:000

Actionable Conclusions (1-10): Analysts Projected 16.2% To 23.9% Net Gains For Top 10 Healthcare WallStars By October 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker one-year target prices (… read more...

Retirement: How To Manage Risks And Prepare For The Next Downturn

via: SeekingAlpha at 2018-10-13 09:00:00:000

Let's say you already have a million dollar portfolio, mostly invested in the index funds. The bull market of the last 10 years has helped your portfolio tremendously due to the outperformance of the broad market indexes. It has been difficult for most people and strategies to beat the broad m… read more...

Retirement: How To Manage Risks And Prepare For The Next Downturn

via: SeekingAlpha at 2018-10-13 09:00:00:000

Let's say you already have a million dollar portfolio, mostly invested in the index funds. The bull market of the last 10 years has helped your portfolio tremendously due to the outperformance of the broad market indexes. It has been difficult for most people and strategies to beat the broad m… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-12 08:52:08:000

Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more … read more...

Stocks making the biggest move premarket: JPM, PNC, MSFT, EL, INTC & more

via: CNBC at 2018-10-12 07:38:00:000

No summary available. read more...

AbbVie settles Humira patent dispute with Sandoz; shares up 1% after hours

via: SeekingAlpha at 2018-10-11 16:59:06:000

AbbVie (NYSE: ABBV ) has settled its patent infringement litigation with Novartis (NYSE: NVS ) unit Sandoz related to top seller HUMIRA ( adalimumab). Under the terms of the deal, it will grant Sandoz a non-exclusive license effective on September 30, 2023 in the U.S. that will not be acce… read more...

AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Sandoz

via: PR Newswire at 2018-10-11 16:32:00:000

NORTH CHICAGO, Ill. , Oct. 11, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today a global resolution of all intellectual property-related litigation with Sandoz over its proposed biosimilar adalimumab product. Under the ter… read more...

John's August Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-10-09 10:32:02:000

Investment Thesis August marks the sixth month that I have been tracking John's retirement accounts in an article. I apologize to readers for the tardiness of this article and I am working to get September's series caught up by the end of the week. Since the beginning of January 2018, his po… read more...

John's August Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-10-09 10:32:02:000

Investment Thesis August marks the sixth month that I have been tracking John's retirement accounts in an article. I apologize to readers for the tardiness of this article and I am working to get September's series caught up by the end of the week. Since the beginning of January 2018, his po… read more...

Quarterly Review Of DivGro: Q3 2018

via: SeekingAlpha at 2018-10-09 06:34:46:000

Welcome to the Q3-2018 review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these reviews … read more...

Quarterly Review Of DivGro: Q3 2018

via: SeekingAlpha at 2018-10-09 06:34:46:000

Welcome to the Q3-2018 review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these reviews … read more...

Gilead Sciences: We're Not In Bull Territory Yet

via: SeekingAlpha at 2018-10-08 13:47:21:000

I agree with Gilead Sciences' ( GILD ) recent downgrade by Baird. The lack of clear financial catalysts for the next few quarters mean there is likely very little to move the stock price. There is a lot of chatter about the company's pipeline, but the monetary benefit isn't there yet. Furthe… read more...

Road To Financial Independence: Best September Ever, Investing Into Technology Stocks Amid Mounting Trade Woes

via: SeekingAlpha at 2018-10-08 13:43:24:000

The stock markets continued their strong momentum from August in September setting new records despite increasing concerns on a full-scale trade war, an appreciating U.S. dollar, rising commodity cost and interest rates rising further. While the broad market indices set new records select t… read more...

AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting

via: PR Newswire at 2018-10-08 08:33:00:000

NORTH CHICAGO, Ill. , Oct. 8, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data from multiple studies of upadacitinib, an investigational oral JAK1-selective inhibitor, and HUMIRA (adalimumab) at the 201… read more...

My Dividend Growth Portfolio - Q3 2018 Summary

via: SeekingAlpha at 2018-10-07 14:02:42:000

Introduction It's time to summarize another quarter. This quarter was another mediocre quarter for me. I have been lagging the S&P 500 this entire year, and this quarter was no different. The total return in Q3 was 1.2% lower than the S&P 500. While it's not my ultimate benchmark, I … read more...

Health Canada OKs AbbVie's elagolix for endometriosis-related pain

via: SeekingAlpha at 2018-10-06 14:20:06:000

AbbVie (NYSE: ABBV ) and licensor Neurocrine Biosciences (NASDAQ: NBIX ) announce that Health Canada has approved ORILISSA (elagolix) for the treatment of moderate-to-severe pain associated with endometriosis. More news on: AbbVie Inc., Neurocrine Biosciences, Inc., Healthcare stocks new… read more...

ABBV LOSS NOTICE: Rosen Law Firm Files First Securities Class Action Lawsuit against Abbvie Inc. - ABBV

via: Business Wire at 2018-10-06 12:00:00:000

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of AbbVie Inc. (NYSE: ABBV) from October 25, 2013 through September 18, 2018, inclusive (the Class Period). The lawsuit seeks to recover … read more...

Neurocrine: Time To Reduce?

via: SeekingAlpha at 2018-10-05 18:01:50:000

Company Background Neurocrine Biosciences ( NBIX ) is a company focused on neurological and endocrine diseases. The portfolio of products and candidates includes INGREZZA (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders which was ap… read more...

PII Dividend Growth Portfolio - 66 Holdings

via: SeekingAlpha at 2018-10-05 14:33:11:000

Editor's note: Seeking Alpha is proud to welcome Passive Income Investor as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more T… read more...

Q3 Portfolio Review

via: SeekingAlpha at 2018-10-05 06:57:18:000

The portfolio expanded from 30 equities to 49 This is the third quarter review of my retirement income portfolio. It was a very active quarter that included a final pension rollover to my IRA. About half of the rollover funds have been deployed. Some existing positions were trimmed to ta… read more...

Buy Clorox At $140 - Cramer's Lightning Round (10/3/18)

via: SeekingAlpha at 2018-10-04 06:54:44:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, October 3 . Bullish Calls Clorox (CLX): The stock will go down as interest rates keep going up. Buy it when it hits $140. New Relic (NEWR): The stock does not deserve to go down. Buy it in th… read more...

Cramer's lightning round: The sweet spot for buying shares of Clorox

via: CNBC at 2018-10-03 18:49:00:000

No summary available. read more...

The hidden dangers of testosterone replacement therapy you should know about

via: CNBC at 2018-10-03 09:26:00:000

No summary available. read more...

Healthcare And Biotechnology Dashboard - Update

via: SeekingAlpha at 2018-10-03 05:23:09:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued with regards to historical averages in 2 out of 3 valu… read more...

The Rose 96 Stock Portfolio Due Diligence Criteria Exposed Along With Some Value Buys

via: SeekingAlpha at 2018-10-02 14:32:12:000

First and foremost, my investing focus has been to build a portfolio of quality blue chip mostly defensive common stock for increased value creation and rising income for the future. The current investments in this portfolio also include RIC (regulated investment companies), high yield, ETFs a… read more...

5%+ Dividend Yield Portfolio: Ignore The Political Circus (Sep 2018 Review)

via: SeekingAlpha at 2018-10-02 13:49:58:000

Outlook If you mix your politics with your investment decisions, youre making a big mistake. - Warren Buffett Politics dominates the headlines these days (even in the financial press) and how could it not with the circus on display. However, allowing your political… read more...

FDA issues new draft guidance aimed at speedier generic approvals

via: SeekingAlpha at 2018-10-02 10:55:35:000

In a statement , FDA Commissioner Scott Gottlieb, M.D., outlines new draft guidance that he says should improve the process for reviewing generic drug marketing applications and boost competition in the prescription drugs market. More news on: ProShares Ultra Nasdaq Biotechnology ETF, T… read more...

RM LAW Announces Class Action Lawsuit Against AbbVie Inc.

via: PR Newswire at 2018-09-28 19:15:00:000

BERWYN, Pa. , Sept. 28, 2018 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) securities between October 25, 2013 through September 18, 2018 , inc… read more...

RM LAW Announces Class Action Lawsuit Against AbbVie Inc.

via: PR Newswire at 2018-09-28 19:15:00:000

BERWYN, Pa. , Sept. 28, 2018 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) securities between October 25, 2013 through September 18, 2018 , inc… read more...

RM LAW Announces Class Action Lawsuit Against AbbVie Inc.

via: PR Newswire at 2018-09-28 19:15:00:000

BERWYN, Pa. , Sept. 28, 2018 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) securities between October 25, 2013 through September 18, 2018 , inc… read more...

RM LAW Announces Class Action Lawsuit Against AbbVie Inc.

via: PR Newswire at 2018-09-28 19:15:00:000

BERWYN, Pa. , Sept. 28, 2018 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) securities between October 25, 2013 through September 18, 2018 , inc… read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AbbVie Inc. Investors

via: Business Wire at 2018-09-28 18:06:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) securities between October 25, 2013andSeptember 18, 2018 ,… read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AbbVie Inc. Investors

via: Business Wire at 2018-09-28 18:06:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) securities between October 25, 2013andSeptember 18, 2018 ,… read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AbbVie Inc. Investors

via: Business Wire at 2018-09-28 18:06:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) securities between October 25, 2013andSeptember 18, 2018 ,… read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AbbVie Inc. Investors

via: Business Wire at 2018-09-28 18:06:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) securities between October 25, 2013andSeptember 18, 2018 ,… read more...

Jane's August Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-09-28 15:27:55:000

Investment Thesis August marks the six months that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Jane's retirement account from February 1st to July 31st of 2018 have demonstrated the following income characteristics: T… read more...

Jane's August Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-09-28 15:27:55:000

Investment Thesis August marks the six months that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Jane's retirement account from February 1st to July 31st of 2018 have demonstrated the following income characteristics: T… read more...

Jane's August Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-09-28 15:27:55:000

Investment Thesis August marks the six months that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Jane's retirement account from February 1st to July 31st of 2018 have demonstrated the following income characteristics: T… read more...

Jane's August Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-09-28 15:27:55:000

Investment Thesis August marks the six months that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Jane's retirement account from February 1st to July 31st of 2018 have demonstrated the following income characteristics: T… read more...

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors of Deadline in Class Action

via: Business Wire at 2018-09-28 10:10:00:000

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE:ABBV) from October 25, 2013 through September 18, 2018, inclusive (the Class Period) of the important November 20, 2018 lead plaintiff deadline in the class action. Th… read more...

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors of Deadline in Class Action

via: Business Wire at 2018-09-28 10:10:00:000

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE:ABBV) from October 25, 2013 through September 18, 2018, inclusive (the Class Period) of the important November 20, 2018 lead plaintiff deadline in the class action. Th… read more...

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors of Deadline in Class Action

via: Business Wire at 2018-09-28 10:10:00:000

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE:ABBV) from October 25, 2013 through September 18, 2018, inclusive (the Class Period) of the important November 20, 2018 lead plaintiff deadline in the class action. Th… read more...

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors of Deadline in Class Action

via: Business Wire at 2018-09-28 10:10:00:000

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE:ABBV) from October 25, 2013 through September 18, 2018, inclusive (the Class Period) of the important November 20, 2018 lead plaintiff deadline in the class action. Th… read more...

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018

via: PR Newswire at 2018-09-27 15:07:00:000

NEW YORK , Sept. 27, 2018 /PRNewswire/ --Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AbbVie Inc.("AbbVie" or the "Company") (NYSE:ABBV) and certain of its officers, on behalf of shar… read more...

Generic HCV Could Benefit Gilead

via: SeekingAlpha at 2018-09-27 12:37:09:000

In my opinion, Gilead ( GILD ) has one of the best management teams in all of healthcare. Unlike competitors, Gilead's management has stayed away from acquiring companies at the height of the market in order to give the illusion of growth. The company is not over-leveraged and does not have to… read more...

Verastem Declines On Its Much-Touted Catalyst, Is It Worth Buying Now?

via: SeekingAlpha at 2018-09-26 13:52:37:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Every developmental biotech … read more...

44 Of 101 S&P 500 'Safer' Dividend Stocks Yield 3% To 6% To September 2019

via: SeekingAlpha at 2018-09-26 11:34:44:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten "Safer" Dividend S&P 500 Stocks Could Net 13.45% to 60.55% Gains By September 2019 Four of the ten tops-by-yield "safer" dividend S&P 500 (tinted in the chart above) were among the top ten gainers for the coming year based on an… read more...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AbbVie Inc. (ABBV)

via: PR Newswire at 2018-09-26 10:18:00:000

NEW YORK , Sept. 26, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AbbVie Inc.("AbbVie" or the "Company") (NYSE:ABBV). Such investors are encouraged to obtain additional informat… read more...

DivGro Pulse: September 2018

via: SeekingAlpha at 2018-09-26 06:15:21:000

I write monthly pulse articles that are strategy-focused and that monitor the health of my portfolio. My overall aim is to reduce portfolio risk and to further diversify DivGro's holdings. In the third quarter of 2018, I'm focusing specifically on strengthening my portfolio's risk profile. T… read more...

ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm

via: Business Wire at 2018-09-25 16:59:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AbbVie Inc. (AbbVie or the Company) (NYSE:ABBV). If you invested in AbbVie stock or options and would like to discuss your legal rights, click h… read more...

Your 50 Top S&P 500 Stocks For Yield, Gains & Upside For September

via: SeekingAlpha at 2018-09-25 15:53:46:000

Actionable Conclusions (1-10): Analysts Estimated 14.25% To 31.69% Net Gains For Ten S&P 500 Dogs To September 2019 Two of ten top S&P 500 dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray … read more...

Pfizer facing difficult path to ramp up biosimilar business

via: SeekingAlpha at 2018-09-25 15:51:13:000

In an entirely predictable scenario, Pfizer ( PFE -0.3% ) is encountering a broad range of competitive roadblocks in its efforts to gain traction in its biosimilar business, a strategic priority since acquiring Hospira for $17B in 2015. More news on: Pfizer Inc., Amgen Inc., Johnson &amp… read more...

'Safer' Dividend Aristocrats See 8.9% To 19.8% Gains Per September Stockbroker Sums

via: SeekingAlpha at 2018-09-25 11:14:00:000

Actionable Conclusions (1-10): Brokers Project Top Ten 'Safer' Dividend Aristocrats Stocks to Net 8.93% to 19.77% Gains To September 2019 Three of ten biggest yield "safer" Dividend Aristocrats (tinted in the chart above) showed up in the Top ten gainers for the coming year based on analys… read more...

Dividend Sensei's Portfolio Update 52: What I'll Be Buying During The Next Bear Market

via: SeekingAlpha at 2018-09-25 08:07:41:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. … read more...

Your 53 Dividend Aristocrats September Scorecard From Dividend Dogcatcher

via: SeekingAlpha at 2018-09-24 22:41:27:000

Actionable Conclusions (1-10): Analysts Cast 9% To 19.8% Net Gains To September 2019 Five of the ten top Aristocrats by yield were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the chart above). Thus, our yie… read more...

Express Scripts taking credit for Gilead's planned launch of generic HCV meds

via: SeekingAlpha at 2018-09-24 16:02:45:000

Express Scripts ( ESRX -0.2% ) is congratulating the organization it sees in the mirror over Gilead Sciences' plan to launch generic versions of HCV meds Epclusa and Harvoni. More news on: Express Scripts, Inc., Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthca… read more...

ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm

via: PR Newswire at 2018-09-24 14:58:00:000

NEW YORK , Sept. 24, 2018 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AbbVie Inc. ("AbbVie" or the "Company") (NYSE:ABBV). If you invested in AbbVie stock or options and would like to discuss y… read more...

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-09-24 11:54:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934… read more...

S&P 500 Q2 2018 Buybacks Increase 58.7% Year-Over-Year to Record $190.6 Billion

via: PR Newswire at 2018-09-24 10:01:00:000

NEW YORK , Sept.24, 2018 /PRNewswire/ --S&P Dow Jones Indices ("S&P DJI") today announced preliminary results indicating that S&P 500 stock buybacks , or share repurchases, totaled $190.6 billion for Q2 2018 , displacing the prior quarterly record of… read more...

Breakout Alert: Healthcare Stocks Are Surging

via: SeekingAlpha at 2018-09-24 09:59:03:000

By most accounts, the stock market has rallied strongly this year. The S&P 500, Dow Jones Industrials, and NASDAQ stock benchmarks continue pressing forward toward record levels, and this has made it difficult for some investors to find specific points of entry for buy positions. One of th… read more...

Gilead to launch generic versions of Epclusa and Harvoni

via: SeekingAlpha at 2018-09-24 08:42:11:000

Gilead Sciences (NASDAQ: GILD ) announces that newly created subsidiary Asegua Therapeutics LLC will launch authorized generic versions of hepatitis C meds Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) in the U.S. More news on: Gilead Sciences, Inc., AbbVie Inc., P… read more...

Big Pharma Levers Up As Deal Activity Settles Down

via: SeekingAlpha at 2018-09-23 16:57:48:000

After a red-hot start to 2018 with over $27 billion in deals closed in January alone, biotech sector activity has slowed down, leaving investors hungry for the next big deal. This month has seen a potential boon to biotech activity as three large-cap biotech/pharma companies lined up debt … read more...

BeiGene's zanubrutinib shows encouraging action in early-stage lymphoma study

via: SeekingAlpha at 2018-09-23 13:25:30:000

Preliminary data from a China-based Phase 1 clinical trial evaluating BeiGene's (NASDAQ: BGNE ) BTK inhibitor zanubrutinib in patients with B-cell lymphoma showed a treatment effect. The results were presented at the Annual Meeting of the Chinese Society of Clinical Oncology in Xiamen. … read more...

AbbVie Class Action: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against AbbVie Inc. - ABBV

via: PR Newswire at 2018-09-23 10:28:00:000

NEW YORK , Sept. 23, 2018 /PRNewswire/ --Bernstein Liebhard LLP, anationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of AbbVie Inc. ("AbbVie" or the "… read more...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against AbbVie Inc. - ABBV

via: Business Wire at 2018-09-21 23:33:00:000

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of AbbVie Inc. (NYSE: ABBV) from October 25, 2013 through September 18, 2018, inclusive (the Class Period). The lawsuit seeks to recover … read more...

Hagens Berman Alerts Investors in AbbVie Inc. (ABBV) to the Firm's Investigation of Possible Humira-Related Health Insurance Fraud and Disclosure Violations

via: PR Newswire at 2018-09-21 17:05:00:000

SAN FRANCISCO , Sept. 21, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in AbbVie Inc. (NYSE: ABBV) to the firm's investigation into possible disclosure violations. If you purchased or otherwise acquired AbbVie securities between November 18, 2017 and Sep… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-09-21 14:12:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) for violations of 10(b) and 20(a) of the Securities Exchang… read more...

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against AbbVie Inc. - ABBV

via: Business Wire at 2018-09-21 09:24:00:000

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AbbVie Inc. (NYSE: ABBV) resulting from allegations that AbbVie may have issued materially misleading business information to the investing public. On… read more...

Feds looking into free services from drug makers - WSJ

via: SeekingAlpha at 2018-09-21 09:15:15:000

The Wall Street Journal reports that federal prosecutors are investigating where certain drug markers, including Sanofi (NYSE: SNY ), Gilead Sciences (NASDAQ: GILD ) and Biogen (NASDAQ: BIIB ), violated laws by providing free services, such as nurses and reimbursement assistance, to doctor… read more...

AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy

via: PR Newswire at 2018-09-21 07:27:00:000

NORTH CHICAGO, Ill. , Sept. 21, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion forV… read more...

ABBV INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of AbbVie Inc. Investors

via: Business Wire at 2018-09-20 19:08:00:000

Law Offices of Howard G. Smithannounces an investigation on behalf of AbbVie Inc.(AbbVie or the Company) (NYSE: ABBV ) investors concerning the Company and its officers possible violations of federal securities laws. On September 18, 2018, Cal… read more...

AbbVie Investigation: Bernstein Liebhard LLP Announces Investigation Of AbbVie Inc. - ABBV

via: PR Newswire at 2018-09-20 14:13:00:000

NEW YORK , Sept. 20, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) resulting from allegations that Ab… read more...

Equillium Begins U.S. IPO Effort

via: SeekingAlpha at 2018-09-20 11:15:02:000

Quick Take Equillium ( EQ ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm develops products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders. EQ is pursuing a Phase 1b/2 trial for its E… read more...

Almirall's tildrakizumab OK'd in Europe for plaque psoriasis

via: SeekingAlpha at 2018-09-19 12:51:18:000

The European Commission approves Almirall's ( OTC:LBTSF ) ILUMETRI (tildrakizumab), an IL-23 inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis. More news on: Almirall SA, Bristol-Myers Squibb Company, AbbVie Inc., Healthcare stocks news, Read more … read more...

Dividend Sensei's Portfolio Update 51: Annual Performance Review

via: SeekingAlpha at 2018-09-19 10:05:45:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. This… read more...

Stocks making the biggest move premarket: TSLA, TLRY, NFLX, ABBV & more

via: CNBC at 2018-09-19 08:08:00:000

No summary available. read more...

After-hours buzz: TLRY, FIT & more

via: CNBC at 2018-09-18 17:33:00:000

No summary available. read more...

AbbVie shares fall after California insurance regulator sues company over alleged kickbacks

via: CNBC at 2018-09-18 14:23:00:000

No summary available. read more...

AbbVie used kickbacks to boost Humira sales - CA insurance commissioner

via: SeekingAlpha at 2018-09-18 14:21:30:000

AbbVie ( ABBV -1.7% ) slips on below-average volume in apparent reaction to a lawsuit filed by the California Insurance Commissioner alleging that the company used a "stealthy" network of nurses and kickbacks to doctors to boost prescriptions of top seller Humira. More news on: AbbVie … read more...

Your Cancer Highlight: AbbVie Quietly Aims For A New Best-In-Class Approval In CLL

via: SeekingAlpha at 2018-09-18 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Treatment of chronic lymphocyt… read more...

EMA accepts Bristol-Myers' marketing application for expanded use of Empliciti

via: SeekingAlpha at 2018-09-18 07:22:50:000

The European Medicines Agency (EMA) accepts for review Bristol-Myers Squibb's (NYSE: BMY ) marketing application seeking approval for EMPLICITI (elotuzumab), in combination with Celgene's (NASDAQ: CELG ) POMALYST (pomalidomide) and low-dose dexamethasone, for the treatment of adult patient… read more...

House nixes drug prices in TV ads

via: SeekingAlpha at 2018-09-17 11:50:23:000

The U.S. House of Representatives breaks with the Senate on a bill that included an amendment requiring drug makers to include list prices in TV drug advertisements. The bipartisan bill passed the Senate a few weeks ago but the House stripped out the price disclosure amendment. More news… read more...

AbbVie to Host Third-Quarter 2018 Earnings Conference Call

via: PR Newswire at 2018-09-17 08:00:00:000

NORTH CHICAGO, Ill. , Sept. 17, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its third-quarter 2018 financial results on Friday, November 2 2018 , before the market opens. AbbVie will host a live webcast of the earnings c… read more...

Stocks To Watch: Oracle Looks To Lift Tech Sector

via: SeekingAlpha at 2018-09-15 09:13:35:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors head into next week with another trade cloud hanging overhead after Presi… read more...

Stocks To Watch: Oracle Looks To Lift Tech Sector

via: SeekingAlpha at 2018-09-15 09:13:35:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors head into next week with another trade cloud hanging overhead after Presi… read more...

Your Daily Scoop: Foamix Zooms, Pfizer And Merck Report Positive

via: SeekingAlpha at 2018-09-13 13:22:38:000

Stocks in News: FOMX, PFE Foamix Pharma +54% as acne drug meets goals in late-stage trial Share price of Foamix Pharmaceuticals ( FOMX ) had a 54.4% spike on September 11 after-hours on the news of positive topline results of third Phase 3 clinical trial of its FMX101 drug. The candida… read more...

Your Daily Scoop: Foamix Zooms, Pfizer And Merck Report Positive

via: SeekingAlpha at 2018-09-13 13:22:38:000

Stocks in News: FOMX, PFE Foamix Pharma +54% as acne drug meets goals in late-stage trial Share price of Foamix Pharmaceuticals ( FOMX ) had a 54.4% spike on September 11 after-hours on the news of positive topline results of third Phase 3 clinical trial of its FMX101 drug. The candida… read more...

AbbVie's upadacitinib shows sustained treatment benefit in mid-stage dermatitis study

via: SeekingAlpha at 2018-09-13 09:49:25:000

New data from a Phase 2b clinical trial evaluating AbbVie's ( ABBV +0.3% ) JAK1 inhibitor upadacitinib in patients with moderate-to-severe atopic dermatitis (AD) showed a sustained treatment effect over 32 weeks. The results are being presented today at the EADV Congress in Paris. M… read more...

AbbVie's upadacitinib shows sustained treatment benefit in mid-stage dermatitis study

via: SeekingAlpha at 2018-09-13 09:49:25:000

New data from a Phase 2b clinical trial evaluating AbbVie's ( ABBV +0.3% ) JAK1 inhibitor upadacitinib in patients with moderate-to-severe atopic dermatitis (AD) showed a sustained treatment effect over 32 weeks. The results are being presented today at the EADV Congress in Paris. M… read more...

AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress

via: PR Newswire at 2018-09-13 09:20:00:000

NORTH CHICAGO, Ill. , Sept. 13, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results from the ongoing Phase 2b study including longer-term (32-week) efficacy and safety data and patient-reported outcomes data evalu… read more...

AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress

via: PR Newswire at 2018-09-13 09:20:00:000

NORTH CHICAGO, Ill. , Sept. 13, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results from the ongoing Phase 2b study including longer-term (32-week) efficacy and safety data and patient-reported outcomes data evalu… read more...

AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis

via: PR Newswire at 2018-09-13 06:20:00:000

NORTH CHICAGO, Ill. , Sept. 13, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from three pivotal Phase 3 trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibit… read more...

AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis

via: PR Newswire at 2018-09-13 06:20:00:000

NORTH CHICAGO, Ill. , Sept. 13, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from three pivotal Phase 3 trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibit… read more...

36 'Safer' Dividend Healthcare WallStars For September

via: SeekingAlpha at 2018-09-12 22:35:54:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.1% to 21.82% Gains To September 2019 Five of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for… read more...

36 'Safer' Dividend Healthcare WallStars For September

via: SeekingAlpha at 2018-09-12 22:35:54:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.1% to 21.82% Gains To September 2019 Five of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for… read more...

AbbVie, Inc. (ABBV) Management Presents at Morgan Stanley 16th Annual Global Healthcare Conference (Transcript)

via: SeekingAlpha at 2018-09-12 15:18:06:000

AbbVie, Inc. (ABBV) Morgan Stanley 16th Annual Global Healthcare Conference September 12, 2018 11:40 AM ET Executives Bill Chase - Chief Financial Officer Scott Brun - Head of AbbVie Ventures and VP of Scientific Affairs Analysts David Risinger - Morgan Stanley Presentatio… read more...

Aceto 72% Target Net Gain Tops WallStar Healthcare Equities For September

via: SeekingAlpha at 2018-09-12 14:40:23:000

Actionable Conclusions (1-10): Analysts Projected 13.4% To 72.2% Net Gains For Top Ten Healthcare WallStars By September 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices…. read more...

Dividend Sensei's Portfolio Update 50: The Best 5 High-Yield Monthly-Paying Dividend Stocks To Buy Today

via: SeekingAlpha at 2018-09-12 05:27:21:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers… read more...

IPO Alert: Strong Order Book For Principia Biopharma IPO; NIO Adds Investor Support

via: SeekingAlpha at 2018-09-11 13:59:10:000

Quick Take The Principia Biopharma ( PRNB ) IPO is indicating significant demand according to IPO information service IPO Boutique . Chinese electric car manufacturer NIO ( NIO ) has said certain existing investors intend to purchase $250 million of the IPO in support of its valuation… read more...

MRD negativity data added to label of AbbVie's Venclexta

via: SeekingAlpha at 2018-09-11 09:31:10:000

AbbVie (NYSE: ABBV ) announces that the FDA has expanded the label for VENCLEXTA(venetoclax tablets), in combination with rituximab, to include information about patients with previously-treated chronic lymphocytic leukemia (CLL) who achieved minimal residual disease (MRD)-negativity… read more...

Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label

via: PR Newswire at 2018-09-11 08:17:00:000

NORTH CHICAGO, Ill. , Sept. 11, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has expanded the label for VENCLEXTA (venetoclax tablets) in combination with rituximab to … read more...

Healthcare And Biotechnology Dashboard - Update

via: SeekingAlpha at 2018-09-10 20:42:53:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued regarding historical averages in 2 out of 3 valuation me… read more...

Gilead Sciences Is On The Right Trajectory Path For Autoimmune Disorders

via: SeekingAlpha at 2018-09-10 10:35:00:000

Recently, Gilead Sciences ( GILD ) and its partner Galapagos ( GLPG ) announced positive results from its phase 2 study treating patients with ankylosing spondylitis ((AS)). These positive results are proof that Gilead is alive and well. Most importantly, filgotinib could potentially becom… read more...

Income Investors: For Every 2 Ts, Buy 1 HD

via: SeekingAlpha at 2018-09-10 09:00:00:000

Today, we are going to provide a slightly different perspective for Income Investors. The term "Income Investors" does not necessarily mean retirees or near-retirees. Even younger investors could be income-oriented investors even though they may not need the income today or even for a decade o… read more...

Arrowhead Pharmaceuticals Could Become The Next Gilead

via: SeekingAlpha at 2018-09-07 13:14:03:000

Arrowhead Pharmaceuticals ( ARWR ) announced clinical data on Thursday, September 6, 2018. The data was with regard to their Hepatitis B Virus (HBV) infection treatment known as ABO-HBV, a potential cure for a currently incurable treatment. The data showed promising results from the viewpoin… read more...

Arrowhead Pharmaceuticals Could Become The Next Gilead

via: SeekingAlpha at 2018-09-07 13:14:03:000

Arrowhead Pharmaceuticals ( ARWR ) announced clinical data on Thursday, September 6, 2018. The data was with regard to their Hepatitis B Virus (HBV) infection treatment known as ABO-HBV, a potential cure for a currently incurable treatment. The data showed promising results from the viewpoin… read more...

Arrowhead Pharmaceuticals Could Become The Next Gilead

via: SeekingAlpha at 2018-09-07 13:14:03:000

Arrowhead Pharmaceuticals ( ARWR ) announced clinical data on Thursday, September 6, 2018. The data was with regard to their Hepatitis B Virus (HBV) infection treatment known as ABO-HBV, a potential cure for a currently incurable treatment. The data showed promising results from the viewpoin… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

AbbVie declares $0.96 dividend

via: SeekingAlpha at 2018-09-07 11:59:02:000

AbbVie (NYSE: ABBV ) declares $0.96/share quarterly dividend , in line with previous. More news on: AbbVie Inc., Dividend News, Read more … read more...

AbbVie declares $0.96 dividend

via: SeekingAlpha at 2018-09-07 11:59:02:000

AbbVie (NYSE: ABBV ) declares $0.96/share quarterly dividend , in line with previous. More news on: AbbVie Inc., Dividend News, Read more … read more...

AbbVie declares $0.96 dividend

via: SeekingAlpha at 2018-09-07 11:59:02:000

AbbVie (NYSE: ABBV ) declares $0.96/share quarterly dividend , in line with previous. More news on: AbbVie Inc., Dividend News, Read more … read more...

AbbVie Declares Quarterly Dividend

via: PR Newswire at 2018-09-07 11:23:00:000

NORTH CHICAGO, Ill. , Sept. 7, 2018 /PRNewswire/ --The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Nov. 15, 2018 to stockholders of record at the close of business on Oct. 15, 2018 . Sin… read more...

AbbVie Declares Quarterly Dividend

via: PR Newswire at 2018-09-07 11:23:00:000

NORTH CHICAGO, Ill. , Sept. 7, 2018 /PRNewswire/ --The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Nov. 15, 2018 to stockholders of record at the close of business on Oct. 15, 2018 . Sin… read more...

AbbVie Declares Quarterly Dividend

via: PR Newswire at 2018-09-07 11:23:00:000

NORTH CHICAGO, Ill. , Sept. 7, 2018 /PRNewswire/ --The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Nov. 15, 2018 to stockholders of record at the close of business on Oct. 15, 2018 . Sin… read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

Monthly Review Of DivGro: August 2018

via: SeekingAlpha at 2018-09-06 09:38:42:000

Welcome to the monthly review of DivGro, my portfolio of dividend growth stocks. My goal with these reviews is to share updates to my portfolio and to detail the dividends I received during the month. I also look at how DivGro's projected annual dividend income (PADI) has changed. In Augus… read more...

5%+ Dividend Yield Portfolio: Foreign Markets Disappointing You Again? (August 2018 Review)

via: SeekingAlpha at 2018-09-05 14:17:18:000

Outlook Call it the pain of international diversification for 2018. With a significant divergence between US and international equities, the cost with holding DM and EM stocks has been significant. The differential between EM and US growth indices is over 25%. - Mark Rzepczynski Ther… read more...

Abivax UC candidate shows positive action in mid-stage study

via: SeekingAlpha at 2018-09-05 12:17:43:000

A 32-subject Phase 2a clinical trial evaluating Abivax's ( OTCPK:AAVXF ) lead drug ABX464 in patients with treatment-resistant moderate-to-severe ulcerative colitis (UC) showed promising efficacy. More news on: Abivax SA, Protagonist Therapeutics, Takeda Pharmaceutical Co., Ltd. ADR,… read more...

Bulletproof Investing Performance Update: Week 40

via: SeekingAlpha at 2018-09-05 11:26:58:000

Safety first: NASCAR driver Johanna Long and her helmet (via Autowise ). Bulletproof Investing: Week 40 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is a… read more...

March To Freedom Fund: Adding Lockheed Martin

via: SeekingAlpha at 2018-09-04 09:14:48:000

The calendar has flipped to September, so it's time to look back at how the March to Freed Fund performed during the month of August. Including dividends, our total return for 2018 is 8.98%. This trails the performance of the S&P 500, which has a total return of 9.94% for the year. After… read more...

AbbVie Reinforces Leadership in Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio at the 27th European Academy of Dermatology and Venereology (EADV) Congress

via: PR Newswire at 2018-09-04 09:00:00:000

NORTH CHICAGO, Ill. , Sept. 4, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new data across investigational medicines and HUMIRA (adalimumab) at the 27 th European Academy of Dermatology and… read more...

The Millennial Portfolio: Longer Than Long Term? (II)

via: SeekingAlpha at 2018-09-03 08:49:30:000

My first portfolio review came out on the last 16th of July. Currently, we are approximately one and a half months further. As I have stated in my first article, I would like to inform millennials about the Millennial Portfolio's performance on a monthly basis. Since the last portfolio review,… read more...

Sector Allocations

via: SeekingAlpha at 2018-09-03 06:29:55:000

This is a follow-up to my August 20, 2018 article , which included a portfolio review, but not sector information. (Note to non-PRO subscribers: I've avoided writing single ticker articles to prevent them from being paywalled, but SA made the dual-ticker August 20 article an Editor's Pick a… read more...

How Big Is The Biosimilar Threat To AbbVie's Humira?

via: SeekingAlpha at 2018-09-03 04:30:46:000

As has been widely discussed, AbbVie ( ABBV ) faces biosimilar competition in EU starting in 4Q18, and a patent dispute in the US, with settlements allowing for competition to begin in the 2022-2023 time frame. This is important given the sizable revenue that Humira is responsible for (65% in … read more...

Road To Financial Independence: Growing Dividends, Endless Opportunities But Limited Capital

via: SeekingAlpha at 2018-09-03 02:53:24:000

The stock markets never stop to amaze me. While July was heavily driven by concerns about a deteriorating trade war, August, in general, was a big rally, with markets hitting new highs and the euro dropping down to as low as $1.13. Overall net capital spending was around $2,650 as I divested… read more...

Celgene Vs. AbbVie: The 2 Cheapest Large Cap Pharma Stocks

via: SeekingAlpha at 2018-08-31 17:48:56:000

Celgene ( CELG ) and AbbVie ( ABBV ) are the two fastest growing large-cap pharma stocks. Both companies are heavily reliant on one drug, Revlimid for Celgene and Humira for AbbVie. Even considering concentration risk for each, I consider both as good buys right now, but I'd give the slight ed… read more...

Celgene Vs. AbbVie: The 2 Cheapest Large Cap Pharma Stocks

via: SeekingAlpha at 2018-08-31 17:48:56:000

Celgene ( CELG ) and AbbVie ( ABBV ) are the two fastest growing large-cap pharma stocks. Both companies are heavily reliant on one drug, Revlimid for Celgene and Humira for AbbVie. Even considering concentration risk for each, I consider both as good buys right now, but I'd give the slight ed… read more...

Celgene Vs. AbbVie: The 2 Cheapest Large Cap Pharma Stocks

via: SeekingAlpha at 2018-08-31 17:48:56:000

Celgene ( CELG ) and AbbVie ( ABBV ) are the two fastest growing large-cap pharma stocks. Both companies are heavily reliant on one drug, Revlimid for Celgene and Humira for AbbVie. Even considering concentration risk for each, I consider both as good buys right now, but I'd give the slight ed… read more...

Et Tu, Bruton?

via: SeekingAlpha at 2018-08-30 11:15:49:000

Introduction: Since it was first approved to treat mantle cell lymphoma in 2013, ibrutinib (Imbruvica) has rapidly become a hematology hegemon. In 2017, AbbVie ( ABBV ) reported over $2.5 billion in net revenues for ibrutinib, a 40% increase over 2016, and forecasts $5 bn in annual sales … read more...

AbbVie: FCF's Ensure Sweet Dividends And Buybacks

via: SeekingAlpha at 2018-08-30 10:51:12:000

Article thesis AbbVie ( ABBV ) is an appealing investment for dividend seekers, as it offers a FCF yield of 8.6% based on a FCF of 13.1B USD this year and the current market cap of 152B USD. The company will produce excess cash flow, which will give investors compelling total returns over th… read more...

Your Daily Pharma Scoop: ESPR Phase 3 Positive, FDA Rejects Volanesorsen, Ozempic Succeeds

via: SeekingAlpha at 2018-08-29 13:18:40:000

Stocks in News: ESPR Esperion announces positive results from phase 3 bempedoic acid/ezetimibe combination pill study Discussion: Positive top-line results from the pivotal Phase 3 trial of Esperions ( ESPR ) bempedoic acid/ezetimibe combination pill study ( 1… read more...

FDA updates on multifaceted plan to combat opioid crisis

via: SeekingAlpha at 2018-08-29 12:44:25:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

AbbVie Does It Again, Another Green Light By The FDA For Blockbuster Imbruvica

via: SeekingAlpha at 2018-08-29 12:24:41:000

Recently, AbbVie ( ABBV ) announced that it had received FDA approval for an Imbruvica and Rituxan combination treatment. This FDA approval was for a rare B-cell lymphoma treatment. This is good news because it greatly expands the market opportunity possible for Imbruvica. That's because Imb… read more...

Denali's Transport Vehicle Platform Holds Hidden Value In Brain Cancers

via: SeekingAlpha at 2018-08-29 07:13:29:000

The passing of an American hero highlights a blindspot in cancer research Sen. McCain in attendance of a baseball game last year in Phoenix. Source Senator John McCain, prisoner of war, torture survivor and longtime civil servant, has passed away following a battle with an aggressiv… read more...

Verastem's Duvelisib And The Competition: A Comparison

via: SeekingAlpha at 2018-08-28 13:18:04:000

When I first covered Verastem ( VSTM ) in March, the stock had not yet started its awesome rise. I also had two major doubts about the company - its cash position, and its competitive position vis-a-vis Imbruvica. So, while I held a small position, I was fairly cautious. My money having almo… read more...

30 Stock Portfolio Summer Review

via: SeekingAlpha at 2018-08-28 12:40:00:000

The goal is financial freedom. The path to get there is investing in growing and income producing businesses. Many of my stocks are, "dividend growth investments" that produce a consistent and rising income stream. Hopefully these DGI stocks will beat the market. My non DGI stocks are, "Seekin… read more...

FDA clamps down on opioid-peddling websites

via: SeekingAlpha at 2018-08-28 10:57:45:000

The FDA has sent Warning Letters to four additional online networks operating a total of 21 websites for illegally promoting opioids to Americans. The action follows the issuance of 13 Warning Letters to more than 70 websites over the summer. More news on: Endo International plc, Mallinc… read more...

AbbVie to Present at the Morgan Stanley 16th Annual Global Healthcare Conference

via: PR Newswire at 2018-08-28 08:00:00:000

NORTH CHICAGO, Ill. , Aug. 28, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Morgan Stanley 16 th Annual Global Healthcare Conference onWednesday, September 12, 2018. Bill Chase , executive vice presi… read more...

Seattle Genetics Is A Solid Buy In 2018

via: SeekingAlpha at 2018-08-27 12:51:36:000

The year 2018 is definitely turning out to be transformational for Seattle Genetics ( SGEN ). It started with the latest FDA approval for Adcetris, the companys only marketed product, as front-line therapy in combination with chemotherapy in stage III or IV classical Hodgkin lymphoma o… read more...

AbbVie: Still A Compelling Buy?

via: SeekingAlpha at 2018-08-27 08:02:48:000

AbbVie ( ABBV ) has traded under pressure since the stock collapsed in January 2018, which has not been a complete surprise given the fact that drug pricing concerns have weighed on the pharmaceutical industry for the past few years. But AbbVies earnings results for the second quarter … read more...

AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer

via: PR Newswire at 2018-08-27 07:00:00:000

NORTH CHICAGO, Ill. , Aug. 27, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, todayannounced that the U.S. Food and Drug Administration (FDA) approved IMBRUVICA (ibrutinib) plus rituximab (RITUXAN )for the treatment … read more...

Worried About Retirement? Then Consider These 11 High-Yield Blue Chip Dividend Growth Stocks

via: SeekingAlpha at 2018-08-27 06:19:16:000

(Source: imgflip ) Note that due to reader requests I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary/stats/watch lists. This is to avoid excessively long articles and maximize the utility to my readers. -------------… read more...

Reata Pharmaceuticals: Thesis Strengthened, Q3 Data Looms

via: SeekingAlpha at 2018-08-24 20:22:30:000

Shares of Reata Pharmaceuticals ( RETA ) have risen by 187% since my update article was published in December of last year, suggesting that readers follow the insiders and establish a pilot position. In the last three months alone the stock price has climbed by 140%, aided by p… read more...

Reata Pharmaceuticals: Thesis Strengthened, Q3 Data Looms

via: SeekingAlpha at 2018-08-24 20:22:30:000

Shares of Reata Pharmaceuticals ( RETA ) have risen by 187% since my update article was published in December of last year, suggesting that readers follow the insiders and establish a pilot position. In the last three months alone the stock price has climbed by 140%, aided by p… read more...

23andMe cuts off app developers from raw genetic data

via: SeekingAlpha at 2018-08-24 13:00:09:000

Privately held 23andMe has informed outside app developers that they will no longer have access to its raw genomic data, one of the largest datasets in the world. More news on: GlaxoSmithKline, Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthcare stocks news, Te… read more...

Neurocrine Biosciences: This Is Only The Beginning

via: SeekingAlpha at 2018-08-24 12:28:07:000

Editor's note: Seeking Alpha is proud to welcome William Wellings as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Company… read more...

Your Daily Pharma Scoop: Mallinckrodt Stumbles, AbbVie Phase 3 Positive, Sierra Makes An Acquisition

via: SeekingAlpha at 2018-08-24 09:23:50:000

Stocks in News: MNK, ABBV FDA rejects Mallinckrodt's stannsoporfin marketing application; shares down 3% premarket Discussion: Mallinckrodt ( MNK ) received a CRL on its marketing application of stannsoporfin for the treatment of severe jaundice in neonatals at risk. The CRL w… read more...

Your Cancer Research Highlight: Bristol-Myers Looks For An In To Earlier Multiple Myeloma

via: SeekingAlpha at 2018-08-24 08:00:00:000

For quite a while now, we've seen a really remarkable transformation in the field of multiple myeloma management. First, we saw the emergence of new crops of targeted therapies with proteasome inhibitors made by outlets like Amgen ( AMGN ) and Takeda ( TKPYY ), as well as Celgene's ( CELG ) su… read more...

Better Buy: Johnson & Johnson Vs. AbbVie

via: SeekingAlpha at 2018-08-23 15:13:19:000

This is the ultimate old versus new battle. On one side, we have old reliable in Johnson & Johnson ( JNJ ), who performs year in and year out with a consistently strong pipeline of new products that grow revenue. On the other side, we have the newcomer on the block or the young gun in AbbV… read more...

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD… read more...

Bulletproof Investing Performance Update: Week 39

via: SeekingAlpha at 2018-08-23 08:32:52:000

Safety first: NASCAR driver Johanna Long and her helmet (via Autowise ). Bulletproof Investing: Week 39 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an … read more...

DGI For The DIY: Q2 2018 Portfolio Update

via: SeekingAlpha at 2018-08-22 16:27:58:000

Project Background The DGI For The DIY portfolio was created in 2013 when I liquidated the mutual funds in my retirement account and began my journey as a dividend growth investor. I've been writing quarterly updates on the portfolio ever since, documenting the portfolio's progress and m… read more...

FDA awards contract to develop guidelines for opioid prescribing

via: SeekingAlpha at 2018-08-22 11:16:23:000

The FDA has awarded a contract to the National Academies of Sciences, Engineering and Medicine to help advance the development of evidence-based guidelines to help physicians prescribe opioid pain meds in a more appropriate way. More news on: Endo International plc, Mallinckrodt PLC, IND… read more...

Will Regeneron Close At $400?

via: SeekingAlpha at 2018-08-22 11:12:42:000

When Regeneron Pharmaceuticals ( REGN ) reported strong second-quarter earnings earlier this month, the stock soared to around my 30 percent upside target . Now that it met the market's expectations, what upside remains? The stock topped $397 on August 2 and began a descent to around $362 o… read more...

AbbVie's elagolix shows positive effect in late-stage extension study in uterine fibroids

via: SeekingAlpha at 2018-08-22 08:51:11:000

Results from a Phase 3 extension study, ELARIS UF-EXTEND , evaluating AbbVie's (NYSE: ABBV ) elagolix, combined with low-dose hormone therapy, for reducing heavy menstrual bleeding in women with uterine fibroids showed a treatment benefit. Specifically, 87.9% of treated women achieved cl… read more...

AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

via: PR Newswire at 2018-08-22 08:30:00:000

NORTH CHICAGO, Ill. , Aug. 22, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that results from the Phase 3 ELARIS UF-EXTEND extension study (MI2-816) showed at mo… read more...

Argenx up 4% premarket on license of ARGX-115 to AbbVie

via: SeekingAlpha at 2018-08-22 07:52:51:000

Argenx (NASDAQ: ARGX ) is up 4% premarket on light volume on the heels of its announcement that AbbVie (NYSE: ABBV ) has exercised its option for exclusive rights to GARP inhibitor ARGX-115 as allowed under their April 2016 agreement. More news on: Argenx SE, AbbVie Inc., Hea… read more...

Jane's July Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-08-21 15:10:10:000

Investment Thesis July marks the fifth month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the Taxable Account, we did not start making significant changes to her retirement accounts until after the first of the year. Because of this, there were a numb… read more...

Dividend Sensei's Portfolio Update 48: The Best Way To Overcome Your Biggest Investing Problem

via: SeekingAlpha at 2018-08-21 14:43:00:000

(Source: imgflip ) Note that due to reader requests I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. This … read more...

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) and Lead Plaintiff Deadline - September 24, 2018

via: PR Newswire at 2018-08-21 10:10:00:000

NEW YORK , Aug. 21, 2018 /PRNewswire/ --Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AbbVie Inc.("AbbVie" or the "Company") (NYSE:ABBV). and certain of its officers, on behalf of shar… read more...

IPO Biotech Preview: Principia Biopharma

via: SeekingAlpha at 2018-08-20 20:25:42:000

Principia Biopharma ( PRNB ) is gearing up for an $86 million IPO . I believe that it has good clinical candidates in the pipeline which can be used for a variety of diseases. In addition it has already been able to form partnerships with big pharmaceutical companies like Sanofi ( SNY )… read more...

Antares Pharma: Proven Business Model Set To Move Much Higher

via: SeekingAlpha at 2018-08-20 07:49:28:000

Following a big move of Antares Pharma ( ATRS ) shares from about $2.00 at the beginning of 2018 to near $3.40 currently (70% gain) some investors may question the potential for further upside in the shares near term. However, near-term catalysts bode well for a continued rally through at leas… read more...

March To Freedom Fund: July Update

via: SeekingAlpha at 2018-08-19 22:36:04:000

The March to Freedom Fund, which will provide the dividends that pay my wife's and my expenses in retirement, has spent much of the last year or so trailing the S&P 500 ( SPY ). That is something that I am fine with for two reasons: 1) In previous years weve outperformed the index … read more...

'Safer' Dividend Aristocrats Show 12.9%-28.2% Top Gains By 10

via: SeekingAlpha at 2018-08-18 20:34:55:000

Actionable Conclusions (1-10): Brokers Project Top Ten 'Safer' Dividend Aristocrats Stocks to Net 14.66% to 38.2% Gains To July, 2019 Three of ten biggest yield "safer" Dividend Aristocrats (tinted in the chart above) showed up in the Top ten gainers for the coming year based on analyst 1 … read more...

Principia Biopharma readies IPO

via: SeekingAlpha at 2018-08-18 18:36:18:000

South San Francisco-based Principia Biopharma ( PRNB ) has filed a preliminary prospectus for an $86M IPO. More news on: Principia Biopharma, AbbVie Inc., Sanofi, Healthcare stocks news, IPOs, Read more … read more...

Stocks To Watch: Alibaba, Target And Energy Plays To Center Stage

via: SeekingAlpha at 2018-08-18 09:17:10:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A China delegation will visit the U.S. next week for trade talks in a development t… read more...

Aristocrats: Nucor, Chevron, Leggett, Exxon, & Air Products Flash 15.4% To 24.85% Net Gains Per August Broker Targets

via: SeekingAlpha at 2018-08-17 17:56:55:000

Actionable Conclusions (1-10): Analysts Cast 12.9% To 24.85% Net Gains To August, 2019 Six of the ten top Aristocrats by yield were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the chart above). Thus, our yi… read more...

AbbVie: Remarkable Return Potential Over Next Decade (Dividend Sensei)

via: SeekingAlpha at 2018-08-17 08:59:28:000

The story behind the interview: According to Dividend Sensei, AbbVie ( ABBV ) is the Apple of the pharma world. Thanks to a powerful pipeline and great management it has the potential to return 700% over the next 10 years. For those who prefer to read, my full interview notes are copied be… read more...

Bulletproof Investing Performance Update: Week 38

via: SeekingAlpha at 2018-08-16 16:05:51:000

Safety first: Sprint car driver McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 38 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This… read more...

White House proposing cuts in opioid production

via: SeekingAlpha at 2018-08-16 15:24:55:000

Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &… read more...

Verastem: An Undervalued Rare Oncology Gem With Big Upcoming Catalysts

via: SeekingAlpha at 2018-08-14 22:50:31:000

Editor's note: Seeking Alpha is proud to welcome Juha Natunen as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Editor's not… read more...

Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review

via: SeekingAlpha at 2018-08-14 08:58:04:000

Stocks in News: RDHL, REGN RedHill Bio nabs U.S. patent covering RHB-104 and RHB-204 Discussion : RedHill Biopharma ( RDHL ) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The … read more...

Is Cocrystal Beating The Dead Hepatitis C Horse?

via: SeekingAlpha at 2018-08-14 05:00:00:000

Introduction The discovery of a safe and highly effective cure for Chronic Hepatitis C is perhaps one of the intriguing biotech success stories of the decade. Over the course of 20 years, the standard of care for Hepatitis C had evolved from a combined course of ribavarin and pegylated i… read more...

ArQule's ARQ 531 shows encouraging action in preclinical studies; shares up 2% after hours

via: SeekingAlpha at 2018-08-13 16:50:25:000

ArQule (NASDAQ: ARQL ) is up 2% after hours on light volume in response to its announcement of positive data from preclinical studies of Bruton's tyrosine kinase (BTK) inhibitor ARQ 531. The results were just published in Cancer Discovery . More news on: ArQule, Inc., AbbVie… read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV

via: PR Newswire at 2018-08-13 14:32:00:000

NEW YORK , Aug. 13, 2018 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors ofAbbVie Inc.("AbbVie" or the "Company") (NYSE:ABBV). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 88… read more...

Dividend Sensei's Portfolio Update 47: Overcoming Adversity And Soaring To New Heights

via: SeekingAlpha at 2018-08-13 07:44:11:000

(Source: imgflip ) Note that due to reader requests I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. This … read more...

How To Retire Comfortably By 62 With A Million

via: SeekingAlpha at 2018-08-12 08:01:00:000

Lets say you and your spouse both are 50-years old right now. You have saved about $200,000 in retirement savings in addition to some equity in the house. It is not bad at all. In a short 12 years from now, you will be 62. You may or may not retire at 62, but you decide to at least m… read more...

Venture Capital Deals Of The Week: SoftBank Hands WeWork $1B

via: SeekingAlpha at 2018-08-11 10:58:19:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Did we miss a notable deal? Let us know in the comments. WeWork gets $1B: WeWork (VWORK) secured a $1B… read more...

Stocks To Watch: Any Privacy For Tesla?

via: SeekingAlpha at 2018-08-11 09:07:58:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. During what's supposed to be a sleepy period of low-volume market activity amid the… read more...

How To Build A Safe High-Yield Retirement Portfolio Part 2: 10 Blue Chips To Start With

via: SeekingAlpha at 2018-08-10 16:27:32:000

(Source: imgflip ) Note that due to reader requests I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. -----… read more...

Stay Away From Coal Stocks - Cramer's Lightning Round (8/9/18)

via: SeekingAlpha at 2018-08-10 07:19:23:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, August 9. Bullish Calls Greed Dot Corp. (GDOT): It's a fintech play that Cramer likes even though the stock is at a 52-week high. Sherwin-Williams Company (SHW): Book partial profits and let th… read more...

Watchlist August 2018

via: SeekingAlpha at 2018-08-10 01:13:55:000

It's time for the monthly watchlist report. As always, you can find the updated info at any time here Dividend Income Spreadsheet and the Portfolio Spreadsheet . Summary Few stocks look interesting right now, but there are still some attractive candidates. Analyzed the past "watchli… read more...

Cramer's lightning round: Coal may be in a renaissance, but don't buy the stocks

via: CNBC at 2018-08-09 18:50:00:000

No summary available. read more...

Roche: Details On Growing Through The Patent Cliff (Part 2 Of 2)

via: SeekingAlpha at 2018-08-09 12:08:01:000

Introduction to Part 2 Part 1 of this 2-part series on Roche ( RHHBY ), the world's largest biotech company, delves into some of the details of its strategy to overcome the ongoing, rolling EU/US patent expirations of its Big 3 oncology products of MabThera/Rituxan, Herceptin and Avastin, … read more...

Bulletproof Investing Performance Update: Week 37

via: SeekingAlpha at 2018-08-09 07:24:44:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 37 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is a… read more...

AbbVie Is Looking For New Growth Before Generic Competitors Roll In

via: SeekingAlpha at 2018-08-07 21:27:58:000

AbbVie (ABBV) will be in a huge bind in the coming months and years. That's because its top-selling product, Humira, will have generic competition rolling out. That would cause a huge loss in sales, thus, it is scrambling in hopes of potentially acquiring another pharmaceutical company to ge… read more...

AbbVie and Enanta down on loss of preferred status in HCV with Express Scripts

via: SeekingAlpha at 2018-08-07 12:46:14:000

AbbVie ( ABBV -3% ) and collaboration partner Enanta Pharmaceuticals ( ENTA -8.9% ) are down in apparent response to the news that PBM Express Scripts ( ESRX +1.5% ) has dropped HCV med MAVYRET (glecaprevir/pibrentasvir) from its formulary in favor of Merck's ( MRK +0.4% ) ZEPATIER… read more...

AbbVie's Outlook Remains Blurred

via: SeekingAlpha at 2018-08-07 10:13:01:000

Image Source: Global Panorama By Alexander J. Poulos We continue to monitor even miniscule changes in the trajectory of the clinical pipeline in the pharma/biotech sector as the productivity of the pipeline offers what could be described as an early warning system (&#x201… read more...

Biogen Hits A Potential Home Run

via: SeekingAlpha at 2018-08-07 10:09:33:000

By Alexander J. Poulos We closely follow the progress of the clinical pipeline of companies in the pharma/biotech sector. Unlike other less product-driven industries, the pharma/biotech sector can experience wide swings in operating performance as a result of the lapsing of patent protection… read more...

Dividend Update - July 2018

via: SeekingAlpha at 2018-08-07 09:02:36:000

July has ended, putting us on the back end of the year. After reviewing my financial goals , it looks like I am on track to break last year's dividend record with a decent amount of growth. It has been a pretty uneventful July as far as my portfolio is concerned. I was able to make one pu… read more...

Dividend Portfolio Review: Busy Earnings Season, Heavy Buying, Growing Dividends

via: SeekingAlpha at 2018-08-07 08:55:00:000

More ups and downs in July with earnings season hitting its peak and trade threats and denials coming in every couple of days led to accelerated buying culminating in around $4,400 in fresh capital deployed. Earnings season often triggers some remarkable selloffs and rallies but this time I… read more...

Beat The Recession With Dividends

via: SeekingAlpha at 2018-08-07 08:52:23:000

While the media keeps saying a recession is just around the corner, when is it going to strike? The truth is that no one knows. All we can do is give estimates. In my last article about the economy, which I published on November 2, 2017, I warned that interest rates and debt could pull the e… read more...

Dividend Sensei's Portfolio Update 46: More Concentrated Portfolio Is Off To A Great Start

via: SeekingAlpha at 2018-08-06 21:14:49:000

(Source: imgflip ) Note that due to reader requests I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Thi… read more...

Rose Portfolio Options: Covered Puts And Calls - Nothing Naked

via: SeekingAlpha at 2018-08-06 14:33:31:000

My gosh, I never thought I would say " Roll Up and Out"! I actually only figured out I had done it, after I did it, at least I think I did it. To me it means I closed a current option by buying it back before expiration and then selling the same option again for a higher strike price or a… read more...

The Rose 93 Stock July Portfolio Update: Delightful Spicy Dividends Up 60.2% From 2017

via: SeekingAlpha at 2018-08-06 06:23:43:000

I received 60.2% more income in this past July than I did in 2017. It is up hugely secondary to adding Regulated Investment Companies (RICs) and some preferred income with high yield from numerous sectors. They are spicy yummy income providers. Dividends/distributions or income for the portf… read more...

Tracking Yacktman Asset Management Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-08-06 05:43:25:000

This article is part of a series that provides an ongoing analysis of the changes made to Yacktman's 13F stock portfolio on a quarterly basis. It is based on Yacktman Asset Management's regulatory 13F Form filed on 08/03/2018. Please visit our Tracking Yacktman Asset Management series to g… read more...

Regeneron: How This Bull Can Continue To Gore The Bears

via: SeekingAlpha at 2018-08-03 13:04:40:000

Introduction Regeneron ( REGN ) pleased the bulls Thursday, reporting Q2 results and holding a conference call before the market opened. The stock traded up from the start and closed at a multi-month high, closing around $397. Revenues were up only 9% yoy, but since all the Sanofi ( SNY … read more...

Regeneron: How This Bull Can Continue To Gore The Bears

via: SeekingAlpha at 2018-08-03 13:04:40:000

Introduction Regeneron ( REGN ) pleased the bulls Thursday, reporting Q2 results and holding a conference call before the market opened. The stock traded up from the start and closed at a multi-month high, closing around $397. Revenues were up only 9% yoy, but since all the Sanofi ( SNY … read more...

Regeneron: How This Bull Can Continue To Gore The Bears

via: SeekingAlpha at 2018-08-03 13:04:40:000

Introduction Regeneron ( REGN ) pleased the bulls Thursday, reporting Q2 results and holding a conference call before the market opened. The stock traded up from the start and closed at a multi-month high, closing around $397. Revenues were up only 9% yoy, but since all the Sanofi ( SNY … read more...

5%+ Dividend Yield Portfolio: Sticking To The Plan (July 2018 Review)

via: SeekingAlpha at 2018-08-03 09:49:55:000

Outlook "Nothing so undermines your financial judgement as the sight of your neighbor getting rich. - J.P. Morgan For fundamentals driven investors with a value tilt like me, July was likely a solid month with decent gains in holdings value. However, most value focused investors p… read more...

5%+ Dividend Yield Portfolio: Sticking To The Plan (July 2018 Review)

via: SeekingAlpha at 2018-08-03 09:49:55:000

Outlook "Nothing so undermines your financial judgement as the sight of your neighbor getting rich. - J.P. Morgan For fundamentals driven investors with a value tilt like me, July was likely a solid month with decent gains in holdings value. However, most value focused investors p… read more...

5%+ Dividend Yield Portfolio: Sticking To The Plan (July 2018 Review)

via: SeekingAlpha at 2018-08-03 09:49:55:000

Outlook "Nothing so undermines your financial judgement as the sight of your neighbor getting rich. - J.P. Morgan For fundamentals driven investors with a value tilt like me, July was likely a solid month with decent gains in holdings value. However, most value focused investors p… read more...

My Dirty Dozen Undervalued Dividend Growth Stocks

via: SeekingAlpha at 2018-08-03 06:26:49:000

Introduction Relative to historical norms, the overall stock market as measured by the S&P 500 is overvalued with the current blended P/E ratio of 19.2. Historically, the S&P 500 would be considered fairly valued when its P/E ratio was between 15 and 16. Therefore, some could argue… read more...

My Dirty Dozen Undervalued Dividend Growth Stocks

via: SeekingAlpha at 2018-08-03 06:26:49:000

Introduction Relative to historical norms, the overall stock market as measured by the S&P 500 is overvalued with the current blended P/E ratio of 19.2. Historically, the S&P 500 would be considered fairly valued when its P/E ratio was between 15 and 16. Therefore, some could argue… read more...

My Dirty Dozen Undervalued Dividend Growth Stocks

via: SeekingAlpha at 2018-08-03 06:26:49:000

Introduction Relative to historical norms, the overall stock market as measured by the S&P 500 is overvalued with the current blended P/E ratio of 19.2. Historically, the S&P 500 would be considered fairly valued when its P/E ratio was between 15 and 16. Therefore, some could argue… read more...

Healthcare Dashboard - Update

via: SeekingAlpha at 2018-08-03 00:26:12:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued regarding historical averages in 2 out of 3 valuation … read more...

Healthcare Dashboard - Update

via: SeekingAlpha at 2018-08-03 00:26:12:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued regarding historical averages in 2 out of 3 valuation … read more...

Healthcare Dashboard - Update

via: SeekingAlpha at 2018-08-03 00:26:12:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued regarding historical averages in 2 out of 3 valuation … read more...

Medical Stock Investing: 2018 Update

via: SeekingAlpha at 2018-08-02 09:37:22:000

Given that we are just past the midpoint, I thought it would be a good time to review and update my 2018 forecast and stock picks. As I suggested, 2018 has turned out to be a stockpicker's year. The fundamentals of the US healthcare industry remain strong, as demographics, chronic disease prev… read more...

Recent Stock Purchase: July 2018

via: SeekingAlpha at 2018-08-02 04:25:40:000

Originally posted July 20, 2018 Been away on a family road trip for ten days across Arizona and haven't been paying too much attention to the markets as of late which is why I have not made my July buy till now. Looking at my July stock considerations , I was really pining for some Star… read more...

Bulletproof Investing Performance Update: Week 36

via: SeekingAlpha at 2018-08-02 03:24:05:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 36 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is a… read more...

Meet The 'Safer' 35 Healthcare High Yield WallStars For July

via: SeekingAlpha at 2018-08-01 20:18:44:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.75% to 22.98% Gains To July 2019 Three of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for th… read more...

Neurocrine Biosciences - 2 Blockbusters Approved, And Likely More To Come

via: SeekingAlpha at 2018-08-01 11:38:22:000

Mid-cap biotech Neurocrine Biosciences ( NBIX ) continues to rack up the good news, but the market is still reluctant to give full value to the shares. Not only will this company have two presumptive blockbusters-to-be on the market this year, but it will soon be profitable at the operatin… read more...

Actions And Reactions During Earnings Season - The Idea Guide

via: SeekingAlpha at 2018-08-01 11:24:14:000

By Daniel Shvartsman Earnings season can change the narrative on a given stock fast. Facebook ( FB ) and Netlfix ( NFLX ) provide obvious examples, but the reverberations are bigger with smaller companies. At the same time, the market may not price everything in right away, or in its eff… read more...

August 2018 Stock Considerations

via: SeekingAlpha at 2018-08-01 10:26:52:000

With summer in full swing and a new month upon us, it is time for me to outline my potential stock picks for August. Looking forward, it seems that we are heading into the month on a strong note (some notable tech companies excluded). Of course, as individual stock pickers, it's our job to wee… read more...

Wall Street Favorite Healthcare Equities For July Topped By CVS Health

via: SeekingAlpha at 2018-08-01 02:27:38:000

Actionable Conclusions (1-10): Analysts Projected 12.6% To 28.5% Net Gains For Top Ten Healthcare WallStars By July 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (The… read more...

Madrigal: Reduced Buyout Prospects Quiet Investor Bullishness, Refocus Investment Thesis

via: SeekingAlpha at 2018-08-01 01:08:49:000

Figure 1: Investor myopia - how far do speculative biotechnology investors look into the future when buying or selling stock? I often think to myself, "How myopic are speculative biotechnology investors?" It's interesting because I believe there is a way to systematically quantify and qu… read more...

5 Reasons I Just Quadrupled My Position In This High-Yield Blue Chip

via: SeekingAlpha at 2018-07-31 14:19:20:000

(Source: imgflip ) The goal of my high-yield dividend growth retirement portfolio is to put my savings to work in the best long-term income growth opportunities I can find. This means I'm looking for "rock star" companies with: wide moat business models world-class management team… read more...

Pfizer's Read thinks drug rebates going bye-bye in U.S.

via: SeekingAlpha at 2018-07-31 11:45:57:000

In this morning's earnings call, Pfizer ( PFE +3% ) chief Ian Read said he believes the Trump administration plans to eliminate rebates on prescription drug purchases, although he has no clear idea when such a policy would be implemented. More news on: Pfizer Inc., Health Care Select S… read more...

U.S. healthcare spending nearing 20% of GDP

via: SeekingAlpha at 2018-07-31 11:25:57:000

The WSJ reports that healthcare spending in the U.S. will soon reach 20% of GDP, a significantly higher proportion than any other major economy. The key cost driver has been price hikes, not increased demand. Since 1960, the CPI has risen ~700% while medical costs have risen 2,000%. Since … read more...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AbbVie Inc. (ABBV)

via: PR Newswire at 2018-07-31 10:10:00:000

NEW YORK , July 31, 2018 /PRNewswire/ --Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AbbVie Inc.("AbbVie" or the "Company") (NYSE:ABBV). Such investors are encouraged to obtain additional info… read more...

AbbVie: Undervalued And Strong Growth On The Horizon

via: SeekingAlpha at 2018-07-31 09:42:38:000

Pharmaceutical Overview AbbVie Inc. first gained notoriety in 2013, after it was formed during a split of Abbot Laboratories. This was because ( ABBV ) retained the rights to Humira and continued to develop and market the drug. As a treatment for rheumatoid arthritis, crohn's disease, pso… read more...

AbbVie Offers GARP As Consensus Forecast For Humira Is Too Pessimistic

via: SeekingAlpha at 2018-07-31 09:27:59:000

AbbVie ( ABBV ) investors that fear biosimilars sold the beat-and-raise 2nd quarter earnings report on Friday while Mylan ( MYL ) simultaneously reported positive CHMP opinion for Humira biosimilar, Hulio. Humira will remain the world's top-selling drug in 2018 according to EvaluatePharma …. read more...

AbbVie: No Pain, No Gain

via: SeekingAlpha at 2018-07-31 09:23:07:000

Shares of AbbVie Inc. ( ABBV ) are down 24.20% since peaking on January 26, 2018, and in my opinion, the shares of this maker of Humira are poised to move higher. The company has a solid history of generating strong earnings growth, and the future growth ratios point to accelerated growth over… read more...

AbbVie's Future Is Looking Shaky

via: SeekingAlpha at 2018-07-31 09:00:00:000

AbbVie Inc. ( ABBV ), though still a new company within the healthcare space, having been founded in 2013, the team has been together for much longer. CEO Rick Gonzalez and CFO Bill Chase have both been with the company 31 years and 20 years, respectively. The company is a spin off from Abbott… read more...

Redhill Achieves Positive Results For Phase 2b Study, FDA Meeting On Deck

via: SeekingAlpha at 2018-07-31 00:49:15:000

Recently, Redhill Biopharma ( RDHL ) announced that it had obtained positive results for a late-stage study treating patients with Crohn's Disease. This study was able to meet on both the primary and secondary endpoints of the study. With this positive data on hand, it intends to meet wi… read more...

Dividend Sensei's Portfolio Update 45: Time For Some Spring Cleaning

via: SeekingAlpha at 2018-07-30 11:53:17:000

(Source: imgflip ) Note that due to reader requests I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. In… read more...

Buying The Latest AbbVie Sell-Off With Vigor

via: SeekingAlpha at 2018-07-30 05:01:21:000

Background The mega-cap biotech AbbVie ( ABBV ) was spun off from Abbott ( ABT ) 5 1/2 years ago as the second step in ABT's deconglomeration. It appears that it has returned roughly 22% per year since then. I believe that the stock is undervalued and that the combination of the Citron sho… read more...

3 Things In Biotech, July 29: When Europe Determines Your Fate

via: SeekingAlpha at 2018-07-29 03:31:27:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Amgen gets a rebuff from the EMA Company: Amgen ( AMGN ) Therapy: Blinatumomab Disease:… read more...

Biotech Analysis Central Pharma News: Merck Notches A Win, resTORbio's Positive Phase 2b, Abbvie's Endometriosis Pain Drug Approval

via: SeekingAlpha at 2018-07-28 16:03:25:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Merck Notches Another Win For Keytruda News: Recently, Merck ( MRK ) announced that it had obtained positive results for its phase 3 study treat… read more...

Venture Capital Deals Of The Week: WeWork China Gets $500M

via: SeekingAlpha at 2018-07-28 10:20:21:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. WeWork China: SoftBank ([[SFTBF]], [[SFTBY]]) and SoftBank Vision Fund participated in a $500M Series B … read more...

High-Multiple Medical Devices Companies: Sign Of The Times?

via: SeekingAlpha at 2018-07-28 08:30:00:000

By Daniel Shvartsman At this stage in the market, I'm interested in sectors where valuations seem out of whack but that are less obvious. Everyone knows about FANG or tech, but there are plenty of other sectors attracting money. Medical devices is one that stands out, and today's Idea Gu… read more...

AbbVie Inc.'s (ABBV) CEO Rick Gonzalez on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-27 17:45:55:000

AbbVie, Inc. (ABBV) Q2 2018 Earnings Conference Call July 27, 2018 09:00 am ET Executives Liz Shea VP, IR Rick Gonzalez Chairman, CEO Mike Severino EVP, Research & Development and Chief Scientific Officer Bill Chase EVP and CFO Analyst… read more...

AbbVie Q2 reveues up 19%; non-GAAP EPS up 41%; raises non-GAAP EPS guidance

via: SeekingAlpha at 2018-07-27 07:53:15:000

AbbVie ( ABBV ) Q2 results : Revenues: $8,278M (+19.2%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

AbbVie beats by $0.03, beats on revenue

via: SeekingAlpha at 2018-07-27 07:38:58:000

AbbVie (NYSE: ABBV ): Q2 EPS of $2.00 beats by $0.03 . More news on: AbbVie Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

AbbVie Reports Second-Quarter 2018 Financial Results

via: PR Newswire at 2018-07-27 07:38:00:000

NORTH CHICAGO,Ill., July27, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV) announced financial results for the second quarter ended June30, 2018. "We are extremely pleased with the strong momentum of our business in the quarter and progress year-to-date. We've driven stron… read more...

Keller Lenkner LLC Files Class Action Suit Against AbbVie Inc.

via: PR Newswire at 2018-07-26 18:06:00:000

CHICAGO , July 26, 2018 /PRNewswire/ --Keller Lenkner LLC ("Keller Lenkner") today announced that a class action has been commenced by an institutional investor on behalf of purchasers of AbbVie Inc. ("AbbVie" or the "Company") (NYSE:ABBV) securities on May 30, 2018 (the "Class Pe… read more...

Notable earnings before Friday's open

via: SeekingAlpha at 2018-07-26 17:30:56:000

ABBV , ABCB , ALV , AON , B , BEN , CHSP , CL , COG , CVX , GT , GWR , HRC , IMGN , IMO , IRM , LPNT , MCO , MGLN , MOG.A , MRK , PFS , POR , PSX , PSXP , SAH , SBSI , SYF , TCF , TEN , TPH , TWTR , VIRT , VTR , WETF , WY , XOM , ZBH For Seeking Alp… read more...

Biogen slump pressures other biotechs

via: SeekingAlpha at 2018-07-26 10:32:00:000

Biogen's ( BIIB -8.9% ) post-BAN2401 data-stoked drop appears to be affecting some of the other Alzheimer's players. More news on: Biogen Inc., SPDR Biotech ETF, Eisai Co., Ltd. ADR, Healthcare stocks news, Stocks on the move, News on ETFs, Read more … read more...

Baby DivHut Dividend Income Portfolio Update Q2 2018

via: SeekingAlpha at 2018-07-26 08:05:47:000

Every quarter, I like to review baby DivHut's portfolio and dividend income. With the second quarter of 2018 already in the books, it's time to see how his portfolio has fared. Generally speaking, there is not much change in his portfolio on a month-to-month basis, as fresh capital is not alwa… read more...

Citron Research Explains Why AbbVie Is On Its Way To $60

via: SeekingAlpha at 2018-07-25 11:09:18:000

Disclosure: Read more … read more...

Citron details rationale for bearish view on AbbVie

via: SeekingAlpha at 2018-07-25 09:09:56:000

In a new report , Citron Research details its view that AbbVie (NYSE: ABBV ) is headed to $60 (34% downside risk) per share. More news on: AbbVie Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Abbot: A "Forever" Stock, But Wait For A Better Entry

via: SeekingAlpha at 2018-07-24 14:07:01:000

Much to my surprise Abbot Laboratories ( ABT ) has only been covered in seven articles so far this year (!). This is surprising to me, considering its good track record both in terms of total returns and dividend growth. ABT has outperformed the S&P 500 by a wide margin over the last 50 ye… read more...

Dividend Sensei's Portfolio Update 44: 5 Important Charts All Investors Need To See

via: SeekingAlpha at 2018-07-24 09:40:42:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique,… read more...

FDA OKs AbbVie's elagolix for endometriosis; shares up 1% premarket

via: SeekingAlpha at 2018-07-24 08:42:50:000

The FDA approves AbbVie's (NYSE: ABBV ) ORILISSA (elagolix) for the treatment of women with moderate-to-severe pain related to endometriosis. More news on: AbbVie Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

AbbVie Receives U.S. FDA Approval of ORILISSA(TM) (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis

via: PR Newswire at 2018-07-24 08:30:00:000

NORTH CHICAGO, Ill. , July 24, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the U.S. Food and Drug Administration (FDA) approved ORILISSA (elagolix)… read more...

New FDA Biosimilars Action Plan Poses No Material Threat To Biologic Producers

via: SeekingAlpha at 2018-07-24 08:28:53:000

Biosimilars Action Plan Major biologic drug producers are becoming short targets in the wake of more ostensible FDA action to break up the biopharmaceutical oligopoly. Commissioner Scott Gottlieb again lambasted industry giants in remarks adjunct to Wednesday's announcement of the new Bio… read more...

4 Members Of The $800+ Billion Market Cap Club

via: SeekingAlpha at 2018-07-24 05:37:20:000

Below is an updated look at the 35 largest S&P 500 companies. It's worth noting that recent gains have put four companies into the $800+ billion market cap club . Apple (AAPL) is still on top with a market cap of $933 billion, followed by Amazon (AMZN) at $873 billion, Alphabet (GOOGL) at… read more...

Quarterly Review Of DivGro: Q2 2018

via: SeekingAlpha at 2018-07-20 23:49:17:000

Welcome to the 22nd quarterly review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these rev… read more...

Quarterly Review Of DivGro: Q2 2018

via: SeekingAlpha at 2018-07-20 23:49:17:000

Welcome to the 22nd quarterly review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these rev… read more...

Quarterly Review Of DivGro: Q2 2018

via: SeekingAlpha at 2018-07-20 23:49:17:000

Welcome to the 22nd quarterly review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these rev… read more...

Citron Protection For AbbVie

via: SeekingAlpha at 2018-07-20 04:31:18:000

Bloomberg TV's Abigail Doolittle (screen cap via the episode linked to below). Abbvie Targeted By Citron Shares of AbbVie ( ABBV ) were down more than 7% at one point on Thursday, after the Citron Research shared the tweet below. Bloomberg TV's Abigail Doolittle pushed back aga… read more...

My Dividend Growth Portfolio - Q2 2018 Summary

via: SeekingAlpha at 2018-07-19 19:20:37:000

Introduction It's time to summarize another quarter. This quarter came after a mediocre quarter for me. The first month was a direct continuation of the first quarter. My portfolio suffered from negative returns while the other two months made up for it. The total return in Q2 was 2.2%, whic… read more...

Jane's June Dividend Increases And Income - Retirement Accounts

via: SeekingAlpha at 2018-07-19 16:23:16:000

Investment Thesis June marks the fourth month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the taxable account, we did not start making significant changes to her retirement accounts until after the first of the year. Because of this, there were a num… read more...

Big Pharma in the red on ramped up pressure on drug prices

via: SeekingAlpha at 2018-07-19 11:10:23:000

Drug makers are under pressure as the Trump administration dials up the heat with its plan to corral prices. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, SPDR Biotech ETF, Healthcare stocks news, Stocks on the move, , News on ETFs, Read more … read more...

AbbVie: Fundamental Disconnect

via: SeekingAlpha at 2018-07-19 00:28:43:000

AbbVie Synopsis The performance of AbbVie ( ABBV ) shares through 2018 can be characterized as lackluster. It has performed similar to the S&P 500 and is just above break-even at .8% return on the year. A lot of pessimism is built into the share price relating to two failed clinical test… read more...

FDA committed to easing approval path for biosimilars

via: SeekingAlpha at 2018-07-18 15:08:45:000

In remarks prepared for a presentation to the Brookings Institution, FDA Commissioner Scott Gottlieb, M.D. says the agency is committed to doing its part to reduce healthcare costs, especially as its relates to biosimilars. So far, the market impact of the 11 biosimilars approved in the U… read more...

AbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan

via: PR Newswire at 2018-07-17 08:05:00:000

NORTH CHICAGO, Ill. , July 17, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV) announced today patent license agreements with Mylan over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Mylan a non-exclusive license on specified dates to AbbVi… read more...

50 Is Nifty

via: SeekingAlpha at 2018-07-16 18:49:13:000

I'm a dividend growth investor, recently retired, preparing for a final rollover from a pension account to my IRA. I've been raising some cash, which is now 17.3% of the portfolio (a high percentage for me). I'm in the equity market for the long term, in spite of multiple reasons for caution… read more...

Dividend Sensei's Portfolio Update 43: The 3 Essential Things All Investors Need To Get Rich

via: SeekingAlpha at 2018-07-16 16:49:29:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique,… read more...

The Millennial Portfolio: Longer Than Long Term?

via: SeekingAlpha at 2018-07-16 10:34:54:000

My first article came out on the 26th of March. Since then, I have published a total of 11 articles, covering 8 different stocks. As I have stated in my profile, my goal is to inform millennial investors. It would take a long time to cover every stock I hold in my long-term investment portfoli… read more...

The Smart Way To Find Undervalued Stocks

via: SeekingAlpha at 2018-07-16 08:14:32:000

Value investing is not just about buying stocks with a low price to earnings ratio, thats a too simplistic and ultimately myopic approach. The true essence of value investing is buying a company for a market price below the intrinsic value of the business. Growth is one of the variable… read more...

Biotech Analysis Central Pharma News: Zogenix's Late-Stage Win, Zynerba's Bounce Back, Abbvie's Expanded Venetoclax Use

via: SeekingAlpha at 2018-07-16 01:51:50:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Zogenix Announces Positive Phase 3 Results For Dravet Syndrome News: Recently, Zogenix ( ZGNX ) announced that it had obtained positive phase 3 resul… read more...

Your Daily Pharma Scoop: Zogenix Zooms, Zynerba's Changing Fortunes, AbbVie Proceeds

via: SeekingAlpha at 2018-07-15 01:26:33:000

Stocks in News: ZGNX, ZYNE Zogenix's ZX008 successful in second late-stage study in Dravet Discussion : Zogenix ( ZGNX ) announced positive result of a second Phase 3 clinical trial of its ZX008 (low-dose fenfluramine hydrochloride) in Dravet syndrome. The disease is a rare and severe… read more...

March To Freedom Fund Mid-Year Review

via: SeekingAlpha at 2018-07-13 12:48:30:000

It has been a long time since Ive updated how the dividend growth portfolio of my wife and I has performed. Apparently, one-year-old boys have two speeds: fast and very fast. I havent had much time to write updates because I spend most of my time chasing the Lil Dividend Bro ar… read more...

March To Freedom Fund Mid-Year Review

via: SeekingAlpha at 2018-07-13 12:48:30:000

It has been a long time since Ive updated how the dividend growth portfolio of my wife and I has performed. Apparently, one-year-old boys have two speeds: fast and very fast. I havent had much time to write updates because I spend most of my time chasing the Lil Dividend Bro ar… read more...

3 Things In Biotech, July 13: AbbVie Swings, And AbbVie Also Misses

via: SeekingAlpha at 2018-07-13 08:00:00:000

Funny thing about your birthday falling on the 13th of the month is that it can create some very odd feelings of doom. Not great when you're looking to stay in the markets! With Advaxis (ADXS) taking its dive into new lows, this writer's birthday feel all that much worth celebrating. But we … read more...

3 Things In Biotech, July 13: AbbVie Swings, And AbbVie Also Misses

via: SeekingAlpha at 2018-07-13 08:00:00:000

Funny thing about your birthday falling on the 13th of the month is that it can create some very odd feelings of doom. Not great when you're looking to stay in the markets! With Advaxis (ADXS) taking its dive into new lows, this writer's birthday feel all that much worth celebrating. But we … read more...

Your Daily Pharma Scoop: ResTORbio Progresses, Roche Closer To Review, AbbVie Falters

via: SeekingAlpha at 2018-07-13 04:16:50:000

Stocks in News: TORC, RHHBY ResTORbio's RTB101 shows treatment benefit in mid-stage study; shares up 9% Discussion : ResTORbio ( TORC ) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infecti… read more...

Your Daily Pharma Scoop: ResTORbio Progresses, Roche Closer To Review, AbbVie Falters

via: SeekingAlpha at 2018-07-13 04:16:50:000

Stocks in News: TORC, RHHBY ResTORbio's RTB101 shows treatment benefit in mid-stage study; shares up 9% Discussion : ResTORbio ( TORC ) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infecti… read more...

43 Of 101 S&P 500 Stocks Show 'Safer' Dividends Yielding 3% To 5.55% For July

via: SeekingAlpha at 2018-07-13 03:39:43:000

Actionable Conclusions (1-10): Brokers Estimate Top 10 "Safer" Dividend S&P 500 Stocks Could Net 14.5% to 29.66% Gains By June 2019 Three of the ten tops-by-yield "safer" Dividend S&P 500 (tinted in the chart above) were among the top 10 gainers for the coming year based on ana… read more...

43 Of 101 S&P 500 Stocks Show 'Safer' Dividends Yielding 3% To 5.55% For July

via: SeekingAlpha at 2018-07-13 03:39:43:000

Actionable Conclusions (1-10): Brokers Estimate Top 10 "Safer" Dividend S&P 500 Stocks Could Net 14.5% to 29.66% Gains By June 2019 Three of the ten tops-by-yield "safer" Dividend S&P 500 (tinted in the chart above) were among the top 10 gainers for the coming year based on ana… read more...

Drug prices still marching upward - Bloomberg

via: SeekingAlpha at 2018-07-12 12:20:07:000

Bloomberg reports that, despite the recent concession from Pfizer to delay its price hikes until year-end, some drug makers are ignoring the political climate and instituting price increases now. Recent examples: More news on: Celgene Corporation, Novo Nordisk A/S, Intercept Pharmaceutic… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-07-12 07:58:53:000

AbbVie (NYSE: ABBV ) initiated with Hold rating and $105 (11% upside) price target. Shares are up a fraction premarket. More news on: AbbVie Inc., bluebird bio, Inc., Galmed Pharmaceuticals Ltd., Healthcare stocks news, Stocks on the move, , Read more … read more...

AbbVie files U.S. marketing application for expanded use for Venclexta

via: SeekingAlpha at 2018-07-12 07:00:26:000

AbbVie (NYSE: ABBV ) files a supplemental New Drug Application with the FDA seeking approval to use VENCLEXTA (venetoclax tablets), in combination with a hypomethylating agent or low-dose cytarabine, to treat newly diagnosed patients with acute myeloid leukemia (AML) who are ineligible for… read more...

AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

via: PR Newswire at 2018-07-12 01:01:00:000

Acute myeloid leukemia (AML) is one of the most aggressive cancers, with a very low survival rate and few options available for patients who are ineligible for intensive chemotherapy Median survival is five to 10 months in older AML patients who are ineligible for in… read more...

10 Top 'Safer' Dividend Aristocrats Show 12.5-32.9% Gains Per July Audit

via: SeekingAlpha at 2018-07-11 21:28:30:000

Actionable Conclusions (1-10): Brokers Project Top Ten 'Safer' Dividend Aristocrats Stocks to Net 14.66% to 38.2% Gains To July 2019 Four of the ten biggest yield "safer" Dividend Aristocrats (tinted in the chart above) showed up in the Top ten gainers for the coming year, based on analyst… read more...

Top 10 Of 53 Dividend Aristocrats Yield 3.4%-6.2% In July Update

via: SeekingAlpha at 2018-07-11 17:41:46:000

Actionable Conclusions (1-10): Analysts Cast 16% To 29.2% Net Gains To June 2019 Five of ten top Aristocrats by yield were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices (they are tinted gray in the chart above). Thus, our yield-based … read more...

Big Pharma in the red after Pfizer backs away from price hikes

via: SeekingAlpha at 2018-07-11 09:54:56:000

Members of Big Pharma are down in early trade after Pfizer ( PFE -0.6% ) rolled back its planned price increases after direct intervention from President Trump. Investors apparently perceive diminished prospects for large price increases in the future for drug makers. More news on: Pfize… read more...

AbbVie's Imbruvica flunks late-stage DLBCL study; shares down 2% premarket

via: SeekingAlpha at 2018-07-11 08:20:55:000

AbbVie (NYSE: ABBV ) slips 2% premarket on light volume on the heels of its announcement that a Phase 3 clinical trial, DBL3001, evaluating IMBRUVICA (ibrutinib) + R-CHOP chemo in treatment-naive patients with diffuse large B-cell lymphoma (DLBCL) failed to demonstrate a treatm… read more...

AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program

via: PR Newswire at 2018-07-11 08:00:00:000

- The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases.Fourteen Phase 3 company-sponsored studies are ongoing. - The DBL3001 study targeted a subtype of… read more...

2018 Second Quarter Portfolio Review - Passive Portfolio Management A Success

via: SeekingAlpha at 2018-07-11 06:55:53:000

How much do you need? When do you need it? How sure are you that it will be there? The above mantra from Chowder represents his most often repeated advise when it comes to portfolio construction. How it is applied depends in large part on how many years before the investor star… read more...

Fix Your Roof While The Sun Is Shining: The Dividend Aristocrats Are (Sorta) On Sale

via: SeekingAlpha at 2018-07-11 01:51:05:000

A large number of articles on Seeking Alpha are dedicated to dividend growth investing, and one finds no shortage of articles exhorting investors to consider the Dividend Aristocrats. To Seeking Alpha readers, these stocks need no introduction, but as regular contributor Ploutos reminds us… read more...

Pricing transparency law in California having effect, drug makers nix planned increases

via: SeekingAlpha at 2018-07-10 16:12:53:000

Bloomberg reports that some drug firms have axed plans to increase pricing for certain products or have rolled back hikes in response to a new law in California aimed at pricing transparency. The law, requiring drug makers to give advance notice of significant price increases, is designed … read more...

AbbVie to Host Second-Quarter 2018 Earnings Conference Call

via: PR Newswire at 2018-07-10 08:00:00:000

NORTH CHICAGO, Ill. , July 10, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its second-quarter 2018 financial results on Friday, July 27, 2018 , before the market opens. AbbVie will host a live webcast of the earnings … read more...

Using Ratios To Identify Stocks Set To Outperform Their Peers: Pharmaceutical Rankings Update

via: SeekingAlpha at 2018-07-09 09:18:26:000

Introduction Moving on to the third article in this series, the focus will be on major pharmaceutical companies. The stocks included are Johnson & Johnson ( JNJ ), Abbvie ( ABBV ), Merck ( MRK ), Gilead Sciences ( GILD ), and Pfizer ( PFE ). For the readers who haven't seen my previous r… read more...

Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets

via: SeekingAlpha at 2018-07-09 08:00:00:000

The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul… read more...

Game Plan For The Week - Cramer's Mad Money (7/6/18)

via: SeekingAlpha at 2018-07-09 07:35:03:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday , July 6. The jobs report on Friday was good but the trade war issue still looms. "Ive said many times that trade is a tough issue and we may need to accept some short-term pain if we&#x2019… read more...

Dividend Sensei's Portfolio Update 42: 3 Reasons A Perfect Jobs Report Spells Great News For Stocks

via: SeekingAlpha at 2018-07-09 02:16:58:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique,… read more...

Retirement: Should You Prepare For The Next Downturn Now?

via: SeekingAlpha at 2018-07-07 10:00:00:000

We are not trying to sound an alarm. In fact, the markets are just doing fine. Even though the volatility is a bit high and there are worries over trade and tariffs, rising interest rates and host of other issues, but the markets may eventually climb over the wall of worry and continue to touc… read more...

Retirement: Should You Prepare For The Next Downturn Now?

via: SeekingAlpha at 2018-07-07 10:00:00:000

We are not trying to sound an alarm. In fact, the markets are just doing fine. Even though the volatility is a bit high and there are worries over trade and tariffs, rising interest rates and host of other issues, but the markets may eventually climb over the wall of worry and continue to touc… read more...

The Story Depends On How You Look At It

via: SeekingAlpha at 2018-07-06 14:49:16:000

On a large n level, and looking at most stocks, markets seem to me to be relatively efficient. I am not looking at academic research and don't have the time to pull this together to make a convincing case. But it is difficult to outperform indices, it is difficult for individuals to predict th… read more...

Alzheimer's players in the green on Biogen news

via: SeekingAlpha at 2018-07-06 10:12:33:000

Most players in the Alzheimer's disease space are in the green after Biogen announced positive mid-stage data on BAN2401. More news on: vTv Therapeutics, Tonix Pharmaceuticals Holding Corp., ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Healthcare Dashboard - Update

via: SeekingAlpha at 2018-07-05 18:47:10:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive Summary Biotechnology is undervalued regarding historical averages in 2 metrics: price/earn… read more...

AbbVie prevails in second AndroGel liability case; shares up 1%

via: SeekingAlpha at 2018-07-05 15:07:28:000

Attorneys for AbbVie ( ABBV +1.3% ) successfully persuaded a Chicago district court judge to toss a previous $140M award related to allegations that the company concealed the heart attack risks of testosterone replacement therapy AndroGel. More news on: AbbVie Inc., Healthcare stocks new… read more...

AbbVie: The Right Combination Of Dividends And Growth

via: SeekingAlpha at 2018-07-05 14:46:07:000

Article Thesis AbbVie ( ABBV ) is an attractive investment for income seekers, as it offers a 4%+ dividend yield with a lot of growth potential. The company's shares will produce compelling total returns over the coming years, through a combination of earnings growth, share repurchases, and … read more...

Insurers making headway on corralling drug costs with copay accumulators

via: SeekingAlpha at 2018-07-05 09:24:45:000

Reuters reports that drug makers are "scrambling" to limit the financial impact of copay accumulator programs by insurers and pharmacy benefit managers (PBMs). The scheme, which forces drug manufacturers to pony up more money to assist patients with copay costs or face declining demand for… read more...

A Real Dividend Growth Machine: Q2 2018 Portfolio Review

via: SeekingAlpha at 2018-07-05 03:47:22:000

Introduction The purpose of this article is to review my investing progress in the second quarter of 2018. I follow a value-oriented dividend growth investing strategy that involves buying attractively valued stocks of companies that consistently pay and grow their dividends. My long-term in… read more...

Rose Portfolio 93 Stock Cost Per Share Revealed In The First Half And Q2 2018 Report

via: SeekingAlpha at 2018-07-03 11:17:50:000

The Rose Portfolio 93 investments in the Rose portfolio and all golden to me, while chosen with utmost care and consideration for quality and dividend reliability. In a previous article here , I discuss S&P credit ratings and consistency of dividend raises. These traits are importa… read more...

Rose Portfolio 93 Stock Cost Per Share Revealed In The First Half And Q2 2018 Report

via: SeekingAlpha at 2018-07-03 11:17:50:000

The Rose Portfolio 93 investments in the Rose portfolio and all golden to me, while chosen with utmost care and consideration for quality and dividend reliability. In a previous article here , I discuss S&P credit ratings and consistency of dividend raises. These traits are importa… read more...

Pfizer boosts prices of certain drugs by almost 10%

via: SeekingAlpha at 2018-07-03 11:17:01:000

The Wall Street Journal reports that Pfizer ( PFE +0.5% ) has increased the list prices for over 40 medications, its second hike this year. Some, including Xalkori, Norvasc, Celebrex and Zoloft, were bumped 9.4%. More news on: Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Healt… read more...

Pfizer boosts prices of certain drugs by almost 10%

via: SeekingAlpha at 2018-07-03 11:17:01:000

The Wall Street Journal reports that Pfizer ( PFE +0.5% ) has increased the list prices for over 40 medications, its second hike this year. Some, including Xalkori, Norvasc, Celebrex and Zoloft, were bumped 9.4%. More news on: Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Healt… read more...

5 Dividend Increases: June 25-29, 2018

via: SeekingAlpha at 2018-07-03 09:25:56:000

I like monitoring dividend increases for stocks on my watch list of dividend growth stocks because I consider such stocks to be candidates for further analysis. Companies that regularly raise dividends show confidence in the potential growth of future earnings. The CCC List provides a good… read more...

5 Dividend Increases: June 25-29, 2018

via: SeekingAlpha at 2018-07-03 09:25:56:000

I like monitoring dividend increases for stocks on my watch list of dividend growth stocks because I consider such stocks to be candidates for further analysis. Companies that regularly raise dividends show confidence in the potential growth of future earnings. The CCC List provides a good… read more...

FDA withdraws draft guidance related to biosimilar development

via: SeekingAlpha at 2018-07-02 12:59:00:000

The FDA has withdrawn its draft guidance on statistical methods to assess analytical similarity between biosimilars and reference drugs after receiving public comments and a lone citizen petition from Pharmaceutical Scientist founder Sarfaraz Niazi, an adjunct professor at the University o… read more...

Abbott Labs And Abbvie - 5 Years Later

via: SeekingAlpha at 2018-07-02 08:55:52:000

At the start of 2013, Abbott Laboratories ( ABT ) spun off its branded pharmaceutical business, which has traded since then as Abbvie Inc. ( ABBV ). Prior to the split, Abbott Laboratories was a massively diversified healthcare firm with operations in diagnostics, medical devices, nutrition an… read more...

Dividend Sensei's Portfolio Update 41: 3 Growing Economic Risks You Need To Be Aware Of

via: SeekingAlpha at 2018-07-02 07:12:50:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique,… read more...

AbbVie Trying Its Hand At All-In-One Screwdriver CAR-T Cancer Immunotherapy

via: SeekingAlpha at 2018-06-30 03:09:40:000

CAR-T technology seems to be evolving and progressing faster than smartphones, at least in theoretical prototypes if not actual treatments. The latest exciting move comes from AbbVie ( ABBV ), which is moving to the CAR-T space in a licensing partnership with the California Institute for Biome… read more...

AbbVie Trying Its Hand At All-In-One Screwdriver CAR-T Cancer Immunotherapy

via: SeekingAlpha at 2018-06-30 03:09:40:000

CAR-T technology seems to be evolving and progressing faster than smartphones, at least in theoretical prototypes if not actual treatments. The latest exciting move comes from AbbVie ( ABBV ), which is moving to the CAR-T space in a licensing partnership with the California Institute for Biome… read more...

AbbVie, partner to pay $448M in AndroGel antitrust case, judge rules

via: SeekingAlpha at 2018-06-29 23:32:10:000

A U.S. District Judge today ordered AbbVie (NYSE: ABBV ) and partner Besins Healthcare to pay $448M for using sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from reaching the market. More news on: AbbVie Inc., Healthcare stocks news, R… read more...

AbbVie, partner to pay $448M in AndroGel antitrust case, judge rules

via: SeekingAlpha at 2018-06-29 23:32:10:000

A U.S. District Judge today ordered AbbVie (NYSE: ABBV ) and partner Besins Healthcare to pay $448M for using sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from reaching the market. More news on: AbbVie Inc., Healthcare stocks news, R… read more...

Vertex +7.1% as rival Galapagos stumbles with AbbVie

via: SeekingAlpha at 2018-06-28 19:30:33:000

Vertex Pharmaceuticals (NASDAQ: VRTX ) is up 7.1% after hours following the release of data from rival Galapagos (NASDAQ: GLPG ) that led AbbVie (NYSE: ABBV ) to pull out of plans to proceed on triple combination therapy for cystic fibrosis. More news on: Vertex Pharmaceuticals Incorpo… read more...

Vertex +7.1% as rival Galapagos stumbles with AbbVie

via: SeekingAlpha at 2018-06-28 19:30:33:000

Vertex Pharmaceuticals (NASDAQ: VRTX ) is up 7.1% after hours following the release of data from rival Galapagos (NASDAQ: GLPG ) that led AbbVie (NYSE: ABBV ) to pull out of plans to proceed on triple combination therapy for cystic fibrosis. More news on: Vertex Pharmaceuticals Incorpo… read more...

Galapagos -13% after AbbVie pulls out of cystic fibrosis development plans

via: SeekingAlpha at 2018-06-28 18:09:08:000

Galapagos (NASDAQ: GLPG ) -13.3% after-hours following news that AbbVie (NYSE: ABBV ) decided not to proceed with a study of a combination therapy for cystic fibrosis, and GLPG says it is reviewing the future of its collaboration with ABBV. More news on: Galapagos, AbbVie Inc., Healthc… read more...

Galapagos -13% after AbbVie pulls out of cystic fibrosis development plans

via: SeekingAlpha at 2018-06-28 18:09:08:000

Galapagos (NASDAQ: GLPG ) -13.3% after-hours following news that AbbVie (NYSE: ABBV ) decided not to proceed with a study of a combination therapy for cystic fibrosis, and GLPG says it is reviewing the future of its collaboration with ABBV. More news on: Galapagos, AbbVie Inc., Healthc… read more...

AbbVie On A Roll, Buy AbbVie

via: SeekingAlpha at 2018-06-28 04:11:46:000

Back on March 28th I wrote an article on pharmaceutical spinoff AbbVie (NYSE: ABBV ) in the wake of some disappointing trial results regarding new small cell lung cancer treatment Rova-T. While the results for Rova-T were no doubt a setback, I argued that it was only a minor setback because … read more...

AbbVie On A Roll, Buy AbbVie

via: SeekingAlpha at 2018-06-28 04:11:46:000

Back on March 28th I wrote an article on pharmaceutical spinoff AbbVie (NYSE: ABBV ) in the wake of some disappointing trial results regarding new small cell lung cancer treatment Rova-T. While the results for Rova-T were no doubt a setback, I argued that it was only a minor setback because … read more...

Roche Won't Go Down Without A Fight In The Front-Line Cancer Arena

via: SeekingAlpha at 2018-06-27 14:16:29:000

Recently, Roche ( RHHBY ) released news for its Phase 3 trial treating patients with front-line lung cancer. It was shown that small-cell lung cancer ((SCLC)) patients in the front-line setting, given the Tecentriq and chemo combination, lived longer. This should help Roche take the lead for… read more...

3 Things In Biotech, June 27: The Cat Pounces, And You Might Still Have Time! Also, Google Gets Into Healthcare?

via: SeekingAlpha at 2018-06-27 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. AbbVie and Google-backed early biotech look to continue anti-aging research Company: … read more...

Here Are 43 Of 84 'Safer' Healthcare High Yield Dividend Equities For June

via: SeekingAlpha at 2018-06-26 22:51:03:000

Actionable Conclusions (1-10): Brokers Estimated Top 10 High Yield Healthcare "Safer" Dividend Stocks to Net 9% to 22.98% Gains To June 2019 Five of ten top "safer" dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top 10 gainers for the comin… read more...

Alphabet roundup: Ex-Pentagon official "alarmed", $1B commitment with AbbVie

via: SeekingAlpha at 2018-06-26 14:13:34:000

Former Deputy Defense Secretary Robert O. Work says he is alarmed by Googles ( GOOG )( GOOGL ) decision to withdraw from a department initiative using AI to analyze drone footage. More news on: Alphabet, Inc. Cl C, Alphabet, Inc. Cl A, AbbVie Inc., Tech stocks ne… read more...

Google sister company and drug giant chip in another $1 billion to cure age-related diseases

via: CNBC at 2018-06-26 10:54:00:000

No summary available. read more...

AbbVie, Calico to invest combined $1B in extending collaboration

via: SeekingAlpha at 2018-06-26 08:49:27:000

AbbVie (NYSE: ABBV ) +0.9% premarket after announcing an extension of its collaboration with Alphabet-backed life sciences company Calico to develop new therapies for patients with age-related diseases, including neurodegeneration and cancer. More news on: AbbVie Inc., Healthcare … read more...

AbbVie and Calico Announce Extension of Groundbreaking Collaboration

via: PR Newswire at 2018-06-26 08:00:00:000

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. , June 26, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Calico, a company focused on aging research and therapeutics, today announced an extension of their collaboration to disco… read more...

3 Things In Biotech, June 26: One Piece Of Good News Offset By A Cascade Of Bad?

via: SeekingAlpha at 2018-06-26 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche scores a momentous win in small cell lung cancer Company: Roche (RHHBF) Therapy… read more...

Top 5 Healthcare Dividend Stocks - A Must To Build A Core Portfolio

via: SeekingAlpha at 2018-06-26 06:49:39:000

Healthcare can be a profitable sector to have in your portfolio. Any dividend growth investor should consider having at least one healthcare dividend stock. As a market, the healthcare industry is highly regulated and not easy to get into, but yet, new research and findings continue to off… read more...

59 Top-Yield Healthcare Equities For June

via: SeekingAlpha at 2018-06-26 05:02:46:000

Actionable Conclusions (1-10): Analysts Projected 6% To 23% Net Gains For Top Ten Healthcare Stocks By June 2019 Just two of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year, based on broker 1-year target prices. (They a… read more...

Dividend Sensei's Portfolio Update 40: How Dividend Stocks Could Save You A Fortune During The Next Market Crash

via: SeekingAlpha at 2018-06-26 03:51:52:000

(source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my uniqu… read more...

What's In My Portfolio: June 2018 Review

via: SeekingAlpha at 2018-06-25 23:23:09:000

My Portfolio Currently I figured I would offer a brief overview of what is in my portfolio for the followers who are interested. Everyone has their own investment objectives and should try to build a portfolio that meets what they are looking for short or long term. These positions stay st… read more...

The Best Dividend-Paying Biotech Stocks For Your Portfolio

via: SeekingAlpha at 2018-06-25 11:41:16:000

Biopharma and Dividends Biotechnology and Pharmaceutical stocks often grab headlines over spectacular clinical successes or failures that send the price soaring (in either direction!). Indeed, the sector is ripe with speculation trying to find the next multi-billion dollar drug. A consequenc… read more...

IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer

via: PR Newswire at 2018-06-25 09:00:00:000

NORTH CHICAGO, Ill. , June 25, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental New Drug Application (sNDA) for IMBRUVICA (i… read more...

AbbVie and Calibr announce collaboration for next generation T-cell therapies

via: PR Newswire at 2018-06-25 07:00:00:000

NORTH CHICAGO, Ill. and LA JOLLA, Calif. , June 25, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed pr… read more...

Recent Stock Purchase June 2018

via: SeekingAlpha at 2018-06-23 09:37:35:000

With three weeks of June in the rear view mirror, it is time, once again, to highlight my recent stock purchase. As market volatility remains the flavor of the day, we are being presented with some pretty good buying opportunities, if you can stomach these wild swings. Of course, if you have a… read more...

Recent Stock Purchase June 2018

via: SeekingAlpha at 2018-06-23 09:37:35:000

With three weeks of June in the rear view mirror, it is time, once again, to highlight my recent stock purchase. As market volatility remains the flavor of the day, we are being presented with some pretty good buying opportunities, if you can stomach these wild swings. Of course, if you have a… read more...

What Does Breakthrough Therapy Designation Really Mean For My Company?

via: SeekingAlpha at 2018-06-23 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th… read more...

What Does Breakthrough Therapy Designation Really Mean For My Company?

via: SeekingAlpha at 2018-06-23 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th… read more...

AbbVie's Humira could face pressure from biosimilars, analyst says

via: SeekingAlpha at 2018-06-22 15:21:42:000

AbbVie ( ABBV -1.6% ) tumbles to a two-month low after Credit Suisse said the company's blockbuster arthritis treatment Humira could face increasing sales pressure from rival copycat drugs later this year. More news on: AbbVie Inc., Healthcare stocks news, Stocks on the move, Read … read more...

The No. 1 Stock In The World (Redux) - Part 3

via: SeekingAlpha at 2018-06-22 00:41:08:000

Three years ago, I asked a panel of Seeking Alpha regulars to take part in the audacious exercise of choosing the best stock in the world. The three-part series that came out of it ( Part 1 , Part 2 , Part 3 ) turned out to be such a hit with readers that I wanted to do an updated version … read more...

19 'Safer' Dividends From My Readers 36 Most Mentioned June Dividend Stocks

via: SeekingAlpha at 2018-06-19 15:21:46:000

The FoFa/Ro Selection Process Any dividend paying stock mentioned in a message, e-mail or comment to the author is fair game for a listing in this article. Thus, It is possible that only rogues and discontinued or dreadful dividend issues may appear. Lately readers and other contributors h… read more...

19 'Safer' Dividends From My Readers 36 Most Mentioned June Dividend Stocks

via: SeekingAlpha at 2018-06-19 15:21:46:000

The FoFa/Ro Selection Process Any dividend paying stock mentioned in a message, e-mail or comment to the author is fair game for a listing in this article. Thus, It is possible that only rogues and discontinued or dreadful dividend issues may appear. Lately readers and other contributors h… read more...

Dividend Sensei's Portfolio Update 39: 3 Reasons You Should Avoid This Dangerous Type Of High-Yield Stock

via: SeekingAlpha at 2018-06-19 09:21:32:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique,… read more...

Dividend Sensei's Portfolio Update 39: 3 Reasons You Should Avoid This Dangerous Type Of High-Yield Stock

via: SeekingAlpha at 2018-06-19 09:21:32:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique,… read more...

8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week of Possibilities"

via: PR Newswire at 2018-06-19 09:21:00:000

NORTH CHICAGO, Ill. , June 19, 2018 /PRNewswire/ --AbbVie, a global biopharmaceutical company, has teamed up with leading nonprofits to launch its fifth annual "Week of Possibilities" global volunteering program. In more than 50 countries, approximately 8,000 AbbVie employees… read more...

8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week of Possibilities"

via: PR Newswire at 2018-06-19 09:21:00:000

NORTH CHICAGO, Ill. , June 19, 2018 /PRNewswire/ --AbbVie, a global biopharmaceutical company, has teamed up with leading nonprofits to launch its fifth annual "Week of Possibilities" global volunteering program. In more than 50 countries, approximately 8,000 AbbVie employees… read more...

Jane's May Dividend Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-06-18 20:37:28:000

Investment Thesis May marks the third month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the taxable account, we did not start making significant changes to her retirement accounts until after the first of the year. Because of this, there were a num… read more...

Jane's May Dividend Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-06-18 20:37:28:000

Investment Thesis May marks the third month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the taxable account, we did not start making significant changes to her retirement accounts until after the first of the year. Because of this, there were a num… read more...

The No. 1 Stock In The World (Redux) - Part 2

via: SeekingAlpha at 2018-06-18 16:29:54:000

My daughter used to be uncanny at finding money. We'd be walking through a parking lot or on a sidewalk or in a field, and she would look down and gleefully exclaim: "Hey … there's a 5 dollar bill!" Over the years, she found a few $20s, some $10s and lots of $1s. She once even found a $2 bil... read more...

Dividend Portfolio Review: New Dividend Record

via: SeekingAlpha at 2018-06-18 08:40:48:000

It's May and this is the best time of the year for a German dividend investor as this is the month where most of Germany's companies distribute their annual dividends. As such it was no surprise that May set a new record in dividend income but I am still baffled by the amount and the growth co… read more...

3 Things In Biotech, June 16: Do You Know Anything About EHA?

via: SeekingAlpha at 2018-06-17 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech," a daily digest dedicate… read more...

AbbVie: Growth And Dividend In One Package

via: SeekingAlpha at 2018-06-15 14:16:00:000

Abbvie Overview AbbVie ( ABBV ) is a biotechnology company focused on producing therapies across four primary therapeutic areas: immunology, oncology, virology, and neuroscience. It was founded in 2013 as a spin-off of the biopharmaceuticals division of Abbott Labs ( ABT ). Since inception, … read more...

AbbVie: Growth And Dividend In One Package

via: SeekingAlpha at 2018-06-15 14:16:00:000

Abbvie Overview AbbVie ( ABBV ) is a biotechnology company focused on producing therapies across four primary therapeutic areas: immunology, oncology, virology, and neuroscience. It was founded in 2013 as a spin-off of the biopharmaceuticals division of Abbott Labs ( ABT ). Since inception, … read more...

Avoiding The 'Black Hole' Of Disease Development

via: SeekingAlpha at 2018-06-15 12:24:55:000

"Whoever fights monsters should see to it that in the process he does not become a monster. And if you gaze long enough into an abyss, the abyss will gaze back into you." - Friedrich Nietzsche Today, we are going to talk about two major disease areas that are garnering billions of dollars … read more...

Avoiding The 'Black Hole' Of Disease Development

via: SeekingAlpha at 2018-06-15 12:24:55:000

"Whoever fights monsters should see to it that in the process he does not become a monster. And if you gaze long enough into an abyss, the abyss will gaze back into you." - Friedrich Nietzsche Today, we are going to talk about two major disease areas that are garnering billions of dollars … read more...

AbbVie declares $0.96 dividend

via: SeekingAlpha at 2018-06-15 04:33:37:000

AbbVie (NYSE: ABBV ) declares $0.96/share quarterly dividend , in line with previous. More news on: AbbVie Inc., Dividend News, Read more … read more...

AbbVie declares $0.96 dividend

via: SeekingAlpha at 2018-06-15 04:33:37:000

AbbVie (NYSE: ABBV ) declares $0.96/share quarterly dividend , in line with previous. More news on: AbbVie Inc., Dividend News, Read more … read more...

AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress

via: PR Newswire at 2018-06-15 02:45:00:000

NORTH CHICAGO, Ill. , June 15, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase 3 MURA… read more...

AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress

via: PR Newswire at 2018-06-15 02:45:00:000

NORTH CHICAGO, Ill. , June 15, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase 3 MURA… read more...

AbbVie Declares Quarterly Dividend

via: PR Newswire at 2018-06-14 18:52:00:000

NORTH CHICAGO, Ill. , June 14, 2018 /PRNewswire/ --The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Aug. 15, 2018 to stockholders of record at the close of business on July 13, 2018 …. read more...

3 Things In Biotech, June 13: Ripples, Transitions, And A Hint At Something Important

via: SeekingAlpha at 2018-06-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

Dividend Income - May 2018

via: SeekingAlpha at 2018-06-14 07:04:19:000

I hope you don't sell in May. That's not a strategy worth following. That would be like timing the market and blindly doing it. I prefer to stay put, earn my dividend while it's slow, average down with the DRIP and then ride the wave back up. Stock Trades I made no trades in May, but I hav… read more...

AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)

via: PR Newswire at 2018-06-12 18:38:00:000

NORTH CHICAGO, Ill. , June 12, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented new patient-reported outcome data during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials eval… read more...

AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)

via: PR Newswire at 2018-06-12 18:38:00:000

NORTH CHICAGO, Ill. , June 12, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented new patient-reported outcome data during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials eval… read more...

May Update For My 92 Investment Rose Portfolio With Bonus Add On Future Purchasing Evaluation Plan

via: SeekingAlpha at 2018-06-12 11:06:53:000

The Rose portfolio The Rose Portfolio consists of 2 Roths, a taxable trust account and 9 separate company stocks outside of the broker. It now sits at 92 Investments and on average ~4.6% dividend yield on value. I hope to do a quarterly report at the end of June for portfolio value and divid… read more...

May Update For My 92 Investment Rose Portfolio With Bonus Add On Future Purchasing Evaluation Plan

via: SeekingAlpha at 2018-06-12 11:06:53:000

The Rose portfolio The Rose Portfolio consists of 2 Roths, a taxable trust account and 9 separate company stocks outside of the broker. It now sits at 92 Investments and on average ~4.6% dividend yield on value. I hope to do a quarterly report at the end of June for portfolio value and divid… read more...

Dividend Income Update: May 2018

via: SeekingAlpha at 2018-06-12 06:10:24:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online, as it only provides further proof that dividend inves… read more...

Dividend Income Update: May 2018

via: SeekingAlpha at 2018-06-12 06:10:24:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online, as it only provides further proof that dividend inves… read more...

Dividend Sensei's Portfolio Update 38: Why The Stock Market Might Soar 22% In The Next 18 Months And Then Crash 50%

via: SeekingAlpha at 2018-06-12 05:31:25:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my uni… read more...

Dividend Sensei's Portfolio Update 38: Why The Stock Market Might Soar 22% In The Next 18 Months And Then Crash 50%

via: SeekingAlpha at 2018-06-12 05:31:25:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my uni… read more...

Dividend Update - May 2018

via: SeekingAlpha at 2018-06-12 02:13:29:000

May has been an exciting month. The weather is finally starting to turn warmer. Wedding season is in the air. I was fortunate enough to take a small vacation. Also, celebrated my birthday as well as buying myself a little birthday gift of stock when I last purchased ABBV . While the whole tim… read more...

Dividend Update - May 2018

via: SeekingAlpha at 2018-06-12 02:13:29:000

May has been an exciting month. The weather is finally starting to turn warmer. Wedding season is in the air. I was fortunate enough to take a small vacation. Also, celebrated my birthday as well as buying myself a little birthday gift of stock when I last purchased ABBV . While the whole tim… read more...

Monthly Review Of DivGro: May 2018

via: SeekingAlpha at 2018-06-11 10:25:57:000

Welcome to the monthly review of DivGro, my portfolio of dividend growth stocks. I present details of any buys or sells, and I provide a summary of dividends collected. I also look at how DivGro's projected annual dividend income ((PADI)) has changed. In May, I opened three new positions and… read more...

Your Daily Pharma Scoop: Zealand Dips, Eloxx Surges, Venetoclax Approved

via: SeekingAlpha at 2018-06-11 08:00:00:000

Analysis Focus: ZEAL Zealand Pharma ( ZEAL ) is a small Danish company that specializes in gastroenteric and metabolic diseases. The company has late-stage clinical programs with glepaglutide and three dasiglucagon product candidates. They also have a late-stage program in Phase 3 developm… read more...

3 Things In Biotech, June 9: AbbVie Rules The CLL Roost

via: SeekingAlpha at 2018-06-10 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

The 'Dividend Aristocrats' That Live Beyond Their Means

via: SeekingAlpha at 2018-06-10 03:55:27:000

The dividend aristocrats are stocks that have increased their dividends every year for at least 25 years. Unsurprisingly, theyre popular among investors looking for a reliable stream of growing income. However, many of these companies regularly pay out more cash than t… read more...

AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy

via: PR Newswire at 2018-06-08 14:55:00:000

NORTH CHICAGO, Ill. , June 8, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved, under priority review, VENCLEXTA (venetoclax tablets) in combination with rituximab fo… read more...

AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy

via: PR Newswire at 2018-06-08 14:55:00:000

NORTH CHICAGO, Ill. , June 8, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved, under priority review, VENCLEXTA (venetoclax tablets) in combination with rituximab fo… read more...

FDA grants full approval for AbbVie and Roche's venetoclax for CLL & SLL

via: SeekingAlpha at 2018-06-08 13:44:39:000

The FDA grants full (regular) approval for AbbVie ( ABBV +0.6% ) and development partner Roche ( OTCQX:RHHBY -0.8% ) unit Genentech's venetoclax for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at … read more...

FDA grants full approval for AbbVie and Roche's venetoclax for CLL & SLL

via: SeekingAlpha at 2018-06-08 13:44:39:000

The FDA grants full (regular) approval for AbbVie ( ABBV +0.6% ) and development partner Roche ( OTCQX:RHHBY -0.8% ) unit Genentech's venetoclax for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at … read more...

Using Ratios To Identify Stocks Set To Outperform Their Peers: Introducing My Research

via: SeekingAlpha at 2018-06-08 12:10:33:000

Intro I've been fascinated with ratios and their ability to capture certain aspects of a business in just one number for quite a while. Sure, ratios use historical data and thus don't predict future performance, but they can give key insights as to how well a company is running. On this note… read more...

Using Ratios To Identify Stocks Set To Outperform Their Peers: Introducing My Research

via: SeekingAlpha at 2018-06-08 12:10:33:000

Intro I've been fascinated with ratios and their ability to capture certain aspects of a business in just one number for quite a while. Sure, ratios use historical data and thus don't predict future performance, but they can give key insights as to how well a company is running. On this note… read more...

Eloxx Pharma's ELX-02 shows encouraging action in preclinical CF studies; investors unmoved, shares down 11%

via: SeekingAlpha at 2018-06-08 12:06:43:000

Investors appear unimpressed with preclinical data on Eloxx Pharmaceuticals' ( ELOX -10.6% ) lead candidate ELX-02 for the treatment of certain cystic fibrosis (CF) patients. The results were presented at the European Cystic Fibrosis Conference in Belgrade. More news on: Eloxx Pharmace… read more...

Eloxx Pharma's ELX-02 shows encouraging action in preclinical CF studies; investors unmoved, shares down 11%

via: SeekingAlpha at 2018-06-08 12:06:43:000

Investors appear unimpressed with preclinical data on Eloxx Pharmaceuticals' ( ELOX -10.6% ) lead candidate ELX-02 for the treatment of certain cystic fibrosis (CF) patients. The results were presented at the European Cystic Fibrosis Conference in Belgrade. More news on: Eloxx Pharmace… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock - AbbVie, Absolutely

via: SeekingAlpha at 2018-06-07 12:55:50:000

Here's a look from an average investor's perspective about the next stock after APPL currently in my rollover IRA. What's ABBV do? Abbvie is a leading biopharmaceutical company which focuses on an existing portfolio and pipeline development of new pharmaceuticals to manage existing acute a… read more...

10 Top 'Safer' Dividend Aristocrats Yield 3%-4%, With 14%-29% Gains Per June Audit

via: SeekingAlpha at 2018-06-07 12:08:02:000

Actionable Conclusions (1-10): Brokers Project Top Ten 'Safer' Dividend Aristocrats Stocks to Net 14.62% to 29.22% Gains To June 2019 Five of ten top yield "safer" Dividend Aristocrats (tinted in the chart above) were also in the Top ten gainers for the coming year based on analyst 1 year … read more...

Your Daily Pharma Scoop: Endra Zooms, Biogen And Eisai Present Positive Results, Synergy Moves Up

via: SeekingAlpha at 2018-06-07 10:00:00:000

Analysis Focus: NDRA With just $7.8M market capitalization and 13 full-time employees, Endra Life Sciences (NDRA) was part of all financial news sources yesterday when its stock prices jumped +58.1%. The company was incorporated in 2007 and offered its IPO in May 2017. The IPO was priced… read more...

53 Dividend Aristocrats Yield .5% To 6.12% Per June Reckoning

via: SeekingAlpha at 2018-06-07 02:03:17:000

Actionable Conclusions (1-10): Analysts Cast 16% To 29.2% Net Gains To June, 2019 Five of ten top Aristocrats by yield were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the chart above). Thus, our yield… read more...

PBMs one-up drug makers on drug copay assistance schemes

via: SeekingAlpha at 2018-06-06 11:41:10:000

Reuters reports that U.S. drug prices fell 5.6% in Q1, 3.6% more than a year ago. Sector & Sovereign analyst Richard Evans believes most of the decline is from "copay accumulator" programs instituted by pharmacy benefit managers (PBMs) last quarter that do not allow copay assistance pa… read more...

Mining ASCO 2018's Gold, Part 12: Let's Talk About Blood, Baby

via: SeekingAlpha at 2018-06-06 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

More Thoughts On AbbVie's Rova-T Implosion

via: SeekingAlpha at 2018-06-06 05:10:01:000

I wrote a couple of months ago about the disappointing results that AbbVie (ABBV) had obtained with their cancer stem cell therapy "Rova-T" (rovalpituzumab tesirine) in small-cell lung cancer. This was the antibody-drug conjugate that they'd purchased from Stemcentryx - OK, let's clarify tha… read more...

AbbVie: Venclexta, Imbruvica Helping Patients With B Cell Malignancies

via: SeekingAlpha at 2018-06-05 13:28:23:000

AbbVie ( ABBV ) and partners are gradually disrupting the treatment paradigm for CLL (chronic lymphocytic leukemia) and Waldenstrm's macroglobulinemia as evidence accumulates that Venclexta and Imbruvica each extends progression-free survival. Imbruvica is synergistic with Rituxan in … read more...

AbbVie's upadacitinib successful in another late-stage RA study

via: SeekingAlpha at 2018-06-05 12:11:54:000

AbbVie ( ABBV +0.2% ) announces positive results from a fifth pivotal trial, SELECT-EARLY , assessing JAK1 inhibitor upadacitinib in rheumatoid arthritis (RA) patients. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

My 30 Stock Portfolio +3 Adds

via: SeekingAlpha at 2018-06-05 09:45:40:000

Welcome to my second portfolio update of 2018. The goal of my portfolio is financial freedom. My plan is a combination of dividend growth investing and buying stocks that will beat the market. I call the DGI portion of my portfolio my "dividend machine", I do not DRIP, rather build up cash and… read more...

By The Numbers: Consistent Growth Leaders With Strong Fundamentals

via: SeekingAlpha at 2018-06-05 09:12:26:000

Investing in growth stocks can generate outstanding returns over the long term. However, growth stocks are also particularly volatile, and companies with superior growth can many times carry above-average risks too. The key, like usually happens, is separating the fundamentally sound companies… read more...

Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis

via: PR Newswire at 2018-06-05 08:30:00:000

NORTH CHICAGO, Ill. , June 5, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from SELECT-EARLY showing that both doses of upadacitinib monotherapy (15 mg and 30 mg) met the primary endpoints of AC… read more...

Biotech Bio Series #3: Should You Buy The Dip On AbbVie?

via: SeekingAlpha at 2018-06-04 09:27:10:000

This is the third article of the Biotech Bio Series. Big pharma and biotechnology is one of the most exciting sectors in the world today, researching and developing drugs that allow all of us to live longer than ever before. For companies behind this innovation, the approval of one drug may … read more...

AbbVie Announces Final Results of Tender Offer

via: PR Newswire at 2018-06-04 08:00:00:000

NORTH CHICAGO, Ill. , June 4, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, at the end of May 29, 2018 . AbbVie has accepted for purchase 72,815,534 shar… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Translate Bio readies IPO

via: SeekingAlpha at 2018-06-02 11:49:33:000

Lexington, MA-based Translate Bio (TBIO) has filed a prospectus for its U.S. IPO. More news on: Proteostasis Therapeutics, Vertex Pharmaceuticals Incorporated, Verona Pharma plc, Healthcare stocks news, IPOs, Read more … read more...

Translate Bio readies IPO

via: SeekingAlpha at 2018-06-02 11:49:33:000

Lexington, MA-based Translate Bio (TBIO) has filed a prospectus for its U.S. IPO. More news on: Proteostasis Therapeutics, Vertex Pharmaceuticals Incorporated, Verona Pharma plc, Healthcare stocks news, IPOs, Read more … read more...

Translate Bio readies IPO

via: SeekingAlpha at 2018-06-02 11:49:33:000

Lexington, MA-based Translate Bio (TBIO) has filed a prospectus for its U.S. IPO. More news on: Proteostasis Therapeutics, Vertex Pharmaceuticals Incorporated, Verona Pharma plc, Healthcare stocks news, IPOs, Read more … read more...

Translate Bio readies IPO

via: SeekingAlpha at 2018-06-02 11:49:33:000

Lexington, MA-based Translate Bio (TBIO) has filed a prospectus for its U.S. IPO. More news on: Proteostasis Therapeutics, Vertex Pharmaceuticals Incorporated, Verona Pharma plc, Healthcare stocks news, IPOs, Read more … read more...

Stocks To Watch: Eyes On Apple's WWDC, SCOTUS And D.C.

via: SeekingAlpha at 2018-06-02 08:16:15:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The Apple (AAPL) Worldwide Developers Conference begins on June 4 with expectations… read more...

Stocks To Watch: Eyes On Apple's WWDC, SCOTUS And D.C.

via: SeekingAlpha at 2018-06-02 08:16:15:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The Apple (AAPL) Worldwide Developers Conference begins on June 4 with expectations… read more...

Stocks To Watch: Eyes On Apple's WWDC, SCOTUS And D.C.

via: SeekingAlpha at 2018-06-02 08:16:15:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The Apple (AAPL) Worldwide Developers Conference begins on June 4 with expectations… read more...

'Big Dog' Biotech Roche Makes Progress: Will The Stock Notice?

via: SeekingAlpha at 2018-06-02 00:08:40:000

Introduction Roche ADRs ( RHHBY ) remain in a downtrend even as the company has increased its guidance, following detailed but interim Q1 results (no EPS reported), to modest organic growth this year, but high-single-digit growth including the effects of last December's US tax legislation…. read more...

'Big Dog' Biotech Roche Makes Progress: Will The Stock Notice?

via: SeekingAlpha at 2018-06-02 00:08:40:000

Introduction Roche ADRs ( RHHBY ) remain in a downtrend even as the company has increased its guidance, following detailed but interim Q1 results (no EPS reported), to modest organic growth this year, but high-single-digit growth including the effects of last December's US tax legislation…. read more...

'Big Dog' Biotech Roche Makes Progress: Will The Stock Notice?

via: SeekingAlpha at 2018-06-02 00:08:40:000

Introduction Roche ADRs ( RHHBY ) remain in a downtrend even as the company has increased its guidance, following detailed but interim Q1 results (no EPS reported), to modest organic growth this year, but high-single-digit growth including the effects of last December's US tax legislation…. read more...

Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone

via: PR Newswire at 2018-06-01 16:45:00:000

NORTH CHICAGO, Ill. , June 1, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced findings from an interim analysis of the Phase 3 iNNOVATE (PCYC-1127) study evaluating IMBRUVICA (ibrutinib) plus RITUXAN (rituxi… read more...

Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone

via: PR Newswire at 2018-06-01 16:45:00:000

NORTH CHICAGO, Ill. , June 1, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced findings from an interim analysis of the Phase 3 iNNOVATE (PCYC-1127) study evaluating IMBRUVICA (ibrutinib) plus RITUXAN (rituxi… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

Lipotoxicity And Liver Diseases-NASH And PBC: Is Enanta A Player Or Spectator?

via: SeekingAlpha at 2018-06-01 13:43:17:000

A good head and good heart are always a formidable combination -Nelson Mandela Enanta Pharmaceuticals (ENTA) is a small-cap ($1.97B) biopharmaceutical company that is emerging as an innovator of revolutionizing therapies for viral infections and liver diseases. With two FDA approved h… read more...

Lipotoxicity And Liver Diseases-NASH And PBC: Is Enanta A Player Or Spectator?

via: SeekingAlpha at 2018-06-01 13:43:17:000

A good head and good heart are always a formidable combination -Nelson Mandela Enanta Pharmaceuticals (ENTA) is a small-cap ($1.97B) biopharmaceutical company that is emerging as an innovator of revolutionizing therapies for viral infections and liver diseases. With two FDA approved h… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-01 08:42:39:000

CytomX Therapeutics (NASDAQ: CTMX ) initiated with Buy rating and $38 (46% upside) price target at SunTrust. More news on: CytomX Therapeutics, Globus Medical, K2M Group Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-01 08:42:39:000

CytomX Therapeutics (NASDAQ: CTMX ) initiated with Buy rating and $38 (46% upside) price target at SunTrust. More news on: CytomX Therapeutics, Globus Medical, K2M Group Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

EMA advisory group backs four biosimilars

via: SeekingAlpha at 2018-06-01 08:15:29:000

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinionbacking approval for four biosimilars. More news on: Novartis AG, AbbVie Inc., Pfizer Inc., Healthcare stocks news, Read more … read more...

EMA advisory group backs four biosimilars

via: SeekingAlpha at 2018-06-01 08:15:29:000

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinionbacking approval for four biosimilars. More news on: Novartis AG, AbbVie Inc., Pfizer Inc., Healthcare stocks news, Read more … read more...

FDA issues draft guidance aimed at easing regulatory path for generic drugs

via: SeekingAlpha at 2018-05-31 11:27:37:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. announces draft guidance aimed at curtailing behavior by branded drug makers to delay competition from generics. More news on: iShares U.S. Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, VanEck Vectors Pharmaceutical ETF, Heal… read more...

Mining ASCO 2018's Gold, Part 7: Digest This News And Get Valuable Information

via: SeekingAlpha at 2018-05-31 09:00:00:000

Continuing on our ASCO journey, we now move into the gastrointestinal malignancies, which have several incredibly difficult-to-treat tumor types. In case you haven't seen the previous editions, I'll link them off below. But this series is designed to help you parse out some of the news that is… read more...

AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European Hematology Association (EHA) Annual Congress

via: PR Newswire at 2018-05-31 08:00:00:000

NORTH CHICAGO, Ill. , May 31, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data from clinical trials across multiple blood cancers evaluating venetoclax, a first-in-class oral B-cell lymphoma-2 (BCL-2) in… read more...

Road To Financial Independence: My April 91-Stock Portfolio Review

via: SeekingAlpha at 2018-05-31 06:15:50:000

With the earnings seasons gaining full swing, stock markets recovered and concentrated on earnings, casting aside doubts about a looming economic downturn. The only exception here were classic dividend stocks which all took a beating, ranging from Procter & Gamble ( PG ), Altria ( MO ), AT… read more...

DivGro Pulse: May 2018

via: SeekingAlpha at 2018-05-30 09:05:18:000

In my monthly pulse articles, I monitor the health of my portfolio of dividend growth stocks. These articles are strategy-focused and my goals are to reduce the risk, increase the diversification, and improve the balance of my portfolio holdings. I update the fair value estimates for every s… read more...

DivGro Pulse: May 2018

via: SeekingAlpha at 2018-05-30 09:05:18:000

In my monthly pulse articles, I monitor the health of my portfolio of dividend growth stocks. These articles are strategy-focused and my goals are to reduce the risk, increase the diversification, and improve the balance of my portfolio holdings. I update the fair value estimates for every s… read more...

AbbVie Announces Preliminary Results of Tender Offer

via: PR Newswire at 2018-05-30 08:00:00:000

NORTH CHICAGO, Ill. , May 30, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, at the end of May 29, 2018 . Based on the preliminary count by Computershare… read more...

AbbVie Announces Preliminary Results of Tender Offer

via: PR Newswire at 2018-05-30 08:00:00:000

NORTH CHICAGO, Ill. , May 30, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, at the end of May 29, 2018 . Based on the preliminary count by Computershare… read more...

4 Reasons AbbVie Could Crush The Market Over The Next Decade

via: SeekingAlpha at 2018-05-30 05:56:03:000

(Source: imgflip ) In my retirement dividend growth portfolio I try to own a highly diversified collection of the best quality low/medium-risk companies. That usually means companies with easy to understand business models, which usually doesn't describe the biotech industry. In fact, d… read more...

4 Reasons AbbVie Could Crush The Market Over The Next Decade

via: SeekingAlpha at 2018-05-30 05:56:03:000

(Source: imgflip ) In my retirement dividend growth portfolio I try to own a highly diversified collection of the best quality low/medium-risk companies. That usually means companies with easy to understand business models, which usually doesn't describe the biotech industry. In fact, d… read more...

AbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-05-29 08:00:00:000

NORTH CHICAGO, Ill. , May 29, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 . Richard A. Gonzalez , chairman and chief executive offi… read more...

AbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-05-29 08:00:00:000

NORTH CHICAGO, Ill. , May 29, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 . Richard A. Gonzalez , chairman and chief executive offi… read more...

AbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-05-29 08:00:00:000

NORTH CHICAGO, Ill. , May 29, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 . Richard A. Gonzalez , chairman and chief executive offi… read more...

Dividend Sensei's Portfolio Update 36: To Get Rich First, You Need To Do One Very Important Thing

via: SeekingAlpha at 2018-05-28 03:20:40:000

(Source: imgflip ) Introduction First let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, ru… read more...

Dividend Sensei's Portfolio Update 36: To Get Rich First, You Need To Do One Very Important Thing

via: SeekingAlpha at 2018-05-28 03:20:40:000

(Source: imgflip ) Introduction First let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, ru… read more...

Dividend Sensei's Portfolio Update 36: To Get Rich First, You Need To Do One Very Important Thing

via: SeekingAlpha at 2018-05-28 03:20:40:000

(Source: imgflip ) Introduction First let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, ru… read more...

Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study

via: SeekingAlpha at 2018-05-27 19:15:05:000

Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...

Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study

via: SeekingAlpha at 2018-05-27 19:15:05:000

Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...

Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study

via: SeekingAlpha at 2018-05-27 19:15:05:000

Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...

Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study

via: SeekingAlpha at 2018-05-27 19:15:05:000

Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...

3 Things In Biotech, May 25: A CLL Game Changer

via: SeekingAlpha at 2018-05-26 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 25: A CLL Game Changer

via: SeekingAlpha at 2018-05-26 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 25: A CLL Game Changer

via: SeekingAlpha at 2018-05-26 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 25: A CLL Game Changer

via: SeekingAlpha at 2018-05-26 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 25: A CLL Game Changer

via: SeekingAlpha at 2018-05-26 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

Market Values Stocks Incorrectly In The Short Term - Cramer's Mad Money (5/24/18)

via: SeekingAlpha at 2018-05-25 07:41:10:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 24. The market is having a hard time valuing stocks and putting a dollar amount on anything. Netflix (NFLX) surpassed the market cap of Disney (DIS) for the first time and Cramer found this com… read more...

Market Values Stocks Incorrectly In The Short Term - Cramer's Mad Money (5/24/18)

via: SeekingAlpha at 2018-05-25 07:41:10:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 24. The market is having a hard time valuing stocks and putting a dollar amount on anything. Netflix (NFLX) surpassed the market cap of Disney (DIS) for the first time and Cramer found this com… read more...

Market Values Stocks Incorrectly In The Short Term - Cramer's Mad Money (5/24/18)

via: SeekingAlpha at 2018-05-25 07:41:10:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 24. The market is having a hard time valuing stocks and putting a dollar amount on anything. Netflix (NFLX) surpassed the market cap of Disney (DIS) for the first time and Cramer found this com… read more...

Market Values Stocks Incorrectly In The Short Term - Cramer's Mad Money (5/24/18)

via: SeekingAlpha at 2018-05-25 07:41:10:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 24. The market is having a hard time valuing stocks and putting a dollar amount on anything. Netflix (NFLX) surpassed the market cap of Disney (DIS) for the first time and Cramer found this com… read more...

Market Values Stocks Incorrectly In The Short Term - Cramer's Mad Money (5/24/18)

via: SeekingAlpha at 2018-05-25 07:41:10:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 24. The market is having a hard time valuing stocks and putting a dollar amount on anything. Netflix (NFLX) surpassed the market cap of Disney (DIS) for the first time and Cramer found this com… read more...

Market Values Stocks Incorrectly In The Short Term - Cramer's Mad Money (5/24/18)

via: SeekingAlpha at 2018-05-25 07:41:10:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 24. The market is having a hard time valuing stocks and putting a dollar amount on anything. Netflix (NFLX) surpassed the market cap of Disney (DIS) for the first time and Cramer found this com… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

via: SeekingAlpha at 2018-05-24 12:24:11:000

Actionable Conclusions (1-10): Analysts Projected 18% To 34.65% Net Gains For Top Ten Healthcare WallStars By May 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They … read more...

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

via: SeekingAlpha at 2018-05-24 12:24:11:000

Actionable Conclusions (1-10): Analysts Projected 18% To 34.65% Net Gains For Top Ten Healthcare WallStars By May 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They … read more...

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

via: SeekingAlpha at 2018-05-24 12:24:11:000

Actionable Conclusions (1-10): Analysts Projected 18% To 34.65% Net Gains For Top Ten Healthcare WallStars By May 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They … read more...

AbbVie's Imbruvica successful in late-stage leukemia study

via: SeekingAlpha at 2018-05-24 09:27:57:000

A Phase 3 clinical trial, iLLUMINATE, evaluating the combination of AbbVie's (NYSE: ABBV ) IMBRUVICA (ibrutinib) and Roche ( OTCQX:RHHBY ) unit Genentech's GAZYVA (obinutuzumab) in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) met the p… read more...

AbbVie's Imbruvica successful in late-stage leukemia study

via: SeekingAlpha at 2018-05-24 09:27:57:000

A Phase 3 clinical trial, iLLUMINATE, evaluating the combination of AbbVie's (NYSE: ABBV ) IMBRUVICA (ibrutinib) and Roche ( OTCQX:RHHBY ) unit Genentech's GAZYVA (obinutuzumab) in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) met the p… read more...

AbbVie's Imbruvica successful in late-stage leukemia study

via: SeekingAlpha at 2018-05-24 09:27:57:000

A Phase 3 clinical trial, iLLUMINATE, evaluating the combination of AbbVie's (NYSE: ABBV ) IMBRUVICA (ibrutinib) and Roche ( OTCQX:RHHBY ) unit Genentech's GAZYVA (obinutuzumab) in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) met the p… read more...

AbbVie's Imbruvica successful in late-stage leukemia study

via: SeekingAlpha at 2018-05-24 09:27:57:000

A Phase 3 clinical trial, iLLUMINATE, evaluating the combination of AbbVie's (NYSE: ABBV ) IMBRUVICA (ibrutinib) and Roche ( OTCQX:RHHBY ) unit Genentech's GAZYVA (obinutuzumab) in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) met the p… read more...

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint

via: PR Newswire at 2018-05-24 09:00:00:000

NORTH CHICAGO, Ill. , May 24, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival (PFS). The study evaluated IMB… read more...

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint

via: PR Newswire at 2018-05-24 09:00:00:000

NORTH CHICAGO, Ill. , May 24, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival (PFS). The study evaluated IMB… read more...

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint

via: PR Newswire at 2018-05-24 09:00:00:000

NORTH CHICAGO, Ill. , May 24, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival (PFS). The study evaluated IMB… read more...

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint

via: PR Newswire at 2018-05-24 09:00:00:000

NORTH CHICAGO, Ill. , May 24, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival (PFS). The study evaluated IMB… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

The Investment Case For InflaRx

via: SeekingAlpha at 2018-05-24 05:00:00:000

InflaRx ( IFRX ) came to my attention two months ago when I was investigating the potential new indication for ChemoCentryx's ( CCXI ) avacopan - hidradenitis suppurativa . ChemoCentryx's interest in HS was actually sparked by very strong phase 2a results of InflaRx's IFX-1 and the fact t… read more...

The Investment Case For InflaRx

via: SeekingAlpha at 2018-05-24 05:00:00:000

InflaRx ( IFRX ) came to my attention two months ago when I was investigating the potential new indication for ChemoCentryx's ( CCXI ) avacopan - hidradenitis suppurativa . ChemoCentryx's interest in HS was actually sparked by very strong phase 2a results of InflaRx's IFX-1 and the fact t… read more...

The Investment Case For InflaRx

via: SeekingAlpha at 2018-05-24 05:00:00:000

InflaRx ( IFRX ) came to my attention two months ago when I was investigating the potential new indication for ChemoCentryx's ( CCXI ) avacopan - hidradenitis suppurativa . ChemoCentryx's interest in HS was actually sparked by very strong phase 2a results of InflaRx's IFX-1 and the fact t… read more...

The Investment Case For InflaRx

via: SeekingAlpha at 2018-05-24 05:00:00:000

InflaRx ( IFRX ) came to my attention two months ago when I was investigating the potential new indication for ChemoCentryx's ( CCXI ) avacopan - hidradenitis suppurativa . ChemoCentryx's interest in HS was actually sparked by very strong phase 2a results of InflaRx's IFX-1 and the fact t… read more...

Gilead: Novartis's Kymriah Is Coming To America

via: SeekingAlpha at 2018-05-24 03:49:06:000

From the movie "Coming To America." Source: Amazon.com Gilead (GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like Gilead would have the U.S. CAR-T market all to itself. However, Novartis's (NVS) Kymriah w… read more...

Gilead: Novartis's Kymriah Is Coming To America

via: SeekingAlpha at 2018-05-24 03:49:06:000

From the movie "Coming To America." Source: Amazon.com Gilead (GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like Gilead would have the U.S. CAR-T market all to itself. However, Novartis's (NVS) Kymriah w… read more...

Gilead: Novartis's Kymriah Is Coming To America

via: SeekingAlpha at 2018-05-24 03:49:06:000

From the movie "Coming To America." Source: Amazon.com Gilead (GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like Gilead would have the U.S. CAR-T market all to itself. However, Novartis's (NVS) Kymriah w… read more...

Gilead: Novartis's Kymriah Is Coming To America

via: SeekingAlpha at 2018-05-24 03:49:06:000

From the movie "Coming To America." Source: Amazon.com Gilead (GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like Gilead would have the U.S. CAR-T market all to itself. However, Novartis's (NVS) Kymriah w… read more...

Is Celgene's Stock A Buy The Dip Opportunity?

via: SeekingAlpha at 2018-05-23 03:09:40:000

Celgene ( CELG ) has three key drugs in its late-stage pipeline and yet the market refuses to buy the stock. Bearishness is building up so much that the stock fell sharply on May 21. This continues the downtrend that began last year in Sept. 2017, when the stock traded at over $140 a share. … read more...

Is Celgene's Stock A Buy The Dip Opportunity?

via: SeekingAlpha at 2018-05-23 03:09:40:000

Celgene ( CELG ) has three key drugs in its late-stage pipeline and yet the market refuses to buy the stock. Bearishness is building up so much that the stock fell sharply on May 21. This continues the downtrend that began last year in Sept. 2017, when the stock traded at over $140 a share. … read more...

Is Celgene's Stock A Buy The Dip Opportunity?

via: SeekingAlpha at 2018-05-23 03:09:40:000

Celgene ( CELG ) has three key drugs in its late-stage pipeline and yet the market refuses to buy the stock. Bearishness is building up so much that the stock fell sharply on May 21. This continues the downtrend that began last year in Sept. 2017, when the stock traded at over $140 a share. … read more...

AbbVie Donates $100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico

via: PR Newswire at 2018-05-22 10:30:00:000

NORTH CHICAGO, Ill. , May 22, 2018 /PRNewswire/ --AbbVie, a research-based global biopharmaceutical company, today announced a donation of $100 million to two organizations, Direct Relief and Habitat for Humanity International, to strengthen access to healthcare and housing in Pu… read more...

AbbVie to Present at the Jefferies 2018 Global Healthcare Conference

via: PR Newswire at 2018-05-22 08:00:00:000

NORTH CHICAGO, Ill. , May 22, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6, 2018 . Bill Chase , executive vice president and chief financial officer, … read more...

CytomX earns $25M milestone from AbbVie on CX-2029 IND

via: SeekingAlpha at 2018-05-22 07:49:59:000

The FDA has signed off on CytomX Therapeutics' (NASDAQ: CTMX ) IND for Probody drug conjugate CX-2029. The action triggers a $25M milestone payment from development partner AbbVie (NYSE: ABBV ). More news on: CytomX Therapeutics, AbbVie Inc., Healthcare stocks news, Read more … read more...

Dividend Sensei's Portfolio Update 35: If You Want To Get Rich, Follow The Data

via: SeekingAlpha at 2018-05-22 02:21:53:000

(Source: imgflip ) First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, rule-based, meth… read more...

AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting

via: PR Newswire at 2018-05-16 16:59:00:000

NORTH CHICAGO, Ill. , May 16, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data about the company's portfolio of investigational oncology medicines during the American Society of Clinical Oncology (ASCO) … read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

Jane's April Dividend Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-05-15 18:13:02:000

Investment Thesis April marks the second month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the taxable account, we did not start making significant changes to Jane's retirement accounts until after the first of the year. Because of this, there are a … read more...

Jane's April Dividend Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-05-15 18:13:02:000

Investment Thesis April marks the second month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the taxable account, we did not start making significant changes to Jane's retirement accounts until after the first of the year. Because of this, there are a … read more...

Jane's April Dividend Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-05-15 18:13:02:000

Investment Thesis April marks the second month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the taxable account, we did not start making significant changes to Jane's retirement accounts until after the first of the year. Because of this, there are a … read more...

Glenview added Express Scripts, exited Apple in Q1

via: SeekingAlpha at 2018-05-15 17:11:45:000

Larry Robbins and Mark Horowitz's Glenview Capital discloses the addition of Express Scripts (NASDAQ: ESRX ) to its investments while exiting Apple (NASDAQ: AAPL ) in Q1, according to its 13F filing . More news on: Express Scripts, Inc., Apple Inc., T-Mobile US, Inc., Read more … read more...

Glenview added Express Scripts, exited Apple in Q1

via: SeekingAlpha at 2018-05-15 17:11:45:000

Larry Robbins and Mark Horowitz's Glenview Capital discloses the addition of Express Scripts (NASDAQ: ESRX ) to its investments while exiting Apple (NASDAQ: AAPL ) in Q1, according to its 13F filing . More news on: Express Scripts, Inc., Apple Inc., T-Mobile US, Inc., Read more … read more...

Glenview added Express Scripts, exited Apple in Q1

via: SeekingAlpha at 2018-05-15 17:11:45:000

Larry Robbins and Mark Horowitz's Glenview Capital discloses the addition of Express Scripts (NASDAQ: ESRX ) to its investments while exiting Apple (NASDAQ: AAPL ) in Q1, according to its 13F filing . More news on: Express Scripts, Inc., Apple Inc., T-Mobile US, Inc., Read more … read more...

Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO

via: SeekingAlpha at 2018-05-15 12:38:40:000

Quick Take Kiniksa Pharmaceuticals ( KNSA ) intends to raise $126 million in a U.S. IPO of its Class A common stock, according to an amended S-1/A registration statement . The company is developing a pipeline of drug treatments for autoinflammatory and autoimmune diseases. KNSA is mak… read more...

Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO

via: SeekingAlpha at 2018-05-15 12:38:40:000

Quick Take Kiniksa Pharmaceuticals ( KNSA ) intends to raise $126 million in a U.S. IPO of its Class A common stock, according to an amended S-1/A registration statement . The company is developing a pipeline of drug treatments for autoinflammatory and autoimmune diseases. KNSA is mak… read more...

Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO

via: SeekingAlpha at 2018-05-15 12:38:40:000

Quick Take Kiniksa Pharmaceuticals ( KNSA ) intends to raise $126 million in a U.S. IPO of its Class A common stock, according to an amended S-1/A registration statement . The company is developing a pipeline of drug treatments for autoinflammatory and autoimmune diseases. KNSA is mak… read more...

Dividend Sensei's Portfolio Update 34: Why The Future Of Work Will Be Glorious

via: SeekingAlpha at 2018-05-15 06:25:00:000

(Source: imgflip ) First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, rule-based, meth… read more...

Dividend Sensei's Portfolio Update 34: Why The Future Of Work Will Be Glorious

via: SeekingAlpha at 2018-05-15 06:25:00:000

(Source: imgflip ) First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, rule-based, meth… read more...

Dividend Sensei's Portfolio Update 34: Why The Future Of Work Will Be Glorious

via: SeekingAlpha at 2018-05-15 06:25:00:000

(Source: imgflip ) First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, rule-based, meth… read more...

Dividend Growth Portfolio: May 2018 Update

via: SeekingAlpha at 2018-05-14 18:44:20:000

It has been about a year and a half since I retired and subsequently wrote my first Seeking Alpha article detailing my dividend growth portfolio. I had intended to write periodic articles detailing the portfolio updates and changes (as many other authors do here), but life events sidetracked m… read more...

Oryzon Genomics commences mid-stage study of Alzheimer's candidate

via: SeekingAlpha at 2018-05-14 12:27:31:000

Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, … read more...

DGI For The DIY: Q1 2018 Portfolio Update

via: SeekingAlpha at 2018-05-13 11:13:05:000

Better late than never, right? My apologies for not getting the quarterly portfolio review out until a week after May Day. A busy couple of months at work and home have severely cut down on my writing time, but I think that situation should be improving a bit going forward. I briefly consi… read more...

Bulletproof Investing Performance Update: Week 24

via: SeekingAlpha at 2018-05-12 15:55:22:000

Safety First: NASCAR driver Johanna Long and her helmet (Credit: Gearheads ) Bulletproof Investing: Week 24 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is … read more...

AbbVie: Time To Trim Our Position?

via: SeekingAlpha at 2018-02-12 10:55:59:000

AbbVie ( ABBV ) first appeared in the March to Freedom Fund when the company split up from Abbott Laboratories ( ABT ) in 2013. Shortly after the breakup, I sold my shares of Abbott and doubled my position in AbbVie. This turned out to be a good move because AbbVie has done very well for our p… read more...

AbbVie: Time To Trim Our Position?

via: SeekingAlpha at 2018-02-12 10:55:59:000

AbbVie ( ABBV ) first appeared in the March to Freedom Fund when the company split up from Abbott Laboratories ( ABT ) in 2013. Shortly after the breakup, I sold my shares of Abbott and doubled my position in AbbVie. This turned out to be a good move because AbbVie has done very well for our p… read more...

AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting

via: PR Newswire at 2018-02-12 08:00:00:000

NORTH CHICAGO, Ill. , Feb. 12, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced it will present new, late-breaking data across investigational medicines and HUMIRA (adalimumab) at the 2018 American Academy… read more...

AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting

via: PR Newswire at 2018-02-12 08:00:00:000

NORTH CHICAGO, Ill. , Feb. 12, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced it will present new, late-breaking data across investigational medicines and HUMIRA (adalimumab) at the 2018 American Academy… read more...

Amgen As A Source Of Funds

via: SeekingAlpha at 2018-02-12 06:56:28:000

Background The venerable biotech Amgen ( AMGN ) has been one of the all-time great stock market performers. This stellar performance, which revived after more than a decade of stagnation, when the great bull market post-2011 took off and biotech became the leading subsector of the market, … read more...

Amgen As A Source Of Funds

via: SeekingAlpha at 2018-02-12 06:56:28:000

Background The venerable biotech Amgen ( AMGN ) has been one of the all-time great stock market performers. This stellar performance, which revived after more than a decade of stagnation, when the great bull market post-2011 took off and biotech became the leading subsector of the market, … read more...

Updating The Bullish Case For Regeneron As The Stock Drops

via: SeekingAlpha at 2018-02-09 12:48:40:000

Background Regeneron Pharmaceuticals ( REGN ) is one of the great stock successes of the past 10 years, but has been "resting" for the past 3 1/2 years, and with significant volatility at the upper end of its longer term range: REGN data by YCharts REGN closed Thursday at $322.62… read more...

Updating The Bullish Case For Regeneron As The Stock Drops

via: SeekingAlpha at 2018-02-09 12:48:40:000

Background Regeneron Pharmaceuticals ( REGN ) is one of the great stock successes of the past 10 years, but has been "resting" for the past 3 1/2 years, and with significant volatility at the upper end of its longer term range: REGN data by YCharts REGN closed Thursday at $322.62… read more...

Updating The Bullish Case For Regeneron As The Stock Drops

via: SeekingAlpha at 2018-02-09 12:48:40:000

Background Regeneron Pharmaceuticals ( REGN ) is one of the great stock successes of the past 10 years, but has been "resting" for the past 3 1/2 years, and with significant volatility at the upper end of its longer term range: REGN data by YCharts REGN closed Thursday at $322.62… read more...

Updating The Bullish Case For Regeneron As The Stock Drops

via: SeekingAlpha at 2018-02-09 12:48:40:000

Background Regeneron Pharmaceuticals ( REGN ) is one of the great stock successes of the past 10 years, but has been "resting" for the past 3 1/2 years, and with significant volatility at the upper end of its longer term range: REGN data by YCharts REGN closed Thursday at $322.62… read more...

Updating The Bullish Case For Regeneron As The Stock Drops

via: SeekingAlpha at 2018-02-09 12:48:40:000

Background Regeneron Pharmaceuticals ( REGN ) is one of the great stock successes of the past 10 years, but has been "resting" for the past 3 1/2 years, and with significant volatility at the upper end of its longer term range: REGN data by YCharts REGN closed Thursday at $322.62… read more...

It's Like 2008 Again - Cramer's Mad Money (2/8/18)

via: SeekingAlpha at 2018-02-09 07:37:49:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, February 8. The Dow went down another 4.4% on Thursday. While some are blaming the inflation or bond yields or Washington but the fact is that the crash is similar to that of 2008. "The real culpr… read more...

It's Like 2008 Again - Cramer's Mad Money (2/8/18)

via: SeekingAlpha at 2018-02-09 07:37:49:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, February 8. The Dow went down another 4.4% on Thursday. While some are blaming the inflation or bond yields or Washington but the fact is that the crash is similar to that of 2008. "The real culpr… read more...

It's Like 2008 Again - Cramer's Mad Money (2/8/18)

via: SeekingAlpha at 2018-02-09 07:37:49:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, February 8. The Dow went down another 4.4% on Thursday. While some are blaming the inflation or bond yields or Washington but the fact is that the crash is similar to that of 2008. "The real culpr… read more...

It's Like 2008 Again - Cramer's Mad Money (2/8/18)

via: SeekingAlpha at 2018-02-09 07:37:49:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, February 8. The Dow went down another 4.4% on Thursday. While some are blaming the inflation or bond yields or Washington but the fact is that the crash is similar to that of 2008. "The real culpr… read more...

It's Like 2008 Again - Cramer's Mad Money (2/8/18)

via: SeekingAlpha at 2018-02-09 07:37:49:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, February 8. The Dow went down another 4.4% on Thursday. While some are blaming the inflation or bond yields or Washington but the fact is that the crash is similar to that of 2008. "The real culpr… read more...

'Safer' Dividend Aristocrats Top Gainers Are Leggett, Procter, Air, Nucor, & Praxair, Per Broker February Targets

via: SeekingAlpha at 2018-02-07 10:41:14:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten 'Safer' Dividend Aristocrats Stocks to Net 8.23% to 23.59% Gains To February, 2019 Three of ten top yield "safer" Dividend Aristocrats (tinted in the chart above) were also in the Top ten gainers for the coming year based on analyst 1… read more...

'Safer' Dividend Aristocrats Top Gainers Are Leggett, Procter, Air, Nucor, & Praxair, Per Broker February Targets

via: SeekingAlpha at 2018-02-07 10:41:14:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten 'Safer' Dividend Aristocrats Stocks to Net 8.23% to 23.59% Gains To February, 2019 Three of ten top yield "safer" Dividend Aristocrats (tinted in the chart above) were also in the Top ten gainers for the coming year based on analyst 1… read more...

'Safer' Dividend Aristocrats Top Gainers Are Leggett, Procter, Air, Nucor, & Praxair, Per Broker February Targets

via: SeekingAlpha at 2018-02-07 10:41:14:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten 'Safer' Dividend Aristocrats Stocks to Net 8.23% to 23.59% Gains To February, 2019 Three of ten top yield "safer" Dividend Aristocrats (tinted in the chart above) were also in the Top ten gainers for the coming year based on analyst 1… read more...

AbbVie: Looking Very Attractive In 2018

via: SeekingAlpha at 2018-02-07 10:02:16:000

I have always been in love with AbbVie ( ABBV ), and this article is just mostly a reiteration of my belief in this pharmaceutical company. And in its latest earnings release, the company has given me many reasons to believe that there is still significant upside potential left in this stock f… read more...

AbbVie: Looking Very Attractive In 2018

via: SeekingAlpha at 2018-02-07 10:02:16:000

I have always been in love with AbbVie ( ABBV ), and this article is just mostly a reiteration of my belief in this pharmaceutical company. And in its latest earnings release, the company has given me many reasons to believe that there is still significant upside potential left in this stock f… read more...

AbbVie: Looking Very Attractive In 2018

via: SeekingAlpha at 2018-02-07 10:02:16:000

I have always been in love with AbbVie ( ABBV ), and this article is just mostly a reiteration of my belief in this pharmaceutical company. And in its latest earnings release, the company has given me many reasons to believe that there is still significant upside potential left in this stock f… read more...

Why Gilead May Be Undervalued And May Fly High Again

via: SeekingAlpha at 2018-02-07 06:22:48:000

Introduction - sideways consolidation continues Gilead ( GILD ), which spiked nearly to $90 just a week ago, looks to have closed Tuesday's after-hours session in the $78-79 range. This is a price that GILD first reached in January 2014. It reached this level having quadrupled between the … read more...

Why Gilead May Be Undervalued And May Fly High Again

via: SeekingAlpha at 2018-02-07 06:22:48:000

Introduction - sideways consolidation continues Gilead ( GILD ), which spiked nearly to $90 just a week ago, looks to have closed Tuesday's after-hours session in the $78-79 range. This is a price that GILD first reached in January 2014. It reached this level having quadrupled between the … read more...

Why Gilead May Be Undervalued And May Fly High Again

via: SeekingAlpha at 2018-02-07 06:22:48:000

Introduction - sideways consolidation continues Gilead ( GILD ), which spiked nearly to $90 just a week ago, looks to have closed Tuesday's after-hours session in the $78-79 range. This is a price that GILD first reached in January 2014. It reached this level having quadrupled between the … read more...

Annual Review Of DivGro, 2017

via: SeekingAlpha at 2018-02-06 09:49:17:000

Welcome to the 5 th annual review of DivGro, my portfolio of dividend growth stocks. I created DivGro in January 2013 to generate a reliable and growing dividend income stream. Keeping track of DivGro in a public forum helps me to learn and grow as a dividend growth investor. Much of my lea… read more...

5%+ Dividend Yield Portfolio: The Rising Tide Raises My Boat (Jan 2018 Review)

via: SeekingAlpha at 2018-02-06 08:45:33:000

Outlook Picking up where 2017 left off, January 2018 saw the indexes shatter records for new highs resulting in one of the strongest Januarys of the last 50 years! It looks like the bulls arent done yet as the S&P 500 notched a 5.7% gain. It is not all roses though as gains c… read more...

Your Daily Pharma Scoop: AMAG Gets Label Expansion For Feraheme, Bristol-Myers Squibb Reports Results, EyeGate Shares Tumble

via: SeekingAlpha at 2018-02-06 08:00:00:000

Analysis of top Seeking Alpha coverage: AMAG Pharmaceuticals Today we will discuss AMAG Pharmaceuticals ( AMAG ), which as expected got a nod from the FDA for expanded use of Feraheme (ferumoxytol injection) for all eligible adult patients with iron deficiency anemia ( IDA ) who are … read more...

Don't Miss Out, Act Now On AbbVie

via: SeekingAlpha at 2018-02-05 13:08:50:000

Investment Thesis Generally, I would not advocate for considering investing in a stock that trades at all-time highs as this generally implies that there is too high expectation already, however, I found that AbbVie's ( ABBV ) full potential is surprisingly not yet priced in. Background … read more...

OBSEVA: Obstetrics And Women's Health

via: SeekingAlpha at 2018-02-05 07:15:58:000

This is my first article in Seeking Alpha. I have enjoyed following some of the high quality articles by biotech specialists Jonathan Faison , Bhavneesh Sharma , Bret Jensen, Jerome Verony , Altum Research and others. SA is a great platform from which I have already learned a lot and fe… read more...

Will healthcare stocks hold steady amidst broad selloff?

via: SeekingAlpha at 2018-02-05 06:57:34:000

U.S. stock index futures point to another down day today. So far, the only large cap healthcare issue in the red premarket is AbbVie (NYSE: ABBV ), down 3% but on light volume. More news on: AbbVie Inc., ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wel… read more...

Weighing Pros And Cons Of Celgene

via: SeekingAlpha at 2018-02-05 05:59:30:000

Introduction I'd like to do something just a little different in this article on Celgene ( CELG ), and present the pros and cons of the stock as I see them following the latest earnings report and conference call . There are 773.5 MM diluted shares outstanding (fourth-quarter average). … read more...

Tracking Yacktman Asset Management Portfolio - Q4 2017 Update

via: SeekingAlpha at 2018-02-04 09:05:07:000

This article is part of a series that provides an ongoing analysis of the changes made to Yacktmans US stock portfolio on a quarterly basis. It is based on Yacktman Asset Managements regulatory 13F Form filed on 02/02/2018. Please visit our Tracking Yacktman Asset Management… read more...

Dividend Income - January 2018

via: SeekingAlpha at 2018-02-04 05:58:02:000

2018 is in full swing and the dividend keeps on coming. As a Canadian, I hope you have diversified into the US to benefit from the red hot US stock market. Regardless of your investing strategy, you should have exposure to the US market. I was researching industrial stocks and nearly all o… read more...

Dividend Aristocrat Performance: January 2018

via: SeekingAlpha at 2018-02-02 10:15:00:000

Consistent dividend growth investing is one of my " 5 Ways to Beat the Market ." The Dividend Aristocrats, members of the S&P 500 that have managed to increase their dividends for at least 25 consecutive years, have collectively generated market-beating performance. As seen in the chart be… read more...

Dividend Aristocrat Performance: January 2018

via: SeekingAlpha at 2018-02-02 10:15:00:000

Consistent dividend growth investing is one of my " 5 Ways to Beat the Market ." The Dividend Aristocrats, members of the S&P 500 that have managed to increase their dividends for at least 25 consecutive years, have collectively generated market-beating performance. As seen in the chart be… read more...

Dividend Aristocrat Performance: January 2018

via: SeekingAlpha at 2018-02-02 10:15:00:000

Consistent dividend growth investing is one of my " 5 Ways to Beat the Market ." The Dividend Aristocrats, members of the S&P 500 that have managed to increase their dividends for at least 25 consecutive years, have collectively generated market-beating performance. As seen in the chart be… read more...

Investing Themes In A Volatile Market - Cramer's Mad Money (1/31/18)

via: SeekingAlpha at 2018-02-01 07:22:09:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, January 31. Cramer started the show by talking about the method of investing in a volatile market. "You need to have a list where you can say, 'That's it, my buy price has been hit. Time to pull … read more...

Investing Themes In A Volatile Market - Cramer's Mad Money (1/31/18)

via: SeekingAlpha at 2018-02-01 07:22:09:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, January 31. Cramer started the show by talking about the method of investing in a volatile market. "You need to have a list where you can say, 'That's it, my buy price has been hit. Time to pull … read more...

Investing Themes In A Volatile Market - Cramer's Mad Money (1/31/18)

via: SeekingAlpha at 2018-02-01 07:22:09:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, January 31. Cramer started the show by talking about the method of investing in a volatile market. "You need to have a list where you can say, 'That's it, my buy price has been hit. Time to pull … read more...

Baby DivHut Dividend Income Portfolio Update Q4 2017

via: SeekingAlpha at 2018-02-01 05:33:50:000

Every quarter I like to review baby DivHut's portfolio and dividend income. Generally speaking, there is not much change in his portfolio on a month-to-month basis as fresh capital is not always available to make trades for him. Still, with dividend reinvestments, stock spin-offs and a small… read more...

Baby DivHut Dividend Income Portfolio Update Q4 2017

via: SeekingAlpha at 2018-02-01 05:33:50:000

Every quarter I like to review baby DivHut's portfolio and dividend income. Generally speaking, there is not much change in his portfolio on a month-to-month basis as fresh capital is not always available to make trades for him. Still, with dividend reinvestments, stock spin-offs and a small… read more...

Baby DivHut Dividend Income Portfolio Update Q4 2017

via: SeekingAlpha at 2018-02-01 05:33:50:000

Every quarter I like to review baby DivHut's portfolio and dividend income. Generally speaking, there is not much change in his portfolio on a month-to-month basis as fresh capital is not always available to make trades for him. Still, with dividend reinvestments, stock spin-offs and a small… read more...

Galapagos: Continued Upside In 2018

via: SeekingAlpha at 2018-02-01 04:24:12:000

Shares of Belgian biotech Galapagos ( GLPG ) have risen by nearly 40% since my "buy the dip" piece published in December. Since suggesting the stock was "a long-term buy in biotech" in 2016 , it is up 115%. Figure 1: GLPG daily advanced chart (Source: Finviz Elite ) (Disclosure: Conta… read more...

Galapagos: Continued Upside In 2018

via: SeekingAlpha at 2018-02-01 04:24:12:000

Shares of Belgian biotech Galapagos ( GLPG ) have risen by nearly 40% since my "buy the dip" piece published in December. Since suggesting the stock was "a long-term buy in biotech" in 2016 , it is up 115%. Figure 1: GLPG daily advanced chart (Source: Finviz Elite ) (Disclosure: Conta… read more...

Galapagos: Continued Upside In 2018

via: SeekingAlpha at 2018-02-01 04:24:12:000

Shares of Belgian biotech Galapagos ( GLPG ) have risen by nearly 40% since my "buy the dip" piece published in December. Since suggesting the stock was "a long-term buy in biotech" in 2016 , it is up 115%. Figure 1: GLPG daily advanced chart (Source: Finviz Elite ) (Disclosure: Conta… read more...

Cramer Remix: AbbVie and Biogen are the best-in-show biotechs for 2018 so far

via: CNBC at 2018-01-31 19:00:00:000

No summary available. read more...

Cramer Remix: AbbVie and Biogen are the best-in-show biotechs for 2018 so far

via: CNBC at 2018-01-31 19:00:00:000

No summary available. read more...

Cramer Remix: AbbVie and Biogen are the best-in-show biotechs for 2018 so far

via: CNBC at 2018-01-31 19:00:00:000

No summary available. read more...

AbbVie With A Blowout Quarter But Should You Still Buy It?

via: SeekingAlpha at 2018-01-31 18:03:56:000

Big biotech AbbVie ( ABBV ) just posted stellar Q4/2017 results beating estimates top- and bottom-line and exciting investors about its bullish guidance pointing to a further acceleration in growth. Source: AbbVie Investor Relations Fueled by its Humira cash cow and spectacular growth in… read more...

AbbVie With A Blowout Quarter But Should You Still Buy It?

via: SeekingAlpha at 2018-01-31 18:03:56:000

Big biotech AbbVie ( ABBV ) just posted stellar Q4/2017 results beating estimates top- and bottom-line and exciting investors about its bullish guidance pointing to a further acceleration in growth. Source: AbbVie Investor Relations Fueled by its Humira cash cow and spectacular growth in… read more...

AbbVie With A Blowout Quarter But Should You Still Buy It?

via: SeekingAlpha at 2018-01-31 18:03:56:000

Big biotech AbbVie ( ABBV ) just posted stellar Q4/2017 results beating estimates top- and bottom-line and exciting investors about its bullish guidance pointing to a further acceleration in growth. Source: AbbVie Investor Relations Fueled by its Humira cash cow and spectacular growth in… read more...

DGI For The DIY: 2017 Portfolio Review

via: SeekingAlpha at 2018-01-31 18:00:59:000

Happy (belated) New Year! I didn't think it would be possible for time to go any faster than it did in 2017, but January is quickly proving me wrong. My apologies for the delayed update on the portfolio. For those who may be new readers of this project, my name is Eric Landis , and I am a… read more...

DGI For The DIY: 2017 Portfolio Review

via: SeekingAlpha at 2018-01-31 18:00:59:000

Happy (belated) New Year! I didn't think it would be possible for time to go any faster than it did in 2017, but January is quickly proving me wrong. My apologies for the delayed update on the portfolio. For those who may be new readers of this project, my name is Eric Landis , and I am a… read more...

DGI For The DIY: 2017 Portfolio Review

via: SeekingAlpha at 2018-01-31 18:00:59:000

Happy (belated) New Year! I didn't think it would be possible for time to go any faster than it did in 2017, but January is quickly proving me wrong. My apologies for the delayed update on the portfolio. For those who may be new readers of this project, my name is Eric Landis , and I am a… read more...

Big biopharma firms poised to end session in the red after Trump comments on high prices

via: SeekingAlpha at 2018-01-31 15:50:09:000

Large cap biopharma companies continue to be under pressure as the close nears. In last night's State of the Union address, President Trump stated that cutting drug prices is a "top priority." More news on: Johnson & Johnson, AbbVie Inc., Allergan plc, Healthcare stocks news, Stocks … read more...

Big biopharma firms poised to end session in the red after Trump comments on high prices

via: SeekingAlpha at 2018-01-31 15:50:09:000

Large cap biopharma companies continue to be under pressure as the close nears. In last night's State of the Union address, President Trump stated that cutting drug prices is a "top priority." More news on: Johnson & Johnson, AbbVie Inc., Allergan plc, Healthcare stocks news, Stocks … read more...

Big biopharma firms poised to end session in the red after Trump comments on high prices

via: SeekingAlpha at 2018-01-31 15:50:09:000

Large cap biopharma companies continue to be under pressure as the close nears. In last night's State of the Union address, President Trump stated that cutting drug prices is a "top priority." More news on: Johnson & Johnson, AbbVie Inc., Allergan plc, Healthcare stocks news, Stocks … read more...

AbbVie Looks Positioned For Outperformance

via: SeekingAlpha at 2018-01-31 14:48:38:000

Investing is an art as much as a science, and the numbers don't necessarily tell you everything you need to know to make smart investment decisions. However relying on the power of data and technology to find attractive investment opportunities can significantly increase your odds of success… read more...

AbbVie Looks Positioned For Outperformance

via: SeekingAlpha at 2018-01-31 14:48:38:000

Investing is an art as much as a science, and the numbers don't necessarily tell you everything you need to know to make smart investment decisions. However relying on the power of data and technology to find attractive investment opportunities can significantly increase your odds of success… read more...

AbbVie Looks Positioned For Outperformance

via: SeekingAlpha at 2018-01-31 14:48:38:000

Investing is an art as much as a science, and the numbers don't necessarily tell you everything you need to know to make smart investment decisions. However relying on the power of data and technology to find attractive investment opportunities can significantly increase your odds of success… read more...

A Happy First Year Anniversary For The Dividend Growth TR Portfolio

via: SeekingAlpha at 2018-01-31 11:10:11:000

Background This portfolio is a variation of a dividend growth portfolio that I managed for 3 years while working for an RIA and represents growth holdings in my personal portfolio. The DGTR portfolio is designed for investors who seek total return and are comfortable with a lower yield th… read more...

A Happy First Year Anniversary For The Dividend Growth TR Portfolio

via: SeekingAlpha at 2018-01-31 11:10:11:000

Background This portfolio is a variation of a dividend growth portfolio that I managed for 3 years while working for an RIA and represents growth holdings in my personal portfolio. The DGTR portfolio is designed for investors who seek total return and are comfortable with a lower yield th… read more...

A Happy First Year Anniversary For The Dividend Growth TR Portfolio

via: SeekingAlpha at 2018-01-31 11:10:11:000

Background This portfolio is a variation of a dividend growth portfolio that I managed for 3 years while working for an RIA and represents growth holdings in my personal portfolio. The DGTR portfolio is designed for investors who seek total return and are comfortable with a lower yield th… read more...

Should You Buy The Dip, Or Sell The Rally?

via: SeekingAlpha at 2018-01-31 07:51:55:000

It may seem odd that I'm talking about this issue after a benign 1.76% decline in the S&P 500 over the last two days. Over the past year we have become accustomed to small declines followed by higher highs, as the dip buyers continue to dominate trading. So it stands to reason that even … read more...

Should You Buy The Dip, Or Sell The Rally?

via: SeekingAlpha at 2018-01-31 07:51:55:000

It may seem odd that I'm talking about this issue after a benign 1.76% decline in the S&P 500 over the last two days. Over the past year we have become accustomed to small declines followed by higher highs, as the dip buyers continue to dominate trading. So it stands to reason that even … read more...

AbbVie, Lilly particularly vulnerable to BRK/AMZN/JPM venture - BMO

via: SeekingAlpha at 2018-01-30 15:44:02:000

"Increased adoption of biosimilars will be one of the key drivers to lower drug costs," says analyst Alex Arfaei. More news on: AbbVie Inc., Eli Lilly and Company, Healthcare stocks news, Stocks on the move, Quick stock ideas, Read more … read more...

AbbVie, Lilly particularly vulnerable to BRK/AMZN/JPM venture - BMO

via: SeekingAlpha at 2018-01-30 15:44:02:000

"Increased adoption of biosimilars will be one of the key drivers to lower drug costs," says analyst Alex Arfaei. More news on: AbbVie Inc., Eli Lilly and Company, Healthcare stocks news, Stocks on the move, Quick stock ideas, Read more … read more...

Height weighs in on Amazon/Berkshire/JPMorgan healthcare venture

via: SeekingAlpha at 2018-01-30 10:05:07:000

Height Securities' Andrea Harris says managed care firms are not the ones in the crosshairs of Amazon, Berkshire Hathaway and JPMorgan's planned venture into healthcare. The margins are too thin and setting up a care network is expensive and difficult. More news on: Express Scripts, Inc., … read more...

Height weighs in on Amazon/Berkshire/JPMorgan healthcare venture

via: SeekingAlpha at 2018-01-30 10:05:07:000

Height Securities' Andrea Harris says managed care firms are not the ones in the crosshairs of Amazon, Berkshire Hathaway and JPMorgan's planned venture into healthcare. The margins are too thin and setting up a care network is expensive and difficult. More news on: Express Scripts, Inc., … read more...

AbbVie's Bright Future

via: SeekingAlpha at 2018-01-30 03:05:09:000

If you're long AbbVie Inc ( ABBV ) you've been pretty happy lately. Shares jumped a whole 13% on the company's fourth quarter earnings results. Specifically, AbbVie massively upped its 2018 guidance to a midpoint of $7.38 per share, which would be a 32% increase from 2017 earnings of $5.60. Pa… read more...

AbbVie's Bright Future

via: SeekingAlpha at 2018-01-30 03:05:09:000

If you're long AbbVie Inc ( ABBV ) you've been pretty happy lately. Shares jumped a whole 13% on the company's fourth quarter earnings results. Specifically, AbbVie massively upped its 2018 guidance to a midpoint of $7.38 per share, which would be a 32% increase from 2017 earnings of $5.60. Pa… read more...

DivGro Pulse: January 2018

via: SeekingAlpha at 2018-01-29 16:09:57:000

This month I'm celebrating the fifth anniversary of DivGro! I founded DivGro in January 2013 to focus on dividend growth ( DG ) investing. Since then, my portfolio steadily has grown well beyond what I could have imagined ! Just this week, I hit my 10th home run with DivGro, when my pos… read more...

DivGro Pulse: January 2018

via: SeekingAlpha at 2018-01-29 16:09:57:000

This month I'm celebrating the fifth anniversary of DivGro! I founded DivGro in January 2013 to focus on dividend growth ( DG ) investing. Since then, my portfolio steadily has grown well beyond what I could have imagined ! Just this week, I hit my 10th home run with DivGro, when my pos… read more...

Biotech Forum Daily Digest For January 29th

via: SeekingAlpha at 2018-01-29 10:22:44:000

Quality means doing it right when no one is looking . Henry Ford We saw two big acquisitions last week on Monday totaling just over $20 billion. To put this in perspective, acquisitions across the global Life Sciences sector, which includes pharma and biotech, rang up jus… read more...

Biotech Forum Daily Digest For January 29th

via: SeekingAlpha at 2018-01-29 10:22:44:000

Quality means doing it right when no one is looking . Henry Ford We saw two big acquisitions last week on Monday totaling just over $20 billion. To put this in perspective, acquisitions across the global Life Sciences sector, which includes pharma and biotech, rang up jus… read more...

Fractional Shares And No Fees: How To Save Money By Going Direct

via: SeekingAlpha at 2018-01-29 09:34:09:000

If you're a long-term investor like myself, you probably invest via dollar cost average ((DCA)) into your portfolio monthly or quarterly. And if not, you've at least maybe heard of the strategy. In fact you might be a DCA investor and not even realize it. That's right - if you participate in y… read more...

Fractional Shares And No Fees: How To Save Money By Going Direct

via: SeekingAlpha at 2018-01-29 09:34:09:000

If you're a long-term investor like myself, you probably invest via dollar cost average ((DCA)) into your portfolio monthly or quarterly. And if not, you've at least maybe heard of the strategy. In fact you might be a DCA investor and not even realize it. That's right - if you participate in y… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-29 08:18:26:000

T2 Biosystems (NASDAQ: TTOO ) initiated with Neutral rating and $5.20 (flat) price target at Goldman Sachs. More news on: T2 Biosystems, Qiagen N.V., Myriad Genetics, Inc., Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-29 08:18:26:000

T2 Biosystems (NASDAQ: TTOO ) initiated with Neutral rating and $5.20 (flat) price target at Goldman Sachs. More news on: T2 Biosystems, Qiagen N.V., Myriad Genetics, Inc., Healthcare stocks news, Read more … read more...

Game Plan For The Week - Cramer's Mad Money (1/26/18)

via: SeekingAlpha at 2018-01-29 07:41:33:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, January 26. "Even as President Trump made the pitch for doing business in America at Davos, it's the earnings that are front and center," said Cramer. As there are big earnings this week, Cramer jum… read more...

Game Plan For The Week - Cramer's Mad Money (1/26/18)

via: SeekingAlpha at 2018-01-29 07:41:33:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, January 26. "Even as President Trump made the pitch for doing business in America at Davos, it's the earnings that are front and center," said Cramer. As there are big earnings this week, Cramer jum… read more...

Synlogic: Precision-Programmed Probiotics To Treat Human Disease

via: SeekingAlpha at 2018-01-29 07:10:16:000

Synlogic (SYBX) was founded upon research done by its co-founders, MIT professors Jim Collins and Tim Lu. A private company, Synlogic merged with Mirna Therapeutics to become public in May 2017 and hit the market in August. Currently, Synlogic is working with E. coli Nissle , a nonpathoge… read more...

Synlogic: Precision-Programmed Probiotics To Treat Human Disease

via: SeekingAlpha at 2018-01-29 07:10:16:000

Synlogic (SYBX) was founded upon research done by its co-founders, MIT professors Jim Collins and Tim Lu. A private company, Synlogic merged with Mirna Therapeutics to become public in May 2017 and hit the market in August. Currently, Synlogic is working with E. coli Nissle , a nonpathoge… read more...

AbbVie: Too Darn Hot?

via: SeekingAlpha at 2018-01-29 04:46:24:000

Introduction To my surprise, AbbVie ( ABBV ) has turned into a growth stock. As noted next, I began seeing this when the stock was much lower than it is now, and not much has changed. This article addresses matters from the standpoint of an investor wondering about buying ABBV now that i… read more...

AbbVie: Too Darn Hot?

via: SeekingAlpha at 2018-01-29 04:46:24:000

Introduction To my surprise, AbbVie ( ABBV ) has turned into a growth stock. As noted next, I began seeing this when the stock was much lower than it is now, and not much has changed. This article addresses matters from the standpoint of an investor wondering about buying ABBV now that i… read more...

Big Pharma Rules 'Safer' Dividend Healthcare Top Gains Per Broker Targets To January

via: SeekingAlpha at 2018-01-28 13:13:48:000

Actionable Conclusions (1-10): Brokers Calculated Top Ten Healthcare "Safer" Dividend Stocks to Net 1.64% to 13.34% Gains To January, 2019 Four of ten top 'safer' dividend Healthcare dogs by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

Big Pharma Rules 'Safer' Dividend Healthcare Top Gains Per Broker Targets To January

via: SeekingAlpha at 2018-01-28 13:13:48:000

Actionable Conclusions (1-10): Brokers Calculated Top Ten Healthcare "Safer" Dividend Stocks to Net 1.64% to 13.34% Gains To January, 2019 Four of ten top 'safer' dividend Healthcare dogs by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

AbbVie's (ABBV) CEO Richard Gonzalez on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-01-26 16:17:02:000

AbbVie, Inc. (ABBV) Q4 2017 Earnings Conference Call January 26, 2018 09:00 AM ET Executives Elizabeth Shea - Vice President, Investor Relations Richard Gonzalez - Chairman and Chief Executive Officer Michael Severino - Executive Vice President-Research and Chief Scientific Offic… read more...

AbbVie's (ABBV) CEO Richard Gonzalez on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-01-26 16:17:02:000

AbbVie, Inc. (ABBV) Q4 2017 Earnings Conference Call January 26, 2018 09:00 AM ET Executives Elizabeth Shea - Vice President, Investor Relations Richard Gonzalez - Chairman and Chief Executive Officer Michael Severino - Executive Vice President-Research and Chief Scientific Offic… read more...

AbbVie's (ABBV) CEO Richard Gonzalez on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-01-26 16:17:02:000

AbbVie, Inc. (ABBV) Q4 2017 Earnings Conference Call January 26, 2018 09:00 AM ET Executives Elizabeth Shea - Vice President, Investor Relations Richard Gonzalez - Chairman and Chief Executive Officer Michael Severino - Executive Vice President-Research and Chief Scientific Offic… read more...

AbbVie's (ABBV) CEO Richard Gonzalez on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-01-26 16:17:02:000

AbbVie, Inc. (ABBV) Q4 2017 Earnings Conference Call January 26, 2018 09:00 AM ET Executives Elizabeth Shea - Vice President, Investor Relations Richard Gonzalez - Chairman and Chief Executive Officer Michael Severino - Executive Vice President-Research and Chief Scientific Offic… read more...

AbbVie's (ABBV) CEO Richard Gonzalez on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-01-26 16:17:02:000

AbbVie, Inc. (ABBV) Q4 2017 Earnings Conference Call January 26, 2018 09:00 AM ET Executives Elizabeth Shea - Vice President, Investor Relations Richard Gonzalez - Chairman and Chief Executive Officer Michael Severino - Executive Vice President-Research and Chief Scientific Offic… read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

This Dividend Aristocrat Just Blew Past Earnings Estimates - Is It A Buy?

via: SeekingAlpha at 2018-01-26 13:01:43:000

AbbVie's ( ABBV ) performance over the past year has been nothing short of remarkable. After several years of laggard performance caused by concerns about Humira's patent cliff, AbbVie's stock price has risen by more than 75% over the past twelve months. This has been driven by strong fu… read more...

This Dividend Aristocrat Just Blew Past Earnings Estimates - Is It A Buy?

via: SeekingAlpha at 2018-01-26 13:01:43:000

AbbVie's ( ABBV ) performance over the past year has been nothing short of remarkable. After several years of laggard performance caused by concerns about Humira's patent cliff, AbbVie's stock price has risen by more than 75% over the past twelve months. This has been driven by strong fu… read more...

This Dividend Aristocrat Just Blew Past Earnings Estimates - Is It A Buy?

via: SeekingAlpha at 2018-01-26 13:01:43:000

AbbVie's ( ABBV ) performance over the past year has been nothing short of remarkable. After several years of laggard performance caused by concerns about Humira's patent cliff, AbbVie's stock price has risen by more than 75% over the past twelve months. This has been driven by strong fu… read more...

This Dividend Aristocrat Just Blew Past Earnings Estimates - Is It A Buy?

via: SeekingAlpha at 2018-01-26 13:01:43:000

AbbVie's ( ABBV ) performance over the past year has been nothing short of remarkable. After several years of laggard performance caused by concerns about Humira's patent cliff, AbbVie's stock price has risen by more than 75% over the past twelve months. This has been driven by strong fu… read more...

AbbVie continues to deliver with Humira; shares up 10% after strong Q4

via: SeekingAlpha at 2018-01-26 11:11:36:000

AbbVie's ( ABBV +10% ) top seller HUMIRA (adalimumab) continues to be plump cash cow for the company. In a presentation at JPM18, CEO Rick Gonzalez said it will remain so for a few years to come since it has patent protection from biosimilars until 2022. More news on: AbbVie Inc., Health… read more...

AbbVie continues to deliver with Humira; shares up 10% after strong Q4

via: SeekingAlpha at 2018-01-26 11:11:36:000

AbbVie's ( ABBV +10% ) top seller HUMIRA (adalimumab) continues to be plump cash cow for the company. In a presentation at JPM18, CEO Rick Gonzalez said it will remain so for a few years to come since it has patent protection from biosimilars until 2022. More news on: AbbVie Inc., Health… read more...

AbbVie continues to deliver with Humira; shares up 10% after strong Q4

via: SeekingAlpha at 2018-01-26 11:11:36:000

AbbVie's ( ABBV +10% ) top seller HUMIRA (adalimumab) continues to be plump cash cow for the company. In a presentation at JPM18, CEO Rick Gonzalez said it will remain so for a few years to come since it has patent protection from biosimilars until 2022. More news on: AbbVie Inc., Health… read more...

AbbVie continues to deliver with Humira; shares up 10% after strong Q4

via: SeekingAlpha at 2018-01-26 11:11:36:000

AbbVie's ( ABBV +10% ) top seller HUMIRA (adalimumab) continues to be plump cash cow for the company. In a presentation at JPM18, CEO Rick Gonzalez said it will remain so for a few years to come since it has patent protection from biosimilars until 2022. More news on: AbbVie Inc., Health… read more...

AbbVie Q4 revenues up 14%; non-GAAP EPS up 23%; updates guidance

via: SeekingAlpha at 2018-01-26 08:22:46:000

AbbVie ( ABBV +2.6% ) Q4 results : Revenues: $7,739M (+13.9%); Operating Income: $1,794M (-23.9%); Net Income: $52M (-96.3%); EPS: $0.03 (-96.5%); Non-GAAP EPS: $1.48 (+23.3%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read … read more...

AbbVie Q4 revenues up 14%; non-GAAP EPS up 23%; updates guidance

via: SeekingAlpha at 2018-01-26 08:22:46:000

AbbVie ( ABBV +2.6% ) Q4 results : Revenues: $7,739M (+13.9%); Operating Income: $1,794M (-23.9%); Net Income: $52M (-96.3%); EPS: $0.03 (-96.5%); Non-GAAP EPS: $1.48 (+23.3%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read … read more...

AbbVie Q4 revenues up 14%; non-GAAP EPS up 23%; updates guidance

via: SeekingAlpha at 2018-01-26 08:22:46:000

AbbVie ( ABBV +2.6% ) Q4 results : Revenues: $7,739M (+13.9%); Operating Income: $1,794M (-23.9%); Net Income: $52M (-96.3%); EPS: $0.03 (-96.5%); Non-GAAP EPS: $1.48 (+23.3%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read … read more...

AbbVie Q4 revenues up 14%; non-GAAP EPS up 23%; updates guidance

via: SeekingAlpha at 2018-01-26 08:22:46:000

AbbVie ( ABBV +2.6% ) Q4 results : Revenues: $7,739M (+13.9%); Operating Income: $1,794M (-23.9%); Net Income: $52M (-96.3%); EPS: $0.03 (-96.5%); Non-GAAP EPS: $1.48 (+23.3%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read … read more...

AbbVie beats by $0.04, beats on revenue

via: SeekingAlpha at 2018-01-26 07:52:24:000

AbbVie (NYSE: ABBV ): Q4 EPS of $1.48 beats by $0.04 . More news on: AbbVie Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

AbbVie beats by $0.04, beats on revenue

via: SeekingAlpha at 2018-01-26 07:52:24:000

AbbVie (NYSE: ABBV ): Q4 EPS of $1.48 beats by $0.04 . More news on: AbbVie Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

AbbVie beats by $0.04, beats on revenue

via: SeekingAlpha at 2018-01-26 07:52:24:000

AbbVie (NYSE: ABBV ): Q4 EPS of $1.48 beats by $0.04 . More news on: AbbVie Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

AbbVie beats by $0.04, beats on revenue

via: SeekingAlpha at 2018-01-26 07:52:24:000

AbbVie (NYSE: ABBV ): Q4 EPS of $1.48 beats by $0.04 . More news on: AbbVie Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results

via: PR Newswire at 2018-01-26 07:51:00:000

NORTH CHICAGO,Ill., Jan. 26, 2018 /PRNewswire/ --AbbVie (NYSE:ABBV) announced financial results for the fourth quarter ended December31, 2017. "2017 reflects another year of top-tier performance, demonstrating the strong momentum in our business," said Richard A. Gonza… read more...

AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results

via: PR Newswire at 2018-01-26 07:51:00:000

NORTH CHICAGO,Ill., Jan. 26, 2018 /PRNewswire/ --AbbVie (NYSE:ABBV) announced financial results for the fourth quarter ended December31, 2017. "2017 reflects another year of top-tier performance, demonstrating the strong momentum in our business," said Richard A. Gonza… read more...

AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results

via: PR Newswire at 2018-01-26 07:51:00:000

NORTH CHICAGO,Ill., Jan. 26, 2018 /PRNewswire/ --AbbVie (NYSE:ABBV) announced financial results for the fourth quarter ended December31, 2017. "2017 reflects another year of top-tier performance, demonstrating the strong momentum in our business," said Richard A. Gonza… read more...

AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results

via: PR Newswire at 2018-01-26 07:51:00:000

NORTH CHICAGO,Ill., Jan. 26, 2018 /PRNewswire/ --AbbVie (NYSE:ABBV) announced financial results for the fourth quarter ended December31, 2017. "2017 reflects another year of top-tier performance, demonstrating the strong momentum in our business," said Richard A. Gonza… read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

Notable earnings before Friday's open

via: SeekingAlpha at 2018-01-25 17:30:21:000

ABBV , APD , CL , COL , GNTX , HON , HRC , LEA , MOG.A , NEE , PFS , POL , WRLD For Seeking Alpha's full earnings season calendar, click here . More news on: AbbVie Inc., Air Products and Chemicals, Inc., Colgate-Palmolive Co., Earnings news and commentary, read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
2017-10-12 2017-11-15 2017-10-13 2017-09-08 0.64 Dividend income
2017-07-12 2017-08-15 2017-07-14 2017-06-22 0.64 Dividend income Q
2017-04-11 2017-05-15 2017-04-13 2017-02-16 0.64 Dividend income Q
2017-01-11 2017-02-15 2017-01-13 2016-10-28 0.64 Dividend income Q
2016-10-12 2016-11-15 2016-10-14 2016-09-09 0.57 Dividend income Q
2016-07-13 2016-08-15 2016-07-15 2016-06-16 0.57 Dividend income Q
2016-04-13 2016-05-16 2016-04-15 2016-02-18 0.57 Dividend income Q
2016-01-13 2016-02-16 2016-01-15 2015-10-30 0.57 Dividend income Q
2015-10-13 2015-11-16 2015-10-15 2015-09-11 0.51 Dividend income Q
2015-07-13 2015-08-14 2015-07-15 2015-06-18 0.51 Dividend income Q
2015-04-13 2015-05-15 2015-04-15 2015-02-19 0.51 Dividend income Q
2015-01-13 2015-02-13 2015-01-15 2014-10-20 0.49 Dividend income Q
2014-10-10 2014-11-17 2014-10-15 2014-09-19 0.42 Dividend income Q
2014-07-11 2014-08-15 2014-07-15 2014-06-19 0.42 Dividend income Q
2014-04-11 2014-05-15 2014-04-15 2014-02-20 0.42 Dividend income Q
2014-01-13 2014-02-14 2014-01-15 2013-12-12 0.4 Dividend income Q
2013-10-10 2013-11-15 2013-10-15 2013-09-19 0.4 Dividend income Q
2013-07-11 2013-08-15 2013-07-15 2013-06-20 0.4 Dividend income Q
2013-04-11 2013-05-15 2013-04-15 2013-02-15 0.4 Dividend income Q
2013-01-11 2013-02-15 2013-01-15 2013-01-04 0.4 Dividend income Q
2018-01-11 2018-02-15 2018-01-12 2017-10-27 0.71 FI Dividend income
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX